{"db29a8c3db79d215cf49883e8d5c21d2760222b7": [["Case for Diagnosis\u00b7T W O five week old male mixed-breed puppies from the same litter were presented dead for necropsy.", [["puppies", "ORGANISM", 56, 63], ["breed puppies", "PROBLEM", 50, 63], ["necropsy", "PROBLEM", 109, 117]]], ["One puppy (A) had a two-day history of fever, vomiting, and bloody diarrhea prior to death .", [["fever", "DISEASE", 39, 44], ["vomiting", "DISEASE", 46, 54], ["bloody diarrhea", "DISEASE", 60, 75], ["death", "DISEASE", 85, 90], ["fever", "PROBLEM", 39, 44], ["vomiting", "PROBLEM", 46, 54], ["bloody diarrhea", "PROBLEM", 60, 75], ["death", "PROBLEM", 85, 90], ["fever", "OBSERVATION", 39, 44]]], ["The other puppy (B) suddenly appeared very depressed, refused to eat, and then was found dead several hours later.", [["depressed", "DISEASE", 43, 52], ["very depressed", "PROBLEM", 38, 52], ["very", "OBSERVATION_MODIFIER", 38, 42], ["depressed", "OBSERVATION", 43, 52]]], ["At necropsy, the small intestine of puppy A contained segmental serosal hemor- ZMcArdle, B.: Familial Periodic Paralysis .", [["small intestine", "ANATOMY", 17, 32], ["serosal", "ANATOMY", 64, 71], ["Paralysis", "DISEASE", 111, 120], ["intestine", "ORGAN", 23, 32], ["segmental serosal hemor", "PROBLEM", 54, 77], ["Familial Periodic Paralysis", "PROBLEM", 93, 120], ["small intestine", "ANATOMY", 17, 32], ["puppy", "OBSERVATION", 36, 41], ["segmental", "ANATOMY_MODIFIER", 54, 63], ["serosal hemor", "ANATOMY", 64, 77], ["Familial", "OBSERVATION_MODIFIER", 93, 101], ["Periodic Paralysis", "OBSERVATION", 102, 120]]], ["Br.", [["Br.", "CHEMICAL", 0, 3], ["Br.", "SPECIES", 0, 3]]], ["3Satoynski, E., Suzuki, Y., and Abe, T.: Periodic Paralysis and Carbohydrate Metabolism Neurology (Minneap .), 13:24-33, 1963 .", [["Paralysis", "DISEASE", 50, 59], ["Carbohydrate", "CHEMICAL", 64, 76], ["Periodic Paralysis", "PROBLEM", 41, 59], ["Paralysis", "OBSERVATION", 50, 59]]], ["4Biemond, A. and Daniels, A. P.: Familial Periodic Paralysis and Its Transition into Spinal Muscular Atrophy.", [["Muscular", "ANATOMY", 92, 100], ["Paralysis", "DISEASE", 51, 60], ["Spinal Muscular Atrophy", "DISEASE", 85, 108], ["Familial Periodic Paralysis", "PROBLEM", 33, 60], ["Spinal Muscular Atrophy", "PROBLEM", 85, 108], ["Paralysis", "OBSERVATION", 51, 60], ["Spinal Muscular", "ANATOMY", 85, 100], ["Atrophy", "OBSERVATION", 101, 108]]], ["Brain, 57:91-108, 1934 .", [["Brain", "ANATOMY", 0, 5]]], ["5pearson, C. M.: The Periodic Paralysis : Differential Features and Pathologic Observations in Permanent Myopathic Weakness.", [["Paralysis", "DISEASE", 30, 39], ["Myopathic Weakness", "DISEASE", 105, 123], ["The Periodic Paralysis", "PROBLEM", 17, 39], ["Permanent Myopathic Weakness", "PROBLEM", 95, 123], ["Paralysis", "OBSERVATION", 30, 39], ["Myopathic", "OBSERVATION_MODIFIER", 105, 114], ["Weakness", "OBSERVATION", 115, 123]]], ["Brain, 87 :341-354, 1964 .", [["Brain", "ANATOMY", 0, 5]]], ["6MacDonald, R. D., Newcastle, N. B., and Humphrey, J. G.: Myopathy of Hypokalemic Periodic Paralysis .", [["Paralysis", "DISEASE", 91, 100], ["Myopathy", "PROBLEM", 58, 66], ["Hypokalemic Periodic Paralysis", "PROBLEM", 70, 100], ["Myopathy", "OBSERVATION", 58, 66], ["Hypokalemic", "OBSERVATION", 70, 81], ["Periodic Paralysis", "OBSERVATION", 82, 100]]], ["Neurol ..", [["Neurol", "TREATMENT", 0, 6]]], ["7Yan der Meulen, J. P., Gillet, G. J., and Kane, C. A.: Familial Hypokalemic Paralysis with Myotonia.", [["Familial Hypokalemic Paralysis", "DISEASE", 56, 86], ["Myotonia", "DISEASE", 92, 100], ["Familial Hypokalemic Paralysis", "PROBLEM", 56, 86], ["Myotonia", "PROBLEM", 92, 100], ["Hypokalemic Paralysis", "OBSERVATION", 65, 86], ["Myotonia", "OBSERVATION", 92, 100]]], ["N. Engl.", [["Engl", "OBSERVATION", 3, 7]]], ["J. Med., 264 :1-6, 1961. rhages ( Fig. 1) and was flaccid on palpation.", [["flaccid", "DISEASE", 50, 57], ["flaccid", "PROBLEM", 50, 57], ["palpation", "TEST", 61, 70], ["flaccid", "OBSERVATION", 50, 57]]], ["Thesmall intestine was filled with free blood, and the mucosa was severely reddened.", [["Thesmall intestine", "ANATOMY", 0, 18], ["blood", "ANATOMY", 40, 45], ["mucosa", "ANATOMY", 55, 61], ["Thesmall intestine", "ORGAN", 0, 18], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["mucosa", "MULTI-TISSUE_STRUCTURE", 55, 61], ["free blood", "PROBLEM", 35, 45], ["severely reddened", "PROBLEM", 66, 83], ["intestine", "ANATOMY", 9, 18], ["filled", "OBSERVATION", 23, 29], ["free blood", "OBSERVATION", 35, 45], ["mucosa", "ANATOMY", 55, 61], ["severely", "OBSERVATION_MODIFIER", 66, 74], ["reddened", "OBSERVATION", 75, 83]]], ["At necropsy, the lungs of puppy B were wet and heavy, and the liver had rounded edges.", [["lungs", "ANATOMY", 17, 22], ["liver", "ANATOMY", 62, 67], ["lungs", "ORGAN", 17, 22], ["liver", "ORGAN", 62, 67], ["rounded edges", "PROBLEM", 72, 85], ["lungs", "ANATOMY", 17, 22], ["wet", "OBSERVATION", 39, 42], ["heavy", "OBSERVATION_MODIFIER", 47, 52], ["liver", "ANATOMY", 62, 67], ["rounded", "OBSERVATION_MODIFIER", 72, 79], ["edges", "OBSERVATION_MODIFIER", 80, 85]]], ["The heart was grossly unremarkable but contained histologic evidence of a nonsuppurative myocarditis (Fig. 2 ) Diagnosis and discussion appear on page 236.", [["heart", "ANATOMY", 4, 9], ["myocarditis", "DISEASE", 89, 100], ["heart", "ORGAN", 4, 9], ["a nonsuppurative myocarditis", "PROBLEM", 72, 100], ["heart", "ANATOMY", 4, 9], ["grossly", "OBSERVATION_MODIFIER", 14, 21], ["unremarkable", "OBSERVATION", 22, 34], ["nonsuppurative", "OBSERVATION_MODIFIER", 74, 88], ["myocarditis", "OBSERVATION", 89, 100]]], ["(Solution) Diagnosis and discussion of case illustrated on page 231.Case for DiagnosisDiagnosis: Hemorrhagic enteritis and nonsuppurative myocarditis caused by canine parvovirus.Case for DiagnosisCanine parvovirus (C PV) is a newly recognized canine pathogen that can produce enteric disease, which is sometimes fatal, in dogs of all agesl.2.", [["Hemorrhagic enteritis", "DISEASE", 97, 118], ["myocarditis", "DISEASE", 138, 149], ["canine parvovirus", "DISEASE", 160, 177], ["DiagnosisCanine parvovirus (C PV)", "DISEASE", 187, 220], ["enteric disease", "DISEASE", 276, 291], ["canine parvovirus", "ORGANISM", 160, 177], ["DiagnosisCanine parvovirus", "ORGANISM", 187, 213], ["C PV", "ORGANISM", 215, 219], ["canine", "ORGANISM", 243, 249], ["dogs", "ORGANISM", 322, 326], ["canine parvovirus", "SPECIES", 160, 177], ["canine", "SPECIES", 243, 249], ["dogs", "SPECIES", 322, 326], ["canine parvovirus", "SPECIES", 160, 177], ["DiagnosisCanine parvovirus (C", "SPECIES", 187, 216], ["PV", "SPECIES", 217, 219], ["canine", "SPECIES", 243, 249], ["Hemorrhagic enteritis", "PROBLEM", 97, 118], ["nonsuppurative myocarditis", "PROBLEM", 123, 149], ["canine parvovirus", "PROBLEM", 160, 177], ["DiagnosisCanine parvovirus (C PV)", "PROBLEM", 187, 220], ["a newly recognized canine pathogen", "PROBLEM", 224, 258], ["enteric disease", "PROBLEM", 276, 291], ["Hemorrhagic", "OBSERVATION_MODIFIER", 97, 108], ["enteritis", "OBSERVATION", 109, 118], ["nonsuppurative", "OBSERVATION_MODIFIER", 123, 137], ["myocarditis", "OBSERVATION", 138, 149], ["canine parvovirus", "OBSERVATION", 160, 177], ["enteric disease", "OBSERVATION", 276, 291]]], ["6 \u2022 7 \u2022 1 0 and a myocarditis only in young puppies between three and eight weeks of age .!\u00b73-5.8.9 Both syndromes can occur in the same litter of puppies.'Case for DiagnosisCanine parvovirus infects and replicates in rapidly proliferating cells of several tissues, including small intestine, lymphoid tissues, and neonatal myocardium.", [["cells", "ANATOMY", 240, 245], ["tissues", "ANATOMY", 257, 264], ["small intestine", "ANATOMY", 276, 291], ["lymphoid tissues", "ANATOMY", 293, 309], ["neonatal myocardium", "ANATOMY", 315, 334], ["myocarditis", "DISEASE", 18, 29], ["DiagnosisCanine parvovirus", "DISEASE", 165, 191], ["DiagnosisCanine parvovirus", "ORGANISM", 165, 191], ["cells", "CELL", 240, 245], ["tissues", "TISSUE", 257, 264], ["small intestine", "TISSUE", 276, 291], ["lymphoid tissues", "TISSUE", 293, 309], ["neonatal myocardium", "TISSUE", 315, 334], ["rapidly proliferating cells", "CELL_TYPE", 218, 245], ["DiagnosisCanine parvovirus", "SPECIES", 165, 191], ["a myocarditis", "PROBLEM", 16, 29], ["Both syndromes", "PROBLEM", 100, 114], ["DiagnosisCanine parvovirus infects", "PROBLEM", 165, 199], ["small intestine, lymphoid tissues, and neonatal myocardium", "PROBLEM", 276, 334], ["myocarditis", "OBSERVATION", 18, 29], ["parvovirus infects", "OBSERVATION", 181, 199], ["rapidly", "OBSERVATION_MODIFIER", 218, 225], ["proliferating cells", "OBSERVATION", 226, 245], ["several tissues", "ANATOMY", 249, 264], ["small intestine", "ANATOMY", 276, 291], ["lymphoid tissues", "OBSERVATION", 293, 309], ["neonatal myocardium", "ANATOMY", 315, 334]]], ["In the enteric form, as seen in puppy A, the virus infects and kills intestinal crypt epithelial cells, which was evident histologically as crypt cell necrosis and dilated crypts that were lined by stretched out epithelial cells and filled with cellular debris (Fig. 3 ).", [["intestinal crypt epithelial cells", "ANATOMY", 69, 102], ["crypt cell", "ANATOMY", 140, 150], ["crypts", "ANATOMY", 172, 178], ["epithelial cells", "ANATOMY", 212, 228], ["cellular", "ANATOMY", 245, 253], ["necrosis", "DISEASE", 151, 159], ["puppy A", "CANCER", 32, 39], ["intestinal crypt epithelial cells", "CELL", 69, 102], ["crypt cell", "CELL", 140, 150], ["crypts", "PATHOLOGICAL_FORMATION", 172, 178], ["epithelial cells", "CELL", 212, 228], ["cellular", "CELL", 245, 253], ["intestinal crypt epithelial cells", "CELL_TYPE", 69, 102], ["epithelial cells", "CELL_TYPE", 212, 228], ["the virus infects", "PROBLEM", 41, 58], ["intestinal crypt epithelial cells", "PROBLEM", 69, 102], ["crypt cell necrosis", "PROBLEM", 140, 159], ["dilated crypts", "PROBLEM", 164, 178], ["cellular debris", "PROBLEM", 245, 260], ["enteric form", "OBSERVATION_MODIFIER", 7, 19], ["virus infects", "OBSERVATION", 45, 58], ["crypt epithelial cells", "OBSERVATION", 80, 102], ["crypt cell necrosis", "OBSERVATION", 140, 159], ["dilated", "OBSERVATION_MODIFIER", 164, 171], ["crypts", "OBSERVATION_MODIFIER", 172, 178], ["epithelial cells", "OBSERVATION", 212, 228], ["cellular debris", "OBSERVATION", 245, 260]]], ["Since these crypt cells , which were required for villous epithelial cell renewal, were lost , associated changes included villous necrosis, blunting, and fusion (Fig. 3) .", [["crypt cells", "ANATOMY", 12, 23], ["villous epithelial cell", "ANATOMY", 50, 73], ["villous", "ANATOMY", 123, 130], ["necrosis", "DISEASE", 131, 139], ["crypt cells", "CELL", 12, 23], ["villous epithelial cell", "CELL", 50, 73], ["villous", "MULTI-TISSUE_STRUCTURE", 123, 130], ["crypt cells", "CELL_TYPE", 12, 23], ["these crypt cells", "TEST", 6, 23], ["villous epithelial cell renewal", "PROBLEM", 50, 81], ["villous necrosis", "PROBLEM", 123, 139], ["blunting", "PROBLEM", 141, 149], ["fusion", "PROBLEM", 155, 161], ["crypt cells", "OBSERVATION", 12, 23], ["epithelial cell renewal", "OBSERVATION", 58, 81], ["villous", "OBSERVATION_MODIFIER", 123, 130], ["necrosis", "OBSERVATION", 131, 139], ["blunting", "OBSERVATION_MODIFIER", 141, 149], ["fusion", "OBSERVATION", 155, 161]]], ["Crypt cell hyperplasia with numerous mitotic figures, indicative of mucosal regeneration, may be seen in dogs which survive the infection for several days.", [["Crypt cell", "ANATOMY", 0, 10], ["mucosal", "ANATOMY", 68, 75], ["infection", "DISEASE", 128, 137], ["Crypt cell", "CELL", 0, 10], ["mucosal", "TISSUE", 68, 75], ["dogs", "ORGANISM", 105, 109], ["dogs", "SPECIES", 105, 109], ["Crypt cell hyperplasia", "PROBLEM", 0, 22], ["numerous mitotic figures", "PROBLEM", 28, 52], ["mucosal regeneration", "PROBLEM", 68, 88], ["the infection", "PROBLEM", 124, 137], ["cell hyperplasia", "OBSERVATION", 6, 22], ["numerous", "OBSERVATION_MODIFIER", 28, 36], ["mitotic figures", "OBSERVATION", 37, 52], ["indicative of", "UNCERTAINTY", 54, 67], ["mucosal regeneration", "OBSERVATION", 68, 88], ["may be seen", "UNCERTAINTY", 90, 101], ["infection", "OBSERVATION", 128, 137]]], ["Eventually, the normal architecture is restored in most cases.", [["normal", "OBSERVATION", 16, 22], ["architecture", "OBSERVATION_MODIFIER", 23, 35]]], ["In some individuals, Case for Diagnosis however, the degree of damage is so marked that repair is incomplete and the mucosal lining appears bizarre and distorted.s Clinically, such individuals may exhibit a malabsorption syndrome and a slow growth rate.Case for DiagnosisCanine parvovirus also infects proliferating hematopoietic cells in bone marrow and lymphoid tissues throughout the body.", [["mucosal lining", "ANATOMY", 117, 131], ["hematopoietic cells", "ANATOMY", 316, 335], ["bone marrow", "ANATOMY", 339, 350], ["lymphoid tissues", "ANATOMY", 355, 371], ["body", "ANATOMY", 387, 391], ["malabsorption syndrome", "DISEASE", 207, 229], ["mucosal lining", "TISSUE", 117, 131], ["individuals", "ORGANISM", 181, 192], ["Canine parvovirus", "ORGANISM", 271, 288], ["hematopoietic cells", "CELL", 316, 335], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 339, 350], ["lymphoid tissues", "TISSUE", 355, 371], ["body", "ORGANISM_SUBDIVISION", 387, 391], ["proliferating hematopoietic cells", "CELL_TYPE", 302, 335], ["Canine parvovirus", "SPECIES", 271, 288], ["Canine parvovirus", "SPECIES", 271, 288], ["damage", "PROBLEM", 63, 69], ["repair", "TREATMENT", 88, 94], ["bizarre", "PROBLEM", 140, 147], ["a malabsorption syndrome", "PROBLEM", 205, 229], ["a slow growth rate", "PROBLEM", 234, 252], ["Canine parvovirus", "PROBLEM", 271, 288], ["proliferating hematopoietic cells in bone marrow", "PROBLEM", 302, 350], ["damage", "OBSERVATION", 63, 69], ["repair", "OBSERVATION", 88, 94], ["mucosal lining", "ANATOMY", 117, 131], ["bizarre", "OBSERVATION_MODIFIER", 140, 147], ["malabsorption syndrome", "OBSERVATION", 207, 229], ["slow", "OBSERVATION_MODIFIER", 236, 240], ["growth", "OBSERVATION_MODIFIER", 241, 247], ["parvovirus", "OBSERVATION", 278, 288], ["infects", "OBSERVATION_MODIFIER", 294, 301], ["proliferating hematopoietic cells", "OBSERVATION", 302, 335], ["bone marrow", "ANATOMY", 339, 350], ["lymphoid tissues", "OBSERVATION", 355, 371], ["body", "ANATOMY", 387, 391]]], ["Severe infections are manifested clinically by panleukopenia, a poor prognostic indica tor .w Puppy A had depletion and necrosis of lymphoid cells in the thymus, spleen, tonsils, mesenteric lymph nodes, and gut-associated lymphoid tissue, and depletion and necrosis of hematopoietic cells in the bone marrow.Case for DiagnosisIn the myocardial form of the disease seen in puppy B, enteric and lymphoid lesions were absent.", [["lymphoid cells", "ANATOMY", 132, 146], ["thymus", "ANATOMY", 154, 160], ["spleen", "ANATOMY", 162, 168], ["tonsils", "ANATOMY", 170, 177], ["mesenteric lymph nodes", "ANATOMY", 179, 201], ["gut", "ANATOMY", 207, 210], ["lymphoid tissue", "ANATOMY", 222, 237], ["hematopoietic cells", "ANATOMY", 269, 288], ["bone marrow", "ANATOMY", 296, 307], ["myocardial", "ANATOMY", 333, 343], ["lymphoid lesions", "ANATOMY", 393, 409], ["infections", "DISEASE", 7, 17], ["panleukopenia", "DISEASE", 47, 60], ["necrosis", "DISEASE", 120, 128], ["necrosis", "DISEASE", 257, 265], ["myocardial form of the disease", "DISEASE", 333, 363], ["lymphoid cells", "CELL", 132, 146], ["thymus", "ORGAN", 154, 160], ["spleen", "ORGAN", 162, 168], ["tonsils", "ORGAN", 170, 177], ["mesenteric lymph nodes", "MULTI-TISSUE_STRUCTURE", 179, 201], ["gut-associated lymphoid tissue", "TISSUE", 207, 237], ["hematopoietic cells", "CELL", 269, 288], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 296, 307], ["myocardial", "MULTI-TISSUE_STRUCTURE", 333, 343], ["puppy B", "CANCER", 372, 379], ["enteric", "PATHOLOGICAL_FORMATION", 381, 388], ["lymphoid lesions", "CANCER", 393, 409], ["lymphoid cells", "CELL_TYPE", 132, 146], ["hematopoietic cells", "CELL_TYPE", 269, 288], ["Severe infections", "PROBLEM", 0, 17], ["panleukopenia", "PROBLEM", 47, 60], ["depletion", "PROBLEM", 106, 115], ["necrosis of lymphoid cells in the thymus", "PROBLEM", 120, 160], ["mesenteric lymph nodes", "PROBLEM", 179, 201], ["associated lymphoid tissue", "PROBLEM", 211, 237], ["depletion", "PROBLEM", 243, 252], ["necrosis of hematopoietic cells in the bone marrow", "PROBLEM", 257, 307], ["the disease", "PROBLEM", 352, 363], ["puppy B, enteric and lymphoid lesions", "PROBLEM", 372, 409], ["infections", "OBSERVATION", 7, 17], ["necrosis", "OBSERVATION", 120, 128], ["lymphoid cells", "OBSERVATION", 132, 146], ["thymus", "ANATOMY", 154, 160], ["spleen", "ANATOMY", 162, 168], ["tonsils", "ANATOMY", 170, 177], ["mesenteric", "ANATOMY", 179, 189], ["lymph nodes", "OBSERVATION", 190, 201], ["gut", "ANATOMY", 207, 210], ["lymphoid tissue", "OBSERVATION", 222, 237], ["depletion", "OBSERVATION_MODIFIER", 243, 252], ["necrosis", "OBSERVATION_MODIFIER", 257, 265], ["hematopoietic cells", "OBSERVATION", 269, 288], ["bone marrow", "ANATOMY", 296, 307], ["myocardial", "ANATOMY", 333, 343], ["disease", "OBSERVATION", 356, 363], ["enteric", "ANATOMY", 381, 388], ["lymphoid", "ANATOMY", 393, 401], ["lesions", "OBSERVATION", 402, 409]]], ["The heart was the only organ with microscopic evidence of viral infection.", [["heart", "ANATOMY", 4, 9], ["organ", "ANATOMY", 23, 28], ["viral infection", "DISEASE", 58, 73], ["heart", "ORGAN", 4, 9], ["organ", "ORGAN", 23, 28], ["viral infection", "PROBLEM", 58, 73], ["heart", "ANATOMY", 4, 9], ["evidence of", "UNCERTAINTY", 46, 57], ["viral", "OBSERVATION_MODIFIER", 58, 63], ["infection", "OBSERVATION", 64, 73]]], ["Microscopic changes included separation of myocardial fibers, necrosis of individual fibers, an interstitial infiltrate of lymphocytes, plasma cells, and macrophages, and scattered homogeneous basophilic inclusions which completely filled the nuclei of myocardial cells (Fig. 4) .", [["myocardial fibers", "ANATOMY", 43, 60], ["fibers", "ANATOMY", 85, 91], ["interstitial infiltrate", "ANATOMY", 96, 119], ["lymphocytes", "ANATOMY", 123, 134], ["plasma cells", "ANATOMY", 136, 148], ["macrophages", "ANATOMY", 154, 165], ["basophilic inclusions", "ANATOMY", 193, 214], ["nuclei", "ANATOMY", 243, 249], ["myocardial cells", "ANATOMY", 253, 269], ["necrosis", "DISEASE", 62, 70], ["myocardial fibers", "TISSUE", 43, 60], ["fibers", "CELLULAR_COMPONENT", 85, 91], ["lymphocytes", "CELL", 123, 134], ["plasma cells", "CELL", 136, 148], ["macrophages", "CELL", 154, 165], ["nuclei", "CELLULAR_COMPONENT", 243, 249], ["myocardial cells", "CELL", 253, 269], ["lymphocytes", "CELL_TYPE", 123, 134], ["plasma cells", "CELL_TYPE", 136, 148], ["macrophages", "CELL_TYPE", 154, 165], ["myocardial cells", "CELL_TYPE", 253, 269], ["Microscopic changes", "PROBLEM", 0, 19], ["myocardial fibers", "PROBLEM", 43, 60], ["necrosis of individual fibers", "PROBLEM", 62, 91], ["an interstitial infiltrate of lymphocytes", "PROBLEM", 93, 134], ["plasma cells", "PROBLEM", 136, 148], ["macrophages", "PROBLEM", 154, 165], ["scattered homogeneous basophilic inclusions", "PROBLEM", 171, 214], ["myocardial cells", "PROBLEM", 253, 269], ["separation", "OBSERVATION_MODIFIER", 29, 39], ["myocardial fibers", "ANATOMY", 43, 60], ["necrosis", "OBSERVATION", 62, 70], ["fibers", "OBSERVATION_MODIFIER", 85, 91], ["interstitial", "ANATOMY_MODIFIER", 96, 108], ["infiltrate", "OBSERVATION", 109, 119], ["lymphocytes", "ANATOMY", 123, 134], ["plasma cells", "OBSERVATION", 136, 148], ["macrophages", "ANATOMY", 154, 165], ["scattered", "OBSERVATION_MODIFIER", 171, 180], ["homogeneous", "OBSERVATION_MODIFIER", 181, 192], ["basophilic inclusions", "OBSERVATION", 193, 214], ["nuclei", "OBSERVATION_MODIFIER", 243, 249], ["myocardial cells", "OBSERVATION", 253, 269]]], ["With electron microscopy, these inclusions can be demonstrated to contain parvoviral particles 20 nm in diameter.Case for DiagnosisPuppies which survive acute viral myocarditis may develop clinical signs of congestive heart failure months later.\"", [["heart", "ANATOMY", 218, 223], ["myocarditis", "DISEASE", 165, 176], ["congestive heart failure", "DISEASE", 207, 231], ["heart", "ORGAN", 218, 223], ["electron microscopy", "TEST", 5, 24], ["DiagnosisPuppies", "TREATMENT", 122, 138], ["acute viral myocarditis", "PROBLEM", 153, 176], ["congestive heart failure", "PROBLEM", 207, 231], ["20 nm", "OBSERVATION_MODIFIER", 95, 100], ["diameter", "OBSERVATION_MODIFIER", 104, 112], ["heart", "ANATOMY", 218, 223], ["failure", "OBSERVATION", 224, 231]]], ["Electrocardiographic changes seen in such puppies include premature ventricular contractions and ventricular tachycardia.", [["ventricular", "ANATOMY", 68, 79], ["ventricular", "ANATOMY", 97, 108], ["premature ventricular contractions", "DISEASE", 58, 92], ["ventricular tachycardia", "DISEASE", 97, 120], ["ventricular", "MULTI-TISSUE_STRUCTURE", 68, 79], ["ventricular", "MULTI-TISSUE_STRUCTURE", 97, 108], ["Electrocardiographic changes", "PROBLEM", 0, 28], ["premature ventricular contractions", "PROBLEM", 58, 92], ["ventricular tachycardia", "PROBLEM", 97, 120], ["premature ventricular contractions", "OBSERVATION", 58, 92], ["ventricular tachycardia", "OBSERVATION", 97, 120]]], ["At necropsy, the hearts of such puppies may contain grossly visible pale streaks and patches in the myocardium, usually of the left ventricle.", [["hearts", "ANATOMY", 17, 23], ["patches", "ANATOMY", 85, 92], ["myocardium", "ANATOMY", 100, 110], ["left ventricle", "ANATOMY", 127, 141], ["hearts", "ORGAN", 17, 23], ["puppies", "ORGANISM", 32, 39], ["pale streaks", "PATHOLOGICAL_FORMATION", 68, 80], ["myocardium", "ORGAN", 100, 110], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 127, 141], ["grossly visible pale streaks and patches in the myocardium", "PROBLEM", 52, 110], ["hearts", "ANATOMY", 17, 23], ["grossly", "OBSERVATION_MODIFIER", 52, 59], ["visible", "OBSERVATION_MODIFIER", 60, 67], ["pale", "OBSERVATION_MODIFIER", 68, 72], ["streaks", "OBSERVATION", 73, 80], ["patches", "OBSERVATION_MODIFIER", 85, 92], ["myocardium", "ANATOMY", 100, 110], ["left ventricle", "ANATOMY", 127, 141]]], ["Other gross findings may include wet heavy lungs, pleural and pericardial effusion, and hepatosplenomegaly.", [["lungs", "ANATOMY", 43, 48], ["pleural", "ANATOMY", 50, 57], ["pericardial", "ANATOMY", 62, 73], ["pleural and pericardial effusion", "DISEASE", 50, 82], ["hepatosplenomegaly", "DISEASE", 88, 106], ["lungs", "ORGAN", 43, 48], ["pleural", "MULTI-TISSUE_STRUCTURE", 50, 57], ["pericardial", "ORGAN", 62, 73], ["wet heavy lungs", "PROBLEM", 33, 48], ["pleural and pericardial effusion", "PROBLEM", 50, 82], ["hepatosplenomegaly", "PROBLEM", 88, 106], ["may include", "UNCERTAINTY", 21, 32], ["wet", "OBSERVATION_MODIFIER", 33, 36], ["heavy", "OBSERVATION_MODIFIER", 37, 42], ["lungs", "ANATOMY", 43, 48], ["pleural", "ANATOMY", 50, 57], ["pericardial", "ANATOMY", 62, 73], ["effusion", "OBSERVATION", 74, 82], ["hepatosplenomegaly", "OBSERVATION", 88, 106]]], ["Microscopically, the heart shows a chronic myocarditis, evidenced by a loss of myocardial fibers , extensive fibrosis with mineralization, and a mild infiltrate of lymphocytes, plasma cells and macro-Case for Diagnosisphages, but no intranuclear inclusion bodies.", [["heart", "ANATOMY", 21, 26], ["myocardial fibers", "ANATOMY", 79, 96], ["lymphocytes", "ANATOMY", 164, 175], ["plasma cells", "ANATOMY", 177, 189], ["myocarditis", "DISEASE", 43, 54], ["loss of myocardial fibers", "DISEASE", 71, 96], ["fibrosis", "DISEASE", 109, 117], ["heart", "ORGAN", 21, 26], ["myocardial fibers", "TISSUE", 79, 96], ["lymphocytes", "CELL", 164, 175], ["plasma cells", "CELL", 177, 189], ["lymphocytes", "CELL_TYPE", 164, 175], ["plasma cells", "CELL_TYPE", 177, 189], ["a chronic myocarditis", "PROBLEM", 33, 54], ["a loss of myocardial fibers", "PROBLEM", 69, 96], ["extensive fibrosis", "PROBLEM", 99, 117], ["mineralization", "PROBLEM", 123, 137], ["a mild infiltrate of lymphocytes", "PROBLEM", 143, 175], ["plasma cells", "TEST", 177, 189], ["Diagnosisphages", "PROBLEM", 209, 224], ["intranuclear inclusion bodies", "PROBLEM", 233, 262], ["heart", "ANATOMY", 21, 26], ["chronic", "OBSERVATION_MODIFIER", 35, 42], ["myocarditis", "OBSERVATION", 43, 54], ["loss", "OBSERVATION_MODIFIER", 71, 75], ["myocardial fibers", "ANATOMY", 79, 96], ["extensive", "OBSERVATION_MODIFIER", 99, 108], ["fibrosis", "OBSERVATION", 109, 117], ["mineralization", "OBSERVATION_MODIFIER", 123, 137], ["mild", "OBSERVATION_MODIFIER", 145, 149], ["infiltrate", "OBSERVATION", 150, 160], ["lymphocytes", "ANATOMY", 164, 175], ["plasma cells", "OBSERVATION", 177, 189], ["no", "UNCERTAINTY", 230, 232], ["intranuclear", "OBSERVATION", 233, 245], ["inclusion bodies", "OBSERVATION", 246, 262]]], ["The cause of death has been attributed to conduction failure caused by blockage of the conduction pathways by the extensive fibrosis.\"Case for DiagnosisThe diagnosis of canine parvoviral enteritis is made from the characteristic gross and microscopic lesions-and the diagnosis of parvoviral myocarditis from the microscopic lesions with demonstration of inclusion bodies.'", [["gross", "ANATOMY", 229, 234], ["lesions", "ANATOMY", 251, 258], ["lesions", "ANATOMY", 324, 331], ["death", "DISEASE", 13, 18], ["conduction failure", "DISEASE", 42, 60], ["fibrosis", "DISEASE", 124, 132], ["parvoviral enteritis", "DISEASE", 176, 196], ["myocarditis", "DISEASE", 291, 302], ["canine", "ORGANISM", 169, 175], ["lesions", "PATHOLOGICAL_FORMATION", 251, 258], ["lesions", "PATHOLOGICAL_FORMATION", 324, 331], ["canine", "SPECIES", 169, 175], ["canine parvoviral enteritis", "SPECIES", 169, 196], ["death", "PROBLEM", 13, 18], ["conduction failure", "PROBLEM", 42, 60], ["blockage of the conduction pathways", "PROBLEM", 71, 106], ["the extensive fibrosis", "PROBLEM", 110, 132], ["canine parvoviral enteritis", "PROBLEM", 169, 196], ["the characteristic gross and microscopic lesions", "PROBLEM", 210, 258], ["parvoviral myocarditis", "PROBLEM", 280, 302], ["the microscopic lesions", "PROBLEM", 308, 331], ["inclusion bodies", "PROBLEM", 354, 370], ["conduction failure", "OBSERVATION", 42, 60], ["blockage", "OBSERVATION", 71, 79], ["extensive", "OBSERVATION_MODIFIER", 114, 123], ["fibrosis", "OBSERVATION", 124, 132], ["canine", "OBSERVATION_MODIFIER", 169, 175], ["parvoviral enteritis", "OBSERVATION", 176, 196], ["gross", "OBSERVATION_MODIFIER", 229, 234], ["microscopic", "OBSERVATION_MODIFIER", 239, 250], ["lesions", "OBSERVATION", 251, 258], ["parvoviral", "ANATOMY", 280, 290], ["myocarditis", "OBSERVATION", 291, 302], ["microscopic", "OBSERVATION_MODIFIER", 312, 323], ["lesions", "OBSERVATION", 324, 331], ["inclusion bodies", "OBSERVATION", 354, 370]]], ["The diagnosis can be confirmed by viral isolation-? or by fluorescent antibody studies on frozen tissues.3,6 Ultrastructural demonstration of viral particles in heart muscle is also confirmatory .'", [["tissues", "ANATOMY", 97, 104], ["heart muscle", "ANATOMY", 161, 173], ["tissues", "TISSUE", 97, 104], ["heart muscle", "ORGAN", 161, 173], ["fluorescent antibody", "PROTEIN", 58, 78], ["viral isolation", "TEST", 34, 49], ["fluorescent antibody studies", "TEST", 58, 86], ["viral particles in heart muscle", "PROBLEM", 142, 173], ["viral isolation", "OBSERVATION", 34, 49], ["viral particles", "OBSERVATION", 142, 157], ["heart muscle", "ANATOMY", 161, 173]]], ["Dogs can be serologically screened for canine parvovirus, using either the hemagglutination inhibition or the serum neutralization test .10Case for DiagnosisThe microscopic differential diagnosis for CPV enteritis includes canine coronavirus, which infects the villous epithelial cells only, leading to villous blunting and fusion and crypt cell hyperplasia, and canine distemper virus, which occasionally produces a mild enteritis with crypt cell necrosis and dilated crypts filled with necrotic debris.", [["serum", "ANATOMY", 110, 115], ["villous epithelial cells", "ANATOMY", 261, 285], ["villous", "ANATOMY", 303, 310], ["crypt cell", "ANATOMY", 335, 345], ["crypt cell", "ANATOMY", 437, 447], ["crypts", "ANATOMY", 469, 475], ["necrotic debris", "ANATOMY", 488, 503], ["canine parvovirus", "DISEASE", 39, 56], ["CPV enteritis", "DISEASE", 200, 213], ["canine coronavirus", "DISEASE", 223, 241], ["canine distemper virus", "DISEASE", 363, 385], ["enteritis", "DISEASE", 422, 431], ["necrosis", "DISEASE", 448, 456], ["necrotic", "DISEASE", 488, 496], ["Dogs", "ORGANISM", 0, 4], ["canine parvovirus", "ORGANISM", 39, 56], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["CPV", "ORGANISM", 200, 203], ["canine coronavirus", "ORGANISM", 223, 241], ["villous epithelial cells", "CELL", 261, 285], ["villous", "TISSUE", 303, 310], ["crypt cell", "CELL", 335, 345], ["canine distemper virus", "ORGANISM", 363, 385], ["crypt cell", "CELL", 437, 447], ["crypts", "PATHOLOGICAL_FORMATION", 469, 475], ["villous epithelial cells", "CELL_TYPE", 261, 285], ["canine parvovirus", "SPECIES", 39, 56], ["canine coronavirus", "SPECIES", 223, 241], ["canine distemper virus", "SPECIES", 363, 385], ["canine parvovirus", "SPECIES", 39, 56], ["CPV", "SPECIES", 200, 203], ["canine coronavirus", "SPECIES", 223, 241], ["canine distemper virus", "SPECIES", 363, 385], ["canine parvovirus", "PROBLEM", 39, 56], ["the hemagglutination inhibition", "TREATMENT", 71, 102], ["the serum neutralization test", "TEST", 106, 135], ["CPV enteritis", "PROBLEM", 200, 213], ["canine coronavirus", "PROBLEM", 223, 241], ["the villous epithelial cells", "PROBLEM", 257, 285], ["villous blunting and fusion", "PROBLEM", 303, 330], ["crypt cell hyperplasia", "PROBLEM", 335, 357], ["canine distemper virus", "PROBLEM", 363, 385], ["a mild enteritis", "PROBLEM", 415, 431], ["crypt cell necrosis", "PROBLEM", 437, 456], ["dilated crypts", "PROBLEM", 461, 475], ["necrotic debris", "PROBLEM", 488, 503], ["enteritis", "OBSERVATION", 204, 213], ["canine coronavirus", "OBSERVATION", 223, 241], ["villous epithelial cells", "OBSERVATION", 261, 285], ["villous", "OBSERVATION_MODIFIER", 303, 310], ["blunting", "OBSERVATION", 311, 319], ["fusion", "OBSERVATION", 324, 330], ["crypt cell hyperplasia", "OBSERVATION", 335, 357], ["canine", "OBSERVATION_MODIFIER", 363, 369], ["distemper virus", "OBSERVATION", 370, 385], ["mild", "OBSERVATION_MODIFIER", 417, 421], ["enteritis", "OBSERVATION", 422, 431], ["crypt cell necrosis", "OBSERVATION", 437, 456], ["dilated", "OBSERVATION_MODIFIER", 461, 468], ["crypts", "OBSERVATION_MODIFIER", 469, 475], ["necrotic", "OBSERVATION_MODIFIER", 488, 496], ["debris", "OBSERVATION", 497, 503]]], ["Canine coronavirus does not infect lymphoid tissues, whereas canine distemper virus does, producing necrosis and depletion of lymphoid cells similar to that seen in canine parvoviral enteritis.", [["lymphoid tissues", "ANATOMY", 35, 51], ["lymphoid cells", "ANATOMY", 126, 140], ["necrosis", "DISEASE", 100, 108], ["parvoviral enteritis", "DISEASE", 172, 192], ["Canine coronavirus", "ORGANISM", 0, 18], ["lymphoid tissues", "TISSUE", 35, 51], ["canine distemper virus", "ORGANISM", 61, 83], ["lymphoid cells", "CELL", 126, 140], ["canine parvoviral enteritis", "ORGANISM", 165, 192], ["lymphoid cells", "CELL_TYPE", 126, 140], ["Canine coronavirus", "SPECIES", 0, 18], ["canine distemper virus", "SPECIES", 61, 83], ["canine", "SPECIES", 165, 171], ["Canine coronavirus", "SPECIES", 0, 18], ["canine distemper virus", "SPECIES", 61, 83], ["canine parvoviral enteritis", "SPECIES", 165, 192], ["Canine coronavirus", "PROBLEM", 0, 18], ["lymphoid tissues", "PROBLEM", 35, 51], ["canine distemper virus", "PROBLEM", 61, 83], ["necrosis", "PROBLEM", 100, 108], ["lymphoid cells", "PROBLEM", 126, 140], ["canine parvoviral enteritis", "PROBLEM", 165, 192], ["coronavirus", "OBSERVATION", 7, 18], ["does not", "UNCERTAINTY", 19, 27], ["infect lymphoid tissues", "OBSERVATION", 28, 51], ["distemper virus", "OBSERVATION", 68, 83], ["necrosis", "OBSERVATION", 100, 108], ["depletion", "OBSERVATION_MODIFIER", 113, 122], ["lymphoid cells", "OBSERVATION", 126, 140], ["canine", "OBSERVATION_MODIFIER", 165, 171], ["parvoviral enteritis", "OBSERVATION", 172, 192]]], ["Lymphoid necrosis is also a characteristic finding in cases of infectious canine hepatitis caused by canine adenovirus I.Case for DiagnosisThe presence of intranuclear inclusion bodies in cases of canine myocarditis is virtually pathognomonic for canine parvovirus.", [["Lymphoid", "ANATOMY", 0, 8], ["intranuclear inclusion bodies", "ANATOMY", 155, 184], ["Lymphoid necrosis", "DISEASE", 0, 17], ["canine hepatitis", "DISEASE", 74, 90], ["myocarditis", "DISEASE", 204, 215], ["canine parvovirus", "DISEASE", 247, 264], ["canine", "ORGANISM", 74, 80], ["canine adenovirus", "ORGANISM", 101, 118], ["canine", "ORGANISM", 197, 203], ["canine parvovirus", "ORGANISM", 247, 264], ["canine", "SPECIES", 101, 107], ["canine parvovirus", "SPECIES", 247, 264], ["canine", "SPECIES", 101, 107], ["canine", "SPECIES", 197, 203], ["canine parvovirus", "SPECIES", 247, 264], ["Lymphoid necrosis", "PROBLEM", 0, 17], ["infectious canine hepatitis", "PROBLEM", 63, 90], ["intranuclear inclusion bodies", "PROBLEM", 155, 184], ["canine myocarditis", "PROBLEM", 197, 215], ["canine parvovirus", "PROBLEM", 247, 264], ["necrosis", "OBSERVATION", 9, 17], ["infectious", "OBSERVATION", 63, 73], ["hepatitis", "OBSERVATION", 81, 90], ["intranuclear", "OBSERVATION_MODIFIER", 155, 167], ["inclusion bodies", "OBSERVATION", 168, 184], ["canine myocarditis", "OBSERVATION", 197, 215]]], ["If inclusions are absent, other causes of myocarditis include some strains of canine distemper virus and several protozoal diseases, in which organisms are usually demonstrable.237Transmission of canine parvovirus is probably via ingestion.", [["myocarditis", "DISEASE", 42, 53], ["canine distemper virus", "DISEASE", 78, 100], ["protozoal diseases", "DISEASE", 113, 131], ["canine parvovirus", "DISEASE", 196, 213], ["canine distemper virus", "ORGANISM", 78, 100], ["canine parvovirus", "ORGANISM", 196, 213], ["canine distemper virus", "SPECIES", 78, 100], ["canine parvovirus", "SPECIES", 196, 213], ["canine distemper virus", "SPECIES", 78, 100], ["canine parvovirus", "SPECIES", 196, 213], ["inclusions", "PROBLEM", 3, 13], ["myocarditis", "PROBLEM", 42, 53], ["canine distemper virus", "PROBLEM", 78, 100], ["several protozoal diseases", "PROBLEM", 105, 131], ["canine parvovirus", "PROBLEM", 196, 213], ["myocarditis", "OBSERVATION", 42, 53], ["canine", "OBSERVATION", 78, 84], ["distemper virus", "OBSERVATION", 85, 100], ["several", "OBSERVATION_MODIFIER", 105, 112], ["protozoal diseases", "OBSERVATION", 113, 131], ["canine parvovirus", "OBSERVATION", 196, 213]]], ["The possibility of in utero transmission also exists.v\" The distribution of the disease is worldwide.", [["the disease", "PROBLEM", 76, 87], ["distribution", "OBSERVATION_MODIFIER", 60, 72], ["disease", "OBSERVATION", 80, 87], ["worldwide", "OBSERVATION_MODIFIER", 91, 100]]], ["The original source of the virus remains speculative.\"", [["the virus", "PROBLEM", 23, 32], ["virus", "OBSERVATION", 27, 32]]], ["Both killed and attenuated vaccines are available to protect dogs from infection.237Population, when unchecked, increases in a geometrical ratio.", [["infection", "DISEASE", 71, 80], ["dogs", "ORGANISM", 61, 65], ["dogs", "SPECIES", 61, 65], ["attenuated vaccines", "TREATMENT", 16, 35], ["infection", "PROBLEM", 71, 80], ["a geometrical ratio", "TEST", 125, 144], ["infection", "OBSERVATION", 71, 80], ["increases", "OBSERVATION_MODIFIER", 112, 121]]], ["Subsistence increases only in an arithmetical ratio.Thomas MalthusThe office of surgeon has been considered as on a footing with that of chaplain, and the administering of medicine to be as inoffensive as giving religious instruction to those with whom we are contending.", [["an arithmetical ratio", "TEST", 30, 51], ["medicine", "TREATMENT", 172, 180], ["arithmetical ratio", "OBSERVATION", 33, 51]]]], "0c21b5dffc143af1bba56c9fa6fe78063e49cb97": [["Understanding the transmission dynamics of COVID-19 is crucial for evaluating its spread pattern, especially in metropolitan areas of China, as its spread could lead to secondary outbreaks.", [["COVID-19", "DNA", 43, 51], ["COVID", "TEST", 43, 48], ["its spread pattern", "PROBLEM", 78, 96], ["secondary outbreaks", "PROBLEM", 169, 188]]], ["In addition, the experiences gained and lessons learned from China have the potential to provide evidence to support other metropolitan areas and large cities outside China with their emerging cases.", [["large", "OBSERVATION_MODIFIER", 146, 151]]], ["We used data reported from January 24, 2020, to February 23, 2020 , to fit a model of infection, estimate the likely number of infections in four high-risk metropolitan areas based on the number of cases reported, and increase the understanding of the COVID-19 spread pattern.", [["infection", "DISEASE", 86, 95], ["infections", "DISEASE", 127, 137], ["infection", "PROBLEM", 86, 95], ["infections", "PROBLEM", 127, 137], ["the COVID", "TEST", 248, 257], ["infection", "OBSERVATION", 86, 95], ["likely", "UNCERTAINTY", 110, 116], ["number", "OBSERVATION_MODIFIER", 117, 123], ["infections", "OBSERVATION", 127, 137]]], ["A group of SEIR model statistical parameters were estimated using Markov chain Monte Carlo (MCMC) methods and fitting on the basis of reported data.", [["Markov chain Monte Carlo (MCMC) methods", "TREATMENT", 66, 105]]], ["For example, in Beijing, the predicted peak number of cases was 467 with a peak time of March 01, 2020; however, if the city were to implement different levels (strict, moderate, or weak) of travel restrictions or regulation measures, the estimation results showed that the transmission dynamics would change and that the peak number of cases would differ by between 54% and 209%.", [["regulation measures", "TREATMENT", 214, 233], ["the estimation", "TEST", 235, 249], ["peak", "OBSERVATION_MODIFIER", 39, 43], ["moderate", "OBSERVATION_MODIFIER", 169, 177]]], ["We concluded that public health interventions would reduce the risk of the spread of COVID-19 and that more rigorous control and prevention measures would effectively contain its further spread, and awareness of prevention should be enhancedINTRODUCTIONThe World Health Organization (WHO) named the virus \"2019 novel coronavirus disease\" (COVID-19) and the novel virus \"severe acute respiratory syndrome coronavirus 2\" (SARS-COV-2), which has attracted worldwide attention.", [["coronavirus disease", "DISEASE", 317, 336], ["acute respiratory syndrome coronavirus", "DISEASE", 377, 415], ["SARS", "DISEASE", 420, 424], ["coronavirus", "ORGANISM", 317, 328], ["virus \"severe acute respiratory syndrome coronavirus", "SPECIES", 363, 415], ["public health interventions", "TREATMENT", 18, 45], ["COVID", "TEST", 85, 90], ["prevention measures", "TREATMENT", 129, 148], ["the virus \"", "PROBLEM", 295, 306], ["novel coronavirus disease", "PROBLEM", 311, 336], ["COVID", "TEST", 339, 344], ["the novel virus \"severe acute respiratory syndrome coronavirus", "PROBLEM", 353, 415], ["severe", "OBSERVATION_MODIFIER", 370, 376], ["acute", "OBSERVATION_MODIFIER", 377, 382], ["respiratory syndrome", "OBSERVATION", 383, 403]]], ["The new coronavirus is a strain that has never been found in humans before.", [["coronavirus", "ORGANISM", 8, 19], ["humans", "ORGANISM", 61, 67], ["humans", "SPECIES", 61, 67], ["humans", "SPECIES", 61, 67], ["The new coronavirus", "PROBLEM", 0, 19], ["a strain", "PROBLEM", 23, 31], ["new", "OBSERVATION_MODIFIER", 4, 7], ["coronavirus", "OBSERVATION", 8, 19]]], ["This virus can cause an acute respiratory disease, and common signs of infection include respiratory symptoms, fever, cough, shortness of breath, and dyspnea.", [["respiratory", "ANATOMY", 30, 41], ["respiratory", "ANATOMY", 89, 100], ["acute respiratory disease", "DISEASE", 24, 49], ["infection", "DISEASE", 71, 80], ["respiratory symptoms", "DISEASE", 89, 109], ["fever", "DISEASE", 111, 116], ["cough", "DISEASE", 118, 123], ["shortness of breath", "DISEASE", 125, 144], ["dyspnea", "DISEASE", 150, 157], ["This virus", "PROBLEM", 0, 10], ["an acute respiratory disease", "PROBLEM", 21, 49], ["infection", "PROBLEM", 71, 80], ["respiratory symptoms", "PROBLEM", 89, 109], ["fever", "PROBLEM", 111, 116], ["cough", "PROBLEM", 118, 123], ["shortness of breath", "PROBLEM", 125, 144], ["dyspnea", "PROBLEM", 150, 157], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["respiratory disease", "OBSERVATION", 30, 49], ["infection", "OBSERVATION", 71, 80], ["dyspnea", "OBSERVATION", 150, 157]]], ["In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure, and even death (1) .INTRODUCTIONAccording to WHO situation reports, the outbreak of COVID-19 has led to 79,407 confirmed cases worldwide and 2,622 deaths in 32 countries as of February 24, 2020, of which 64,287 were from Hubei, China.", [["respiratory", "ANATOMY", 66, 77], ["kidney", "ANATOMY", 88, 94], ["infection", "DISEASE", 22, 31], ["pneumonia", "DISEASE", 42, 51], ["acute respiratory syndrome", "DISEASE", 60, 86], ["kidney failure", "DISEASE", 88, 102], ["death", "DISEASE", 113, 118], ["COVID-19", "CHEMICAL", 188, 196], ["deaths", "DISEASE", 251, 257], ["kidney", "ORGAN", 88, 94], ["infection", "PROBLEM", 22, 31], ["pneumonia", "PROBLEM", 42, 51], ["severe acute respiratory syndrome", "PROBLEM", 53, 86], ["kidney failure", "PROBLEM", 88, 102], ["COVID", "TEST", 188, 193], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["cases", "OBSERVATION", 15, 20], ["infection", "OBSERVATION", 22, 31], ["pneumonia", "OBSERVATION", 42, 51], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory syndrome", "OBSERVATION", 66, 86], ["kidney", "ANATOMY", 88, 94], ["failure", "OBSERVATION", 95, 102]]], ["With the continuously increasing number of cases, understanding the spread pattern of COVID-19 and monitoring spikes in the number of cases are crucial steps in providing evidence that could guide public health intervention strategies and healthcare policy making.INTRODUCTIONSeveral mathematical models and data analysis approaches attempting to estimate the transmission of COVID-19 have been recently reported (2) (3) (4) .", [["COVID-19", "CHEMICAL", 376, 384], ["COVID-19", "DNA", 376, 384], ["COVID", "TEST", 86, 91], ["data analysis", "TEST", 308, 321], ["COVID", "TEST", 376, 381]]], ["Public health interventions and transportation restriction effects for disease transmission have also been evaluated in some studies (5, 6) .", [["Public health interventions", "TREATMENT", 0, 27], ["transportation restriction effects", "TREATMENT", 32, 66], ["disease transmission", "PROBLEM", 71, 91], ["some studies", "TEST", 120, 132]]], ["Some studies indicated that public intervention measures greatly mitigate the final size of the epidemic, and shift the turning point about 24 days before the turning point without these measures (7) .", [["Some studies", "TEST", 0, 12], ["public intervention", "TREATMENT", 28, 47], ["final", "OBSERVATION_MODIFIER", 78, 83], ["size", "OBSERVATION_MODIFIER", 84, 88], ["epidemic", "OBSERVATION_MODIFIER", 96, 104]]], ["And a report from Imperial College COVID-19 Response Team concluded that the intensive intervention or something equivalently effective, such as combining home isolation of suspect cases, home quarantine of those living in the same household as suspect cases, and social distancing of the elderly and others at most risk of severe disease, could reduce transmission.", [["the intensive intervention", "TREATMENT", 73, 99], ["severe disease", "PROBLEM", 324, 338], ["severe", "OBSERVATION_MODIFIER", 324, 330], ["disease", "OBSERVATION", 331, 338]]], ["However, this would need to be maintained until a vaccine becomes available, and the team also predicted that transmission will quickly rebound if interventions are relaxed, so it requires the combination of multiple interventions to have a substantial impact on transmission (9) .", [["a vaccine", "TREATMENT", 48, 57], ["interventions", "TREATMENT", 147, 160], ["multiple interventions", "TREATMENT", 208, 230], ["substantial", "OBSERVATION_MODIFIER", 241, 252], ["impact", "OBSERVATION_MODIFIER", 253, 259]]], ["In order to predict the outbreak size and time, researchers have published many different results for forecasting when the outbreak will peak in different areas (10, 11) .", [["the outbreak", "PROBLEM", 119, 131], ["size", "OBSERVATION_MODIFIER", 33, 37]]], ["These models are certainly useful to understand the emerging trends of COVID-19.", [["COVID-19", "CHEMICAL", 71, 79], ["COVID", "TEST", 71, 76]]], ["Due to barriers, such as the disease incubation period, asymptomatic infection, diagnosis testing capacity, overloaded medical staff, and complicated reporting processes, there can be delays or missed reporting in this evolving situation regarding the confirmation of cases.", [["infection", "DISEASE", 69, 78], ["asymptomatic infection", "PROBLEM", 56, 78], ["asymptomatic", "OBSERVATION_MODIFIER", 56, 68], ["infection", "OBSERVATION", 69, 78]]], ["Furthermore, the adopted models have mostly been complicated with many pre-settings or assumptions or parameter values that are likely not accurate.", [["many pre-settings", "TREATMENT", 66, 83], ["parameter values", "TEST", 102, 118], ["likely not", "UNCERTAINTY", 128, 138]]], ["As a result, those studies achieved different prediction results by using different methods and datasets.INTRODUCTIONTo achieve a relatively objective judgment, given that that this new disease and complicated situation has many unknown factors, we used mathematical modeling methods to characterize COVID-19 transmission and used multiple datasets for ensuring the data reliability.", [["those studies", "TEST", 13, 26], ["this new disease", "PROBLEM", 177, 193], ["mathematical modeling methods", "TEST", 254, 283], ["COVID", "TEST", 300, 305], ["the data reliability", "TEST", 362, 382]]], ["Therefore, we investigated and collected data from four sources, including released data and official daily reports from commercial technology companies, academic institutes, authorities, or local healthcare commissions, and the World Health Organization, to minimize the resulting errors caused by potentially biased single data sources.", [["the resulting errors", "PROBLEM", 268, 288]]], ["The data were obtained from the Beijing Municipal Health Commission (BMHC) (13), Shanghai Municipal Health and Family Planning Commission (SMHFPC) (14) , Health Commission of Guangdong Province (15) , National Bureau of Statistics of China (NBSC) (16), Baidu Migration Big Data Platform (BMBDP) (17) , Center for Systems Science and Engineering (CSSE) of Johns Hopkins University (18) , and WHO coronavirus disease (COVID-2019) situation reports (19) .", [["coronavirus disease", "DISEASE", 395, 414], ["WHO coronavirus disease", "PROBLEM", 391, 414]]], ["Considering that the cases detected in these four cities were all imported or secondary transmission cases, and based on the reported data available after January 20, 2020, Chinese authorities have implemented prevention measures in these cities to contain the outbreak and prevent the disease from spreading; thus, we considered the secondary transmission pattern of COVID-2019 to be different than the early spread pattern in Wuhan, where the virus was rampantly transmitted without any prevention measures.", [["the disease", "PROBLEM", 282, 293], ["the virus", "PROBLEM", 441, 450], ["disease", "OBSERVATION", 286, 293]]], ["Therefore, we collected data from January 24, 2020 (Chinese New Year's Eve) to February 23, 2020 to give an overall objective estimation of COVID-19 development in four high-risk metropolitan areas of China: Beijing, Shanghai, Guangzhou, and Shenzhen.", [["COVID", "TEST", 140, 145]]], ["We estimated how COVID-19 human-to-human transmission occurred in these large cities, which have developed considerable cases.", [["human", "ORGANISM", 26, 31], ["human", "ORGANISM", 35, 40], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 35, 40], ["COVID", "TEST", 17, 22], ["large", "OBSERVATION_MODIFIER", 72, 77]]], ["We further used these estimates to forecast the potential risks and development trends of these four metropolitan areas inside China.METHODSTo evaluate the COVID-19 spread pattern and estimate its transmission in four metropolitan areas, we used an adjusted SEIR model with data.", [["COVID-19", "DNA", 156, 164], ["the COVID", "TEST", 152, 161], ["an adjusted SEIR model", "TREATMENT", 246, 268]]], ["We only considered human-to-human transmission in our models.Adjusted SEIR Model for COVID-19The SEIR model is a deterministic metapopulation transmission model in which the population is divided into four classes: S (susceptible, people who are likely to be infected), E (exposed, people who are exposed), I (infectious, people who are infected), and R (removed, recovered and dead persons).", [["human", "ORGANISM", 19, 24], ["human", "ORGANISM", 28, 33], ["people", "ORGANISM", 231, 237], ["people", "ORGANISM", 282, 288], ["people", "ORGANISM", 322, 328], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 28, 33], ["people", "SPECIES", 231, 237], ["people", "SPECIES", 282, 288], ["people", "SPECIES", 322, 328], ["persons", "SPECIES", 383, 390], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 28, 33], ["COVID", "TEST", 85, 90], ["infected", "OBSERVATION", 259, 267]]], ["We assumed that the epidemic risk started with infectious cases on February 3, 2020, when authorities announced that people were returning to work after the Chinese Spring Festival holiday.", [["people", "ORGANISM", 117, 123], ["people", "SPECIES", 117, 123]]], ["In our estimation, the entire population was initially susceptible since COVID-19 is an emerging new infectious disease and not all people have immunity against it.", [["infectious disease", "DISEASE", 101, 119], ["people", "ORGANISM", 132, 138], ["people", "SPECIES", 132, 138], ["COVID-19", "SPECIES", 73, 81], ["COVID", "TEST", 73, 78], ["an emerging new infectious disease", "PROBLEM", 85, 119], ["new", "OBSERVATION_MODIFIER", 97, 100], ["infectious", "OBSERVATION", 101, 111]]], ["In January (before Chinese New Year), there were an estimated 3.246, 2.847, 3.430, and 3.271 million people flown out from Beijing, Shanghai, Guangzhou, and Shenzhen, respectively.", [["people", "SPECIES", 101, 107]]], ["We assumed that the median incubation period was 5-6 days (ranging from 0-14 days) based on the WHO report (20) .Adjusted SEIR Model for COVID-19Based on the basic SEIR model, we further considered the influence of multiple factors on the transmission pattern as the situation unfolded, including public health intervention measures, people's self-protection behaviors, the diagnosis rate, population flow, etc.Adjusted SEIR Model for COVID-19Assuming that public health interventions contributed to the control of the dynamics of the epidemic, we incorporated a parameter that indicates the changes in the population flow into the model.", [["people", "ORGANISM", 334, 340], ["people", "SPECIES", 334, 340], ["COVID", "TEST", 137, 142], ["public health intervention measures", "TREATMENT", 297, 332], ["the diagnosis rate", "TEST", 370, 388], ["COVID", "TREATMENT", 435, 440], ["public health interventions", "TREATMENT", 457, 484], ["the changes", "PROBLEM", 588, 599], ["population flow", "OBSERVATION", 607, 622]]], ["According to the inflow index, outflow index, and urban daily adjusted index of the travel intensity from the Baidu Migration Big Data Platform, for the period from January 24, 2020 to February 23, 2020, we inferred that people's activity was obviously lower than the normal level for the same period last year.", [["people", "ORGANISM", 221, 227], ["people", "SPECIES", 221, 227], ["the inflow index", "TEST", 13, 29], ["outflow index", "TEST", 31, 44], ["outflow index", "OBSERVATION", 31, 44]]], ["Furthermore, considering the Spring Festival population flow and those returning to work after the holiday (officially announced as February 3, 2020), we regarded that the risk for FIGURE 1 | SEIR model. these four metropolitan areas grows with the inflow population increase starting on February 3, 2020, and the four cities executed 14 days quarantine policy for incoming travelers during that time, the spread was contained strictly, so an average introduced number of cases were counted into the model.Adjusted SEIR Model for COVID-19We also estimated the parameter values within these cities using the MCMC method.", [["FIGURE", "TEST", 181, 187], ["COVID", "TEST", 530, 535], ["the MCMC method", "TREATMENT", 603, 618], ["inflow", "OBSERVATION_MODIFIER", 249, 255], ["population", "OBSERVATION_MODIFIER", 256, 266], ["increase", "OBSERVATION_MODIFIER", 267, 275]]], ["Considering the possible complex influencing factors, we proposed an adjusted SEIR model for COVID-19 estimation, as displayed in Figure 2 .Adjusted SEIR Model for COVID-19In the adjusted SEIR model, we considered the inflow of the city's population, so the total number of people was not fixed, and the population was divided into seven classes: S (susceptible, people who are likely to be infected), E (exposed, people who are exposed), I (infectious, people who are infected), R (recovered and dead persons), Sq (quarantined susceptible persons), Eq (isolated exposed persons), and Iq (isolated infected persons).", [["people", "ORGANISM", 274, 280], ["people", "ORGANISM", 363, 369], ["people", "ORGANISM", 414, 420], ["people", "ORGANISM", 454, 460], ["persons", "ORGANISM", 571, 578], ["persons", "ORGANISM", 607, 614], ["people", "SPECIES", 274, 280], ["people", "SPECIES", 363, 369], ["people", "SPECIES", 414, 420], ["people", "SPECIES", 454, 460], ["persons", "SPECIES", 502, 509], ["persons", "SPECIES", 540, 547], ["persons", "SPECIES", 571, 578], ["persons", "SPECIES", 607, 614], ["an adjusted SEIR model", "TREATMENT", 66, 88], ["COVID", "TEST", 93, 98], ["COVID", "TEST", 164, 169], ["infected", "OBSERVATION", 391, 399]]], ["The transmission dynamics are governed by the following equations:Adjusted SEIR Model for COVID-19where q is the quarantined proportion of exposed individuals, \u03b2 is the transmission probability per contact, c is the contact rate which defines how many people are contacted with an infected person per day, and i is the estimated infected people within the inflow population each day.", [["people", "ORGANISM", 252, 258], ["people", "ORGANISM", 338, 344], ["people", "SPECIES", 252, 258], ["person", "SPECIES", 290, 296], ["people", "SPECIES", 338, 344], ["COVID", "TEST", 90, 95], ["infected", "OBSERVATION", 329, 337]]], ["The quarantined infected people moved to the compartment E q at a rate of \u03b2cq, while the quarantined uninfected people moved to the compartment S q at a rate of (1-\u03b2)cq.", [["people", "ORGANISM", 25, 31], ["\u03b2cq", "GENE_OR_GENE_PRODUCT", 74, 77], ["people", "ORGANISM", 112, 118], ["E q", "DNA", 57, 60], ["people", "SPECIES", 25, 31], ["people", "SPECIES", 112, 118], ["infected", "OBSERVATION_MODIFIER", 16, 24], ["people", "OBSERVATION", 25, 31], ["compartment", "ANATOMY", 132, 143]]], ["Those who were not quarantined, if infected, moved to compartment E at a rate of \u03b2c(1 \u2212 q). \u03b8 is the transmission capability between the latent and the infected population.", [["\u03b8", "GENE_OR_GENE_PRODUCT", 92, 93], ["infected", "PROBLEM", 35, 43], ["the infected population", "PROBLEM", 148, 171], ["latent", "OBSERVATION_MODIFIER", 137, 143], ["infected", "OBSERVATION_MODIFIER", 152, 160], ["population", "OBSERVATION", 161, 171]]], ["According to the reported results of related work, the transmission capability of the people in the incubation period and the diagnosed infected patients are similar (21), we assume that \u03b8 = 1. \u03bb is the transition rate from the quarantined to susceptible population, \u03c3 is the transition rate from the exposed to the infected population, \u03b1 is the mortality rate, \u03b4 I is the transition rate from the infected population to the quarantined infected population, and \u03b3 I is the recovery rate of the infected population. \u03b4 q is the transition rate from the quarantined exposed population to the quarantined infected population, and \u03b3 H is the recovery rate of the quarantined infected population.Parameter Estimate MethodsThe MCMC method is a commonly used algorithm in modern statistical calculations.", [["people", "ORGANISM", 86, 92], ["patients", "ORGANISM", 145, 153], ["\u03b4 I", "GENE_OR_GENE_PRODUCT", 362, 365], ["\u03b3 I", "GENE_OR_GENE_PRODUCT", 462, 465], ["\u03b4 q", "GENE_OR_GENE_PRODUCT", 515, 518], ["\u03b3 H", "GENE_OR_GENE_PRODUCT", 626, 629], ["\u03b3 I", "PROTEIN", 462, 465], ["people", "SPECIES", 86, 92], ["patients", "SPECIES", 145, 153], ["the transition rate", "PROBLEM", 199, 218], ["the transition rate", "PROBLEM", 272, 291], ["the transition rate", "PROBLEM", 369, 388], ["the infected population", "PROBLEM", 490, 513], ["the transition rate", "PROBLEM", 522, 541], ["the quarantined infected population", "PROBLEM", 654, 689], ["infected", "OBSERVATION", 136, 144], ["infected", "OBSERVATION_MODIFIER", 316, 324], ["population", "OBSERVATION", 325, 335], ["infected", "OBSERVATION_MODIFIER", 398, 406], ["infected", "OBSERVATION_MODIFIER", 437, 445], ["population", "OBSERVATION", 446, 456], ["infected", "OBSERVATION_MODIFIER", 494, 502], ["population", "OBSERVATION", 503, 513], ["infected", "OBSERVATION_MODIFIER", 601, 609], ["population", "OBSERVATION", 610, 620], ["infected", "OBSERVATION_MODIFIER", 670, 678], ["population", "OBSERVATION", 679, 689]]], ["This algorithm provides an effective tool for establishing statistical models and is widely used in Bayesian calculations of complex statistical models (22) .", [["This algorithm", "TEST", 0, 14]]], ["We used the MCMC method and Metropolis-Hastings(MH) algorithm sampling (23) with a normal distribution as the recommended distribution, estimated the parameters of the modified SEIR model to obtain the baseline estimation of parameters, incorporated the data collected from infectious disease reports into the above statistical inference, and simulated the process of infectious disease transmission to further fix some parameters on the basis of fitting reported data.", [["SEIR model", "CELL_LINE", 177, 187], ["algorithm sampling", "TEST", 52, 70], ["infectious disease transmission", "TREATMENT", 368, 399], ["infectious", "OBSERVATION", 368, 378]]], ["Using Beijing as an example, the parameter estimates and initial values of the SEIR model are listed in Table 1 .Parameter Estimate MethodsIn addition, to simulate the contact rate for model estimation, we used urban travel index data from Baidu, a major internet company in China that hosts the popular navigator app Baidu Maps, which indirectly monitors the real-time urban travel intensity and population flow.", [["the parameter estimates", "TEST", 29, 52], ["model estimation", "TEST", 185, 201], ["population flow", "TEST", 397, 412], ["population flow", "OBSERVATION", 397, 412]]], ["The Baidu index of travel intensity and population flow was converted into the corresponding coefficients for the contact rate and the quarantined susceptible population.", [["population flow", "TEST", 40, 55], ["the contact rate", "TEST", 110, 126], ["the quarantined susceptible population", "PROBLEM", 131, 169], ["index", "OBSERVATION_MODIFIER", 10, 15], ["population flow", "OBSERVATION", 40, 55]]], ["In terms of the Baidu index, we simulated people's activity level by comparing our observed period (under strict interventions) with a normal level in the same period last year.", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["strict interventions", "TREATMENT", 106, 126]]], ["We also consider the assumption scenario that when people return back to work (limited interventions), accordingly, we added the coefficients (0.6c, 0.8c, c, 1.5c, 2c) for the baseline contact rate to compare different effectiveness of interventions.", [["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["interventions", "TREATMENT", 236, 249]]], ["Similarly, the coefficients were added to baseline quarantine proportion (0.6q, 0.8q, q, 1.5q, 2q).Basic Reproduction Number R 0 EstimatesAt the onset, when all people are susceptible, R 0 is defined as the average number of new infections directly caused by a case in a population of people who are all susceptible.", [["infections", "DISEASE", 229, 239], ["people", "ORGANISM", 161, 167], ["people", "ORGANISM", 285, 291], ["people", "SPECIES", 161, 167], ["people", "SPECIES", 285, 291], ["baseline quarantine proportion", "TREATMENT", 42, 72], ["new infections", "PROBLEM", 225, 239], ["new", "OBSERVATION_MODIFIER", 225, 228], ["infections", "OBSERVATION", 229, 239]]], ["Given the model structure includes quarantine and isolation, we used the next generation matrix to derive a formula for the basic reproduction number after public health interventions were executed, the principal eigenvalue of the next generation matrix is the expectation of population growth and the equation is as follows and the parameter definition is same with adjusted SEIR model.Data CharacterizationTo characterize the overall epidemic size and dynamics, Figure 3 shows the epidemic curve of COVID-19 cases identified in Beijing, Shanghai, Guangzhou, and Shenzhen from January 24, 2020 to February 23, 2020.Adjusted SEIR Model EstimationWe summarized and interpreted the transmission dynamics of COVID-19 in the four metropolitan areas.", [["matrix", "CELLULAR_COMPONENT", 247, 253], ["isolation", "TREATMENT", 50, 59], ["the next generation matrix", "TREATMENT", 69, 95], ["a formula", "TREATMENT", 106, 115], ["public health interventions", "TREATMENT", 156, 183], ["population growth", "PROBLEM", 276, 293], ["the equation", "TEST", 298, 310], ["the parameter definition", "TEST", 329, 353], ["adjusted SEIR model", "TREATMENT", 367, 386], ["the epidemic curve", "TEST", 479, 497], ["COVID", "TEST", 501, 506], ["COVID", "TEST", 705, 710], ["overall", "OBSERVATION_MODIFIER", 428, 435], ["epidemic", "OBSERVATION_MODIFIER", 436, 444], ["size", "OBSERVATION_MODIFIER", 445, 449]]], ["The results are based on an assumption of no further imported cases to these cities since China implemented strong regulation measures during the observation period.", [["strong regulation measures", "TREATMENT", 108, 134]]], ["Based on our observations from the data shown in Table 2 and Figure 5 below, we also found that the number of infected individuals changed with different levels of public health interventions and that strict interventions could decrease the peak number of infected individuals compared with the scenario of weak interventions; accordingly, we used different contact rates to reflect the different levels of interventions.", [["the data", "TEST", 31, 39], ["infected individuals", "PROBLEM", 110, 130], ["public health interventions", "TREATMENT", 164, 191], ["strict interventions", "TREATMENT", 201, 221], ["infected individuals", "PROBLEM", 256, 276], ["weak interventions", "TREATMENT", 307, 325], ["interventions", "TREATMENT", 407, 420], ["infected", "OBSERVATION", 110, 118], ["peak", "OBSERVATION_MODIFIER", 241, 245], ["number", "OBSERVATION_MODIFIER", 246, 252], ["infected", "OBSERVATION", 256, 264]]], ["The baseline contact rate was derived by the MCMC method, and the results show that reducing the contact rate either persistently decreased the peak value or could delay the peak.", [["The baseline contact rate", "TEST", 0, 25], ["the contact rate", "TEST", 93, 109]]], ["In addition, with strict public intervention, the number of infected individuals eventually decreased, and the peak appeared sooner than it would with weak intervention methods.", [["individuals", "ORGANISM", 69, 80], ["strict public intervention", "TREATMENT", 18, 44], ["infected individuals", "PROBLEM", 60, 80], ["weak intervention methods", "TREATMENT", 151, 176], ["infected", "OBSERVATION", 60, 68], ["decreased", "OBSERVATION_MODIFIER", 92, 101]]], ["After February 3, 2020, as people returned to work after a holiday, many people returned to these cities, which was inferred from the Baidu transportation index.", [["people", "ORGANISM", 27, 33], ["people", "ORGANISM", 73, 79], ["people", "SPECIES", 27, 33], ["people", "SPECIES", 73, 79]]], ["Accordingly, the number of infected individuals increased compared with the scenario of a decreased contact rate (0.8c, 0.6c).Adjusted SEIR Model EstimationIn addition, we compared the transmission dynamics with different quarantined proportion of exposed individuals, As shown in Table 3 and Figure 6 , which reflects the contact tracing capability and management efforts of local governments, and the results show that reducing the quarantined proportion of exposed individuals (0.8q, 0.6q) led to an increase in the peak value and delayed the peak time.", [["infected individuals", "PROBLEM", 27, 47], ["a decreased contact rate", "PROBLEM", 88, 112], ["exposed individuals", "PROBLEM", 460, 479], ["the peak value", "TEST", 515, 529], ["infected", "OBSERVATION_MODIFIER", 27, 35], ["individuals", "OBSERVATION_MODIFIER", 36, 47], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["decreased", "OBSERVATION_MODIFIER", 90, 99], ["increase", "OBSERVATION_MODIFIER", 503, 511]]], ["Conversely, the peak value decreased and an earlier peak time occurred with a higher quarantined proportion of exposed individuals (2q, 1.5q).R 0 Estimation ResultsWe used the MCMC method to fit the model and adopted an adaptive MH algorithm to carry out the MCMC procedure.", [["the peak value", "TEST", 12, 26], ["the MCMC method", "TREATMENT", 172, 187], ["an adaptive MH algorithm", "TREATMENT", 217, 241], ["the MCMC procedure", "TREATMENT", 255, 273], ["peak", "OBSERVATION_MODIFIER", 16, 20], ["decreased", "OBSERVATION_MODIFIER", 27, 36]]], ["As a result, we inferred R 0 = 2.91, 2.78, 2.02, and 1.75 for Beijing, Shanghai, Guangzhou, and Shenzhen, respectively.DISCUSSIONSOur analysis results strongly demonstrate that reducing secondary infections among close contacts would effectively limit human-to-human transmission, and public health measures, such as the rapid identification of cases, tracing and following up with people who had contact with an infected person, infection prevention and control in health care settings, and the implementation of health measures for travelers, can greatly prevent further spread of the disease.", [["infections", "DISEASE", 196, 206], ["infection", "DISEASE", 430, 439], ["human", "ORGANISM", 252, 257], ["human", "ORGANISM", 261, 266], ["people", "ORGANISM", 382, 388], ["human", "SPECIES", 252, 257], ["human", "SPECIES", 261, 266], ["people", "SPECIES", 382, 388], ["person", "SPECIES", 422, 428], ["human", "SPECIES", 252, 257], ["human", "SPECIES", 261, 266], ["reducing secondary infections", "PROBLEM", 177, 206], ["tracing", "TEST", 352, 359], ["infection prevention", "TREATMENT", 430, 450], ["health measures", "TREATMENT", 514, 529], ["the disease", "PROBLEM", 583, 594], ["infections", "OBSERVATION", 196, 206], ["infection", "OBSERVATION", 430, 439], ["disease", "OBSERVATION", 587, 594]]], ["The documented COVID-19 reproduction numbers range from 2.0 to 4.9 (6, 11, 25) , which are based on cases that developed during different transmission phases and in different areas.", [["The documented COVID", "TEST", 0, 20]]], ["For instance, the R 0 in Wuhan was obviously higher than that in other cities during the timeframe analyzed.", [["higher", "OBSERVATION_MODIFIER", 45, 51]]], ["Furthermore, after implementing the prevention measures employed by the Chinese government and local authorities, we regarded the inferred R 0 results of the four cities as reasonable and interpretable.DISCUSSIONSIn this study, we aimed to monitor COVID-19 trends after cases were imported into other cities and estimate the spread pattern by mathematical modeling, which can be helpful for evaluating the potential risk and severity of new outbreaks.", [["this study", "TEST", 216, 226], ["COVID", "TEST", 248, 253], ["new outbreaks", "PROBLEM", 437, 450], ["new", "OBSERVATION_MODIFIER", 437, 440], ["outbreaks", "OBSERVATION", 441, 450]]], ["The results of our study show that, for four metropolitan areas of China, the containment measures were an effective control at that time; however, it is imperative to raise awareness in the population and prevent potential outbreak risks going forward.", [["our study", "TEST", 15, 24], ["the containment measures", "TREATMENT", 74, 98]]], ["The study has limitations.", [["The study", "TEST", 0, 9]]], ["The present reported data are insufficient to understand the full epidemiological pattern of COVID-19 transmission and new potential outbreaks.", [["COVID", "TEST", 93, 98], ["new", "OBSERVATION_MODIFIER", 119, 122], ["potential", "OBSERVATION_MODIFIER", 123, 132], ["outbreaks", "OBSERVATION", 133, 142]]], ["For example, the estimates in this manuscript have a certain degree of uncertainty and delays due to the limitations in reporting mechanisms over the course of the natural history of the cases, the impact of other potential asymptomatic cases, and some unreported cases.", [["certain degree", "OBSERVATION_MODIFIER", 53, 67]]], ["Some studies were conducted with the assumption that a small fraction, 20%, were not reported (7) and others reported the estimated asymptomatic proportion was 17.9% (26) or 60% (21) .", [["Some studies", "TEST", 0, 12], ["a small fraction", "TEST", 53, 69], ["small", "OBSERVATION_MODIFIER", 55, 60]]], ["Evidently, such asymptomatic infectious cases are not fully reported by current testing method.", [["such asymptomatic infectious cases", "PROBLEM", 11, 45], ["current testing method", "TEST", 72, 94], ["asymptomatic", "OBSERVATION_MODIFIER", 16, 28], ["infectious", "OBSERVATION", 29, 39]]], ["However, some studies suggested crowdsourced data could be FIGURE 6 | Infected population curve with different quarantined proportion of exposed individuals for four cities.DISCUSSIONScompiled and analyzed as an complementation of officially released data, which could perhaps help in improving the analysis results (27) (28) (29) .DISCUSSIONSAs concluded from the WHO-China Joint Mission report (30), the COVID-19 transmission dynamics are inherently contextual, as are the dynamics for any outbreak, and people worldwide need to work together to defend against this disease.", [["people", "ORGANISM", 506, 512], ["people", "SPECIES", 506, 512], ["some studies", "TEST", 9, 21], ["crowdsourced data", "PROBLEM", 32, 49], ["Infected population curve", "TEST", 70, 95], ["the analysis", "TEST", 295, 307], ["the COVID", "TEST", 402, 411], ["this disease", "PROBLEM", 563, 575], ["Joint", "ANATOMY", 375, 380]]], ["To do this, it is necessary to: (1) enhance the understanding of the evolving COVID-19 and the nature and the impact of ongoing containment measures; (2) share knowledge on the COVID-19 response and preparedness measures being implemented in countries affected by or at risk of importations of COVID-19; (3) generate recommendations for adjusting COVID-19 containment and response measures in China and internationally; and (4) establish priorities for a collaborative program of work, research, and development to address critical gaps in knowledge, responses, readiness tools, and strategies.DISCUSSIONSAs a consequence of our study, we concluded that the outbreak could be greatly reduced by strict public health interventions.", [["the evolving COVID", "TEST", 65, 83], ["ongoing containment measures", "TREATMENT", 120, 148], ["the COVID", "TEST", 173, 182], ["preparedness measures", "TREATMENT", 199, 220], ["adjusting COVID-19 containment", "TREATMENT", 337, 367], ["our study", "TEST", 625, 634], ["strict public health interventions", "TREATMENT", 695, 729], ["reduced", "OBSERVATION_MODIFIER", 684, 691]]], ["The public intervention strategies and implemented protection measures conducted in these four areas may help provide epidemiological suggestions to governments that guide measures for the international cases that are rapidly emerging.DATA AVAILABILITY STATEMENTThe datasets analyzed in this article are not publicly available because they are kept by a private affiliation (Peking Union Medical College Hospital).", [["The public intervention strategies", "TREATMENT", 0, 34], ["implemented protection measures", "TREATMENT", 39, 70]]], ["Requests to access the datasets should be directed to Na Hong (hongna@dchealth.com) or Yun Long (ly_icu@aliyun.com).AUTHOR CONTRIBUTIONSLS, NH, and XZ contributed equally.", [["Na", "CHEMICAL", 54, 56], ["Na", "CHEMICAL", 54, 56], ["the datasets", "TREATMENT", 19, 31]]], ["FC and LH collected and cleaned the data.", [["FC", "CELL", 0, 2], ["LH", "TEST", 7, 9], ["LH", "ANATOMY", 7, 9]]], ["JH, YM, and HJ were responsible for data modeling and analysis.", [["data modeling", "TEST", 36, 49], ["analysis", "TEST", 54, 62], ["HJ", "ANATOMY", 12, 14]]]], "PMC7395576": [], "PMC7241574": [["METHODSWe performed a rapid systematic review to evaluate the current evidence related to the presence of SARS-CoV-2 in breast milk from pregnant women with COVID-19.", [["breast milk", "ANATOMY", 120, 131], ["SARS", "DISEASE", 106, 110], ["breast milk", "DISEASE", 120, 131], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 106, 116], ["breast milk", "ORGANISM_SUBSTANCE", 120, 131], ["women", "ORGANISM", 146, 151], ["women", "SPECIES", 146, 151], ["SARS-CoV", "SPECIES", 106, 114], ["SARS", "PROBLEM", 106, 110], ["COVID", "TEST", 157, 162], ["breast", "ANATOMY", 120, 126]]], ["The study was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines (7), but given emergency-need for this review, PROSPERO registration was not sought.", [["The study", "TEST", 0, 9], ["Systematic reviews", "TEST", 77, 95], ["PROSPERO registration", "TEST", 181, 202]]], ["Using terms related to coronavirus, we searched in PubMed, Web of Science, Scopus, China National Knowledge Infrastructure database, and grey literature (Google Scholar and preprint repositories) to identify studies reporting results of RT-PCR tests on breast milk in pregnant women with laboratory-confirmed SARS-CoV-2 infection.", [["breast milk", "ANATOMY", 253, 264], ["breast milk", "DISEASE", 253, 264], ["SARS-CoV-2 infection", "DISEASE", 309, 329], ["coronavirus", "ORGANISM", 23, 34], ["breast milk", "ORGANISM_SUBSTANCE", 253, 264], ["women", "ORGANISM", 277, 282], ["SARS-CoV-2", "ORGANISM", 309, 319], ["women", "SPECIES", 277, 282], ["CoV-2", "SPECIES", 314, 319], ["SARS-CoV-2", "SPECIES", 309, 319], ["coronavirus", "PROBLEM", 23, 34], ["RT-PCR tests", "TEST", 237, 249], ["breast milk", "TREATMENT", 253, 264], ["SARS", "PROBLEM", 309, 313], ["CoV", "PROBLEM", 314, 317], ["2 infection", "PROBLEM", 318, 329], ["breast", "ANATOMY", 253, 259], ["infection", "OBSERVATION", 320, 329]]], ["Searches were performed up to March 30, 2020 and updated on April 21, 2020.RESULTS AND DISCUSSIONWe found eight studies (8\u201315) analyzing the presence of SARS-CoV-2 RNA in the breast milk of 24 pregnant women with COVID-19 during the third trimester of pregnancy (Table 1).", [["breast milk", "ANATOMY", 175, 186], ["SARS", "DISEASE", 153, 157], ["COVID-19", "CHEMICAL", 213, 221], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 153, 163], ["breast milk", "ORGANISM_SUBSTANCE", 175, 186], ["women", "ORGANISM", 202, 207], ["SARS-CoV-2 RNA", "RNA", 153, 167], ["women", "SPECIES", 202, 207], ["eight studies", "TEST", 106, 119], ["SARS", "PROBLEM", 153, 157], ["COVID", "TEST", 213, 218], ["breast", "ANATOMY", 175, 181]]], ["All patients had fever and/or symptoms of acute respiratory illness and chest computed tomography (CT) images indicative of COVID-19 pneumonia.", [["respiratory", "ANATOMY", 48, 59], ["fever", "DISEASE", 17, 22], ["acute respiratory illness", "DISEASE", 42, 67], ["pneumonia", "DISEASE", 133, 142], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["fever", "PROBLEM", 17, 22], ["symptoms", "PROBLEM", 30, 38], ["acute respiratory illness", "PROBLEM", 42, 67], ["chest computed tomography", "TEST", 72, 97], ["CT) images", "TEST", 99, 109], ["COVID", "TEST", 124, 129], ["pneumonia", "PROBLEM", 133, 142], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["respiratory", "ANATOMY", 48, 59], ["chest", "ANATOMY", 72, 77], ["pneumonia", "OBSERVATION", 133, 142]]], ["Most pregnant women had cesarean delivery (91.7%) and two neonates had low birthweight (< 2,500 g).", [["low birthweight", "DISEASE", 71, 86], ["women", "ORGANISM", 14, 19], ["neonates", "ORGANISM", 58, 66], ["women", "SPECIES", 14, 19], ["cesarean delivery", "TREATMENT", 24, 41], ["low birthweight", "PROBLEM", 71, 86]]], ["Biological samples collected immediately after birth from upper respiratory tract (throat or nasopharyngeal) of neonates and placental tissues showed negative results for the presence SARS-CoV-2 by RT-PCR test.", [["samples", "ANATOMY", 11, 18], ["upper respiratory tract", "ANATOMY", 58, 81], ["throat", "ANATOMY", 83, 89], ["nasopharyngeal", "ANATOMY", 93, 107], ["placental tissues", "ANATOMY", 125, 142], ["upper respiratory", "ORGANISM_SUBDIVISION", 58, 75], ["tract", "ORGANISM_SUBDIVISION", 76, 81], ["throat", "ORGANISM_SUBDIVISION", 83, 89], ["nasopharyngeal", "CANCER", 93, 107], ["neonates", "ORGANISM", 112, 120], ["placental tissues", "TISSUE", 125, 142], ["SARS-CoV", "SPECIES", 184, 192], ["Biological samples", "TEST", 0, 18], ["upper respiratory tract (throat or nasopharyngeal) of neonates and placental tissues", "TEST", 58, 142], ["CoV", "TEST", 189, 192], ["PCR test", "TEST", 201, 209], ["upper", "ANATOMY_MODIFIER", 58, 63], ["respiratory tract", "ANATOMY", 64, 81], ["throat", "ANATOMY", 83, 89], ["nasopharyngeal", "ANATOMY", 93, 107], ["placental tissues", "ANATOMY", 125, 142]]], ["In addition, no breast milk samples were positive for SARS-CoV-2.", [["breast milk samples", "ANATOMY", 16, 35], ["breast milk samples", "ORGANISM_SUBSTANCE", 16, 35], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 54, 64], ["SARS-CoV", "SPECIES", 54, 62], ["breast milk samples", "TEST", 16, 35], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62], ["no", "UNCERTAINTY", 13, 15], ["breast", "ANATOMY", 16, 22]]], ["In three studies (10,12,13) there was a clear recommendation for mother\u2019s to not breastfeed their children despite the lack of evidence on the potential viral transmission via breast milk.RESULTS AND DISCUSSIONAs the coronavirus pandemic takes hold, pregnant women infected with SARS-CoV-2 experience fear and uncertainties regarding the care of their child.", [["breast milk", "ANATOMY", 176, 187], ["breast milk", "DISEASE", 176, 187], ["coronavirus pandemic", "DISEASE", 217, 237], ["SARS", "DISEASE", 279, 283], ["children", "ORGANISM", 98, 106], ["breast milk", "ORGANISM_SUBSTANCE", 176, 187], ["coronavirus", "ORGANISM", 217, 228], ["women", "ORGANISM", 259, 264], ["SARS-CoV-2", "ORGANISM", 279, 289], ["children", "SPECIES", 98, 106], ["coronavirus", "SPECIES", 217, 228], ["women", "SPECIES", 259, 264], ["SARS-CoV", "SPECIES", 279, 287], ["viral transmission via breast milk", "TREATMENT", 153, 187]]], ["Furthermore, there is a lack of consensus among health agencies regarding breastfeeding for women with COVID-19.", [["women", "ORGANISM", 92, 97], ["women", "SPECIES", 92, 97], ["COVID", "TEST", 103, 108]]], ["In February 2020, the National Health Commission of China recommended that neonates of pregnant women with suspected or confirmed COVID-19 should be isolated in a designated unit for at least 14 days and should not be breastfeed due to the high risk of infection (16).", [["COVID-19", "CHEMICAL", 130, 138], ["infection", "DISEASE", 253, 262], ["neonates", "ORGANISM", 75, 83], ["women", "ORGANISM", 96, 101], ["women", "SPECIES", 96, 101], ["COVID", "TEST", 130, 135], ["infection", "PROBLEM", 253, 262], ["infection", "OBSERVATION", 253, 262]]], ["Although this expert working group has suggested breastfeeding only in cases of negative tests for SARS-CoV-2, this warning may contribute to reducing breastfeeding by women with no exposure to the virus which may lead to infant poor health outcomes.", [["SARS", "DISEASE", 99, 103], ["women", "ORGANISM", 168, 173], ["women", "SPECIES", 168, 173], ["SARS-CoV", "SPECIES", 99, 107], ["SARS", "PROBLEM", 99, 103], ["the virus", "PROBLEM", 194, 203]]], ["On the other hand, interim guidance provided by the Centers for Disease Control and Prevention (CDC) (17) and the World Health Organization (WHO) (18) advises that breastfeeding should be determined by the mother in coordination with her family and healthcare providers, and all possible prevention measures to avoid spreading the virus to the infant must be taken including wearing a mask and washing hands and breasts with soap and water before breastfeeding.", [["breasts", "ANATOMY", 412, 419], ["infant", "ORGANISM", 344, 350], ["hands", "ORGANISM_SUBDIVISION", 402, 407], ["breasts", "ORGANISM_SUBDIVISION", 412, 419], ["infant", "SPECIES", 344, 350], ["Disease Control", "TREATMENT", 64, 79], ["prevention measures", "TREATMENT", 288, 307], ["spreading the virus", "PROBLEM", 317, 336], ["a mask", "TREATMENT", 383, 389], ["breasts", "ANATOMY", 412, 419]]], ["If the woman opts to express breast milk, all recommendations for cleaning the breast pumps and utensils after each use must be rigorously followed.", [["breast milk", "ANATOMY", 29, 40], ["breast", "ANATOMY", 79, 85], ["breast milk", "DISEASE", 29, 40], ["woman", "ORGANISM", 7, 12], ["breast milk", "ORGANISM_SUBSTANCE", 29, 40], ["breast", "ORGANISM_SUBDIVISION", 79, 85], ["woman", "SPECIES", 7, 12], ["cleaning the breast pumps", "TREATMENT", 66, 91], ["breast", "ANATOMY", 29, 35], ["breast", "ANATOMY", 79, 85]]], ["Consideration should be given to the possibility of someone healthy providing breast milk to the infant using a cup or spoon.", [["breast milk", "ANATOMY", 78, 89], ["breast milk", "ORGANISM_SUBSTANCE", 78, 89], ["infant", "ORGANISM", 97, 103], ["cup", "ORGANISM_SUBDIVISION", 112, 115], ["infant", "SPECIES", 97, 103]]], ["This person must receive training from a qualified professional before starting procedures.", [["person", "SPECIES", 5, 11]]], ["If there is no production of breast milk by the mother, a human milk bank should be contacted.", [["breast milk", "ANATOMY", 29, 40], ["milk", "ANATOMY", 64, 68], ["breast milk", "ORGANISM_SUBSTANCE", 29, 40], ["human", "ORGANISM", 58, 63], ["milk", "ORGANISM_SUBSTANCE", 64, 68], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["production of breast milk", "PROBLEM", 15, 40], ["a human milk bank", "TREATMENT", 56, 73], ["no", "UNCERTAINTY", 12, 14], ["breast", "ANATOMY", 29, 35]]], ["There are no restrictions on the use of milk from a human breast milk bank (19,20).", [["milk", "ANATOMY", 40, 44], ["breast milk", "ANATOMY", 58, 69], ["milk", "ORGANISM_SUBSTANCE", 40, 44], ["human", "ORGANISM", 52, 57], ["breast milk", "ORGANISM_SUBSTANCE", 58, 69], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["a human breast milk bank", "TREATMENT", 50, 74], ["no", "UNCERTAINTY", 10, 12], ["restrictions", "OBSERVATION", 13, 25]]], ["The possibility of drug excretion into breast milk with potential adverse effects in breastfeed neonates should also be analyzed (21).", [["breast milk", "ANATOMY", 39, 50], ["breast", "ORGANISM_SUBDIVISION", 39, 45], ["milk", "ORGANISM_SUBSTANCE", 46, 50], ["neonates", "ORGANISM", 96, 104], ["drug excretion into breast milk", "TREATMENT", 19, 50], ["potential adverse effects in breastfeed neonates", "PROBLEM", 56, 104], ["possibility of", "UNCERTAINTY", 4, 18], ["drug excretion", "OBSERVATION", 19, 33], ["breast", "ANATOMY", 39, 45]]], ["To date, there is no evidence on the presence of SARS-CoV-2 in breast milk of pregnant women with COVID-19.", [["breast milk", "ANATOMY", 63, 74], ["SARS", "DISEASE", 49, 53], ["breast milk", "DISEASE", 63, 74], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 49, 59], ["breast milk", "ORGANISM_SUBSTANCE", 63, 74], ["women", "ORGANISM", 87, 92], ["women", "SPECIES", 87, 92], ["SARS-CoV", "SPECIES", 49, 57], ["SARS", "PROBLEM", 49, 53], ["CoV", "TEST", 54, 57], ["COVID", "TEST", 98, 103], ["no evidence", "UNCERTAINTY", 18, 29], ["breast", "ANATOMY", 63, 69]]], ["Data provided on current literature are still limited and breastfeeding of women with COVID-19 remains a controversial issue.", [["COVID-19", "CHEMICAL", 86, 94], ["COVID-19", "CHEMICAL", 86, 94], ["women", "ORGANISM", 75, 80], ["women", "SPECIES", 75, 80], ["COVID", "TREATMENT", 86, 91]]], ["Further studies with large samples are needed to confirm these results particularly given the importance of breastfeeding in preventing other childhood illnesses.Author contributions.All authors conceived the original idea and contributed to the analysis and interpretation of the results.", [["Further studies", "TEST", 0, 15], ["large samples", "TEST", 21, 34], ["other childhood illnesses", "PROBLEM", 136, 161], ["the analysis", "TEST", 242, 254]]], ["All authors reviewed and approved the final version.Disclaimer.Authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the RPSP/PAJPH or the Pan American Health Organization (PAHO).", [["the views", "TEST", 100, 109], ["the RPSP/PAJPH", "PROBLEM", 198, 212]]]], "PMC7166898": [["INTRODUCTIONIn large cities, \u201crapid transit\u201d is a term that refers to the efficient movement of people allowing rapid entry and exit from a transportation system.", [["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102], ["large", "OBSERVATION_MODIFIER", 15, 20], ["cities", "OBSERVATION_MODIFIER", 21, 27]]], ["A rapid transit scheme also occurs in the immune system to allow immediate activation of the immune cells toward microbes, transient mode of action, and swift recovery.", [["immune system", "ANATOMY", 42, 55], ["immune cells", "ANATOMY", 93, 105], ["immune system", "ANATOMICAL_SYSTEM", 42, 55], ["immune cells", "CELL", 93, 105], ["immune cells", "CELL_TYPE", 93, 105], ["A rapid transit scheme", "PROBLEM", 0, 22], ["the immune cells", "TREATMENT", 89, 105], ["rapid", "OBSERVATION_MODIFIER", 2, 7], ["transit scheme", "OBSERVATION", 8, 22]]], ["Post\u2010transcriptional regulation contributes significantly to this rapid transit by several mechanisms, including mRNA stability modulation and translational control; collectively, they aim to control the expression of key gene products involved in the immune response.", [["key gene products", "PROTEIN", 218, 235], ["this rapid transit", "PROBLEM", 61, 79], ["mRNA stability modulation", "TREATMENT", 113, 138], ["translational control", "TREATMENT", 143, 164], ["key gene products", "TREATMENT", 218, 235]]], ["Sequence elements, mainly in the 3\u2032 untranslated region (3\u2032UTR), and modulation by RNA\u2010binding proteins can affect mRNA stability and protein translation.", [["RNA\u2010binding proteins", "GENE_OR_GENE_PRODUCT", 83, 103], ["3\u2032 untranslated region", "DNA", 33, 55], ["3\u2032UTR", "DNA", 57, 62], ["RNA\u2010binding proteins", "PROTEIN", 83, 103], ["Sequence elements", "TEST", 0, 17], ["RNA\u2010binding proteins", "TEST", 83, 103]]], ["Many of the gene products involved in the immune system, such as cytokines, harbor destabilization sequence elements in the mRNA, mostly adenylate\u2010uridylate (AU)\u2010rich elements (AREs), which comprise a heterogeneous group of sequence classes that can affect protein interactions with the mRNAs and therefore influence the mRNA decay characteristics [1,2].INTRODUCTIONLarge\u2010scale studies involving profiling of mRNAs that are bound to RNA\u2010binding proteins indicate that many of these genes are involved in the early response to stimuli, host defense, and regulation of RNA metabolism and translation [3,4,5].", [["immune system", "ANATOMY", 42, 55], ["adenylate\u2010uridylate", "CHEMICAL", 137, 156], ["adenylate\u2010uridylate", "SIMPLE_CHEMICAL", 137, 156], ["RNA\u2010binding proteins", "GENE_OR_GENE_PRODUCT", 433, 453], ["cytokines", "PROTEIN", 65, 74], ["mRNA", "RNA", 124, 128], ["adenylate\u2010uridylate (AU)\u2010rich elements", "DNA", 137, 175], ["AREs", "DNA", 177, 181], ["mRNAs", "RNA", 287, 292], ["mRNAs", "RNA", 409, 414], ["RNA\u2010binding proteins", "PROTEIN", 433, 453], ["the gene products", "TREATMENT", 8, 25], ["harbor destabilization sequence elements", "PROBLEM", 76, 116], ["INTRODUCTIONLarge\u2010scale studies", "TEST", 354, 385], ["profiling of mRNAs", "PROBLEM", 396, 414], ["gene products", "OBSERVATION", 12, 25]]], ["The stabilization of cytokine mRNA and other immune response gene products can occur by the activity of mRNA stabilization\u2010promoting proteins such as human antigen (HuR) protein or by inactivation of RNA decay\u2010promoting proteins such as the zinc finger protein, tristetraprolin (TTP).", [["tristetraprolin", "CHEMICAL", 262, 277], ["zinc", "CHEMICAL", 241, 245], ["tristetraprolin", "CHEMICAL", 262, 277], ["human antigen", "GENE_OR_GENE_PRODUCT", 150, 163], ["HuR", "GENE_OR_GENE_PRODUCT", 165, 168], ["zinc finger protein", "GENE_OR_GENE_PRODUCT", 241, 260], ["tristetraprolin", "GENE_OR_GENE_PRODUCT", 262, 277], ["TTP", "GENE_OR_GENE_PRODUCT", 279, 282], ["cytokine mRNA", "RNA", 21, 34], ["immune response gene products", "PROTEIN", 45, 74], ["human antigen (HuR) protein", "PROTEIN", 150, 177], ["RNA decay\u2010promoting proteins", "PROTEIN", 200, 228], ["zinc finger protein", "PROTEIN", 241, 260], ["tristetraprolin", "PROTEIN", 262, 277], ["TTP", "PROTEIN", 279, 282], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 150, 155], ["cytokine mRNA", "TREATMENT", 21, 34], ["other immune response gene products", "TREATMENT", 39, 74], ["mRNA stabilization", "TREATMENT", 104, 122], ["promoting proteins", "PROBLEM", 123, 141], ["human antigen (HuR) protein", "TREATMENT", 150, 177], ["RNA decay\u2010promoting proteins", "PROBLEM", 200, 228], ["the zinc finger protein", "TEST", 237, 260], ["tristetraprolin (TTP)", "TREATMENT", 262, 283], ["cytokine mRNA", "OBSERVATION", 21, 34]]], ["HuR is one of the most characterized RNA\u2010binding proteins; it is a mammalian homologue of embryonic, lethal, abnormal vision proteins, which was first described in Drosophila.", [["embryonic", "ANATOMY", 90, 99], ["HuR", "GENE_OR_GENE_PRODUCT", 0, 3], ["RNA\u2010binding proteins", "GENE_OR_GENE_PRODUCT", 37, 57], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 90, 99], ["HuR", "PROTEIN", 0, 3], ["RNA\u2010binding proteins", "PROTEIN", 37, 57], ["abnormal vision proteins", "PROTEIN", 109, 133], ["Drosophila", "SPECIES", 164, 174], ["Drosophila", "SPECIES", 164, 174], ["abnormal vision proteins", "PROBLEM", 109, 133], ["one of the most characterized", "OBSERVATION_MODIFIER", 7, 36]]], ["It is implicated in the stabilization of many AU\u2010rich mRNAs including those that participate in immunity and inflammation such as TNF\u2010\u03b1, IL\u20103, IL\u20108, and the urokinase activator, urokinase\u2010type plasminogen activator [6,7,8].", [["inflammation", "DISEASE", 109, 121], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 130, 135], ["IL\u20103", "GENE_OR_GENE_PRODUCT", 137, 141], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 143, 147], ["urokinase activator", "GENE_OR_GENE_PRODUCT", 157, 176], ["urokinase\u2010type plasminogen activator", "GENE_OR_GENE_PRODUCT", 178, 214], ["AU\u2010rich mRNAs", "RNA", 46, 59], ["TNF\u2010\u03b1", "PROTEIN", 130, 135], ["IL\u20103", "PROTEIN", 137, 141], ["IL\u20108", "PROTEIN", 143, 147], ["urokinase activator", "PROTEIN", 157, 176], ["urokinase\u2010type plasminogen activator", "PROTEIN", 178, 214], ["many AU\u2010rich mRNAs", "PROBLEM", 41, 59], ["inflammation", "PROBLEM", 109, 121], ["TNF", "TEST", 130, 133], ["IL\u2010", "TREATMENT", 137, 140], ["the urokinase activator", "TREATMENT", 153, 176], ["urokinase\u2010type plasminogen activator", "TREATMENT", 178, 214]]], ["Among RNA\u2010binding proteins that promote mRNA decay is TTP.", [["RNA\u2010binding proteins", "GENE_OR_GENE_PRODUCT", 6, 26], ["TTP", "GENE_OR_GENE_PRODUCT", 54, 57], ["RNA\u2010binding proteins", "PROTEIN", 6, 26], ["mRNA", "RNA", 40, 44], ["Among RNA\u2010binding proteins", "PROBLEM", 0, 26], ["TTP", "PROBLEM", 54, 57], ["TTP", "OBSERVATION", 54, 57]]], ["It is an endotoxin\u2010inducible, early response gene product, which destabilizes several proinflammatory cytokine mRNAs including TNF\u2010\u03b1, GM\u2010CSF, and IL\u20102 by binding to a specific class of AREs in the 3\u2032UTR.", [["3\u2032UTR", "ANATOMY", 197, 202], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 127, 132], ["GM\u2010CSF", "GENE_OR_GENE_PRODUCT", 134, 140], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 146, 150], ["endotoxin\u2010inducible, early response gene product", "PROTEIN", 9, 57], ["proinflammatory cytokine mRNAs", "RNA", 86, 116], ["TNF\u2010\u03b1", "PROTEIN", 127, 132], ["GM", "PROTEIN", 134, 136], ["CSF", "PROTEIN", 137, 140], ["IL\u20102", "PROTEIN", 146, 150], ["AREs", "DNA", 185, 189], ["3\u2032UTR", "DNA", 197, 202], ["several proinflammatory cytokine mRNAs", "PROBLEM", 78, 116], ["TNF\u2010\u03b1", "TEST", 127, 132], ["GM\u2010CSF", "TEST", 134, 140], ["response gene product", "OBSERVATION", 36, 57], ["proinflammatory cytokine mRNAs", "OBSERVATION", 86, 116]]], ["In addition to TTP, K\u2010homology splicing\u2010regulatory protein (KSRP [9]), butyrate response factor (BRF1 [10]), and certain gene products of the ARE RNA\u2010binding protein 1 [ARE/poly(U)\u2010binding/degradation factor 1 (AUF1)] family [2] are considered negative\u2010feedback mediators.", [["butyrate", "CHEMICAL", 71, 79], ["butyrate", "CHEMICAL", 71, 79], ["TTP", "GENE_OR_GENE_PRODUCT", 15, 18], ["K\u2010homology splicing\u2010regulatory protein", "GENE_OR_GENE_PRODUCT", 20, 58], ["KSRP [9]", "GENE_OR_GENE_PRODUCT", 60, 68], ["butyrate response factor", "GENE_OR_GENE_PRODUCT", 71, 95], ["BRF1 [10]", "GENE_OR_GENE_PRODUCT", 97, 106], ["ARE RNA\u2010binding protein 1", "GENE_OR_GENE_PRODUCT", 142, 167], ["ARE", "GENE_OR_GENE_PRODUCT", 169, 172], ["poly(U)\u2010binding/degradation factor 1", "GENE_OR_GENE_PRODUCT", 173, 209], ["AUF1", "GENE_OR_GENE_PRODUCT", 211, 215], ["TTP", "PROTEIN", 15, 18], ["K\u2010homology splicing\u2010regulatory protein", "PROTEIN", 20, 58], ["KSRP [9]", "PROTEIN", 60, 68], ["butyrate response factor", "PROTEIN", 71, 95], ["BRF1", "PROTEIN", 97, 101], ["ARE RNA\u2010binding protein 1", "PROTEIN", 142, 167], ["ARE", "PROTEIN", 169, 172], ["poly(U)\u2010binding/degradation factor 1 (AUF1)] family", "PROTEIN", 173, 224], ["negative\u2010feedback mediators", "PROTEIN", 244, 271], ["TTP", "PROBLEM", 15, 18], ["K\u2010homology", "TEST", 20, 30], ["KSRP", "TEST", 60, 64], ["butyrate response factor", "PROBLEM", 71, 95], ["BRF1", "TEST", 97, 101], ["binding protein", "TEST", 150, 165], ["binding/degradation factor", "PROBLEM", 181, 207], ["TTP", "OBSERVATION", 15, 18]]], ["TTP and several other RNA\u2010binding proteins appear to function by targeting AU\u2010rich mRNA to the exosome, a multiprotein complex with 3\u2032\u20135\u2032 exoRNase activity representing a major degradation machine in eukaryotes [11].", [["exosome", "ANATOMY", 95, 102], ["TTP", "GENE_OR_GENE_PRODUCT", 0, 3], ["RNA\u2010binding proteins", "GENE_OR_GENE_PRODUCT", 22, 42], ["AU\u2010rich", "GENE_OR_GENE_PRODUCT", 75, 82], ["exosome", "CELLULAR_COMPONENT", 95, 102], ["3\u2032\u20135\u2032 exoRNase", "GENE_OR_GENE_PRODUCT", 132, 146], ["TTP", "PROTEIN", 0, 3], ["RNA\u2010binding proteins", "PROTEIN", 22, 42], ["AU\u2010rich mRNA", "RNA", 75, 87], ["exosome", "PROTEIN", 95, 102], ["multiprotein complex", "PROTEIN", 106, 126], ["exoRNase", "PROTEIN", 138, 146], ["TTP", "PROBLEM", 0, 3], ["several other RNA\u2010binding proteins", "PROBLEM", 8, 42]]], ["ARE\u2010binding proteins can also function by recruitment of degradation factors other than the exosome [12,13].", [["exosome", "ANATOMY", 92, 99], ["ARE\u2010binding proteins", "GENE_OR_GENE_PRODUCT", 0, 20], ["ARE\u2010binding proteins", "PROTEIN", 0, 20], ["degradation factors", "PROTEIN", 57, 76], ["exosome", "PROTEIN", 92, 99], ["\u2010binding proteins", "PROBLEM", 3, 20], ["degradation factors", "PROBLEM", 57, 76]]], ["An alternative pathway of 5\u2032\u20133\u2032 decay can also occur during degradation of AU\u2010rich mRNAs in cytoplasmic RNA foci\u2014processing bodies [14].", [["cytoplasmic", "ANATOMY", 92, 103], ["5\u2032\u20133\u2032", "SIMPLE_CHEMICAL", 26, 31], ["cytoplasmic", "ORGANISM_SUBSTANCE", 92, 103], ["AU\u2010rich mRNAs", "RNA", 75, 88], ["AU\u2010rich mRNAs in cytoplasmic RNA foci\u2014processing bodies", "PROBLEM", 75, 130], ["cytoplasmic RNA", "OBSERVATION", 92, 107]]], ["After a brief introduction about the major signaling pathway regulating mRNA turnover, the review is structured in such a way that reflects key functions of the immune cells, including recognition by innate immunity and T cell activation.THE p38 MAPK PATHWAY AS A UNIVERSAL REGULATOR OF CYTOKINE mRNA TURNOVERSignaling pathways that tend to stabilize ARE\u2010mRNAs are multiple and include p38 MAPK, ERK, c\u2010Jun N\u2010terminal kinase, PI\u20103K\u2010AKT, and Wnt/\u03b2\u2010catenin pathways [10,15,16,17].", [["immune cells", "ANATOMY", 161, 173], ["T cell", "ANATOMY", 220, 226], ["immune cells", "CELL", 161, 173], ["T cell", "CELL", 220, 226], ["p38", "GENE_OR_GENE_PRODUCT", 242, 245], ["ARE\u2010mRNAs", "GENE_OR_GENE_PRODUCT", 351, 360], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 386, 394], ["ERK", "GENE_OR_GENE_PRODUCT", 396, 399], ["c\u2010Jun N\u2010terminal kinase", "GENE_OR_GENE_PRODUCT", 401, 424], ["PI\u20103K", "GENE_OR_GENE_PRODUCT", 426, 431], ["AKT", "GENE_OR_GENE_PRODUCT", 432, 435], ["Wnt", "GENE_OR_GENE_PRODUCT", 441, 444], ["\u03b2\u2010catenin", "GENE_OR_GENE_PRODUCT", 445, 454], ["immune cells", "CELL_TYPE", 161, 173], ["p38 MAPK", "PROTEIN", 242, 250], ["ARE\u2010mRNAs", "PROTEIN", 351, 360], ["p38 MAPK", "PROTEIN", 386, 394], ["ERK", "PROTEIN", 396, 399], ["c\u2010Jun N\u2010terminal kinase", "PROTEIN", 401, 424], ["PI\u20103K", "PROTEIN", 426, 431], ["AKT", "PROTEIN", 432, 435], ["\u03b2\u2010catenin", "PROTEIN", 445, 454], ["THE p38 MAPK PATHWAY", "TEST", 238, 258], ["CYTOKINE mRNA TURNOVERSignaling pathways", "TREATMENT", 287, 327], ["p38 MAPK", "TEST", 386, 394], ["ERK", "TEST", 396, 399], ["c\u2010", "TEST", 401, 403], ["Jun", "TEST", 403, 406], ["kinase", "TEST", 418, 424], ["PI", "TEST", 426, 428], ["AKT", "TEST", 432, 435], ["Wnt/\u03b2\u2010catenin pathways", "TEST", 441, 463], ["immune cells", "OBSERVATION", 161, 173]]], ["The p38 MAPK pathway is one of the most common pathways that regulates mRNA stability in multiple cell types.", [["cell", "ANATOMY", 98, 102], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 4, 12], ["cell", "CELL", 98, 102], ["p38 MAPK", "PROTEIN", 4, 12], ["The p38 MAPK pathway", "TEST", 0, 20], ["mRNA", "OBSERVATION_MODIFIER", 71, 75], ["stability", "OBSERVATION_MODIFIER", 76, 85], ["multiple cell types", "OBSERVATION", 89, 108]]], ["Recent work extends the role of the p38 MAPK pathway and its downstream target kinase, MAPK\u2010activated protein kinase 2 (MK2) [18,19,20,21,22].", [["p38 MAPK", "GENE_OR_GENE_PRODUCT", 36, 44], ["MAPK\u2010activated protein kinase 2", "GENE_OR_GENE_PRODUCT", 87, 118], ["MK2", "GENE_OR_GENE_PRODUCT", 120, 123], ["p38 MAPK", "PROTEIN", 36, 44], ["downstream target kinase", "PROTEIN", 61, 85], ["MAPK\u2010activated protein kinase 2", "PROTEIN", 87, 118], ["MK2", "PROTEIN", 120, 123], ["the p38 MAPK pathway", "TEST", 32, 52], ["its downstream target kinase", "TEST", 57, 85], ["MAPK\u2010activated protein kinase", "TEST", 87, 116]]], ["Activation of the p38 MAPK pathway drives the accumulation of TTP via the stabilization of TTP mRNA and protein [18,19,20].", [["p38 MAPK", "GENE_OR_GENE_PRODUCT", 18, 26], ["TTP", "GENE_OR_GENE_PRODUCT", 62, 65], ["TTP", "GENE_OR_GENE_PRODUCT", 91, 94], ["p38 MAPK", "PROTEIN", 18, 26], ["TTP", "PROTEIN", 62, 65], ["TTP mRNA", "RNA", 91, 99], ["the p38 MAPK pathway", "TEST", 14, 34], ["TTP", "PROBLEM", 62, 65], ["TTP mRNA", "TEST", 91, 99], ["protein", "TEST", 104, 111], ["TTP", "OBSERVATION", 62, 65]]], ["Although this remains controversial [22], MK2\u2010mediated phosphorylation of TTP has been reported to impair its function, possibly as a result of reduced binding affinity with the TNF\u2010\u03b1 ARE region [18,23].", [["TTP", "CHEMICAL", 74, 77], ["MK2", "GENE_OR_GENE_PRODUCT", 42, 45], ["TTP", "GENE_OR_GENE_PRODUCT", 74, 77], ["TNF", "GENE_OR_GENE_PRODUCT", 178, 181], ["MK2", "PROTEIN", 42, 45], ["TTP", "PROTEIN", 74, 77], ["TNF", "PROTEIN", 178, 181], ["ARE region", "DNA", 184, 194], ["MK2\u2010mediated phosphorylation", "TREATMENT", 42, 70], ["TTP", "PROBLEM", 74, 77], ["reduced binding affinity", "PROBLEM", 144, 168], ["TTP", "OBSERVATION", 74, 77]]], ["Another p38 MAPK downstream target with structural and functional similarity to MK2 is MK3; it is thought to cooperate with MK2 in TNF\u2010\u03b1 mRNA stabilization [24].", [["p38 MAPK", "GENE_OR_GENE_PRODUCT", 8, 16], ["MK2", "GENE_OR_GENE_PRODUCT", 80, 83], ["MK3", "GENE_OR_GENE_PRODUCT", 87, 90], ["MK2", "GENE_OR_GENE_PRODUCT", 124, 127], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 131, 136], ["p38 MAPK downstream target", "PROTEIN", 8, 34], ["MK2", "PROTEIN", 80, 83], ["MK3", "PROTEIN", 87, 90], ["MK2", "PROTEIN", 124, 127], ["TNF\u2010\u03b1 mRNA", "RNA", 131, 141], ["Another p38 MAPK downstream", "TEST", 0, 27], ["mRNA stabilization", "TREATMENT", 137, 155]]], ["TTP and other RNA decay\u2010promoting proteins, namely BRF1, KSRP, and AUF1, particularly when phosphorylated, are complexed with 14\u20103\u20103 proteins that influence their subcellular localization and mRNA decay activity [10,16,25].", [["subcellular", "ANATOMY", 163, 174], ["TTP", "GENE_OR_GENE_PRODUCT", 0, 3], ["BRF1", "GENE_OR_GENE_PRODUCT", 51, 55], ["KSRP", "GENE_OR_GENE_PRODUCT", 57, 61], ["AUF1", "GENE_OR_GENE_PRODUCT", 67, 71], ["14\u20103\u20103", "GENE_OR_GENE_PRODUCT", 126, 132], ["TTP", "PROTEIN", 0, 3], ["RNA decay\u2010promoting proteins", "PROTEIN", 14, 42], ["BRF1", "PROTEIN", 51, 55], ["KSRP", "PROTEIN", 57, 61], ["AUF1", "PROTEIN", 67, 71], ["14\u20103\u20103 proteins", "PROTEIN", 126, 141], ["TTP", "PROBLEM", 0, 3], ["other RNA decay\u2010promoting proteins", "PROBLEM", 8, 42], ["BRF1", "TEST", 51, 55], ["KSRP", "TEST", 57, 61], ["AUF1", "PROBLEM", 67, 71]]], ["Another player in the post\u2010transcriptional regulation of the immune system by the p38 MAPK pathway is the downstream MAPK signal\u2010integrating kinase, mnk1; this kinase is thought to phosphorylate the eukaryotic initiation factor 4E (eIF4E) and heterogeneous nuclear ribonucleoprotein A1 [26,27].THE p38 MAPK PATHWAY AS A UNIVERSAL REGULATOR OF CYTOKINE mRNA TURNOVERThe p38 MAPK pathway is central to the stabilization of many immune system mRNAs such as those of cytokines during innate and adaptive immune responses.", [["immune system", "ANATOMY", 426, 439], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 82, 90], ["MAPK", "GENE_OR_GENE_PRODUCT", 117, 121], ["mnk1", "GENE_OR_GENE_PRODUCT", 149, 153], ["eukaryotic initiation factor 4E", "GENE_OR_GENE_PRODUCT", 199, 230], ["eIF4E", "GENE_OR_GENE_PRODUCT", 232, 237], ["p38", "GENE_OR_GENE_PRODUCT", 298, 301], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 369, 377], ["p38 MAPK", "PROTEIN", 82, 90], ["MAPK signal\u2010integrating kinase", "PROTEIN", 117, 147], ["mnk1", "PROTEIN", 149, 153], ["eukaryotic initiation factor 4E", "PROTEIN", 199, 230], ["eIF4E", "PROTEIN", 232, 237], ["heterogeneous nuclear ribonucleoprotein A1", "PROTEIN", 243, 285], ["p38 MAPK", "PROTEIN", 298, 306], ["p38 MAPK", "PROTEIN", 369, 377], ["immune system mRNAs", "RNA", 426, 445], ["cytokines", "PROTEIN", 463, 472], ["the p38 MAPK pathway", "TEST", 78, 98], ["the downstream MAPK signal\u2010integrating kinase", "TEST", 102, 147], ["this kinase", "TEST", 155, 166], ["heterogeneous nuclear ribonucleoprotein A1", "PROBLEM", 243, 285], ["THE p38 MAPK PATHWAY", "TEST", 294, 314], ["CYTOKINE mRNA", "TEST", 343, 356], ["MAPK pathway", "TEST", 373, 385], ["many immune system mRNAs", "PROBLEM", 421, 445], ["heterogeneous", "OBSERVATION_MODIFIER", 243, 256], ["ribonucleoprotein A1", "OBSERVATION", 265, 285]]], ["Cytokines can regulate immune response via positive\u2010 and negative\u2010feedback circuits.", [["Cytokines", "PROTEIN", 0, 9], ["Cytokines", "TREATMENT", 0, 9], ["immune response", "TEST", 23, 38], ["positive\u2010", "TEST", 43, 52]]], ["In general, when cytokines amplify a specific immune response, they tend to stabilize mRNAs that participate in such a process.", [["cytokines", "PROTEIN", 17, 26], ["mRNAs", "RNA", 86, 91]]], ["Examples of those cytokines are the proinflammatory cytokines, IL\u20101\u03b1 and TNF\u2010\u03b1, which have been found to stabilize a significant number of cytokines and chemokines, including IFN\u2010\u03b3\u2010inducible protein 10 (IP\u201010), growth\u2010related oncogene proteins, and fractalkine (SCYD1), and several genes involved in regulation of inflammatory responses such as TNF\u2010\u03b1\u2010induced protein 3, NF\u2010\u03baB\u03b1I, and mannose\u2010binding lectin 2 (MBL2) [28,29,30].", [["IL\u20101\u03b1", "GENE_OR_GENE_PRODUCT", 63, 68], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 73, 78], ["IFN\u2010\u03b3\u2010inducible protein 10", "GENE_OR_GENE_PRODUCT", 175, 201], ["IP\u201010", "GENE_OR_GENE_PRODUCT", 203, 208], ["fractalkine", "GENE_OR_GENE_PRODUCT", 249, 260], ["SCYD1", "GENE_OR_GENE_PRODUCT", 262, 267], ["TNF\u2010\u03b1\u2010induced protein 3", "GENE_OR_GENE_PRODUCT", 345, 368], ["NF\u2010\u03baB\u03b1I", "GENE_OR_GENE_PRODUCT", 370, 377], ["mannose\u2010binding lectin 2", "GENE_OR_GENE_PRODUCT", 383, 407], ["MBL2", "GENE_OR_GENE_PRODUCT", 409, 413], ["cytokines", "PROTEIN", 18, 27], ["proinflammatory cytokines", "PROTEIN", 36, 61], ["IL\u20101\u03b1", "PROTEIN", 63, 68], ["TNF\u2010\u03b1", "PROTEIN", 73, 78], ["cytokines", "PROTEIN", 139, 148], ["chemokines", "PROTEIN", 153, 163], ["IFN\u2010\u03b3\u2010inducible protein 10", "PROTEIN", 175, 201], ["IP\u201010", "PROTEIN", 203, 208], ["growth\u2010related oncogene proteins", "PROTEIN", 211, 243], ["fractalkine", "PROTEIN", 249, 260], ["SCYD1", "PROTEIN", 262, 267], ["TNF\u2010\u03b1\u2010induced protein 3", "PROTEIN", 345, 368], ["NF\u2010\u03baB", "PROTEIN", 370, 375], ["\u03b1I", "PROTEIN", 375, 377], ["mannose\u2010binding lectin 2", "PROTEIN", 383, 407], ["MBL2", "PROTEIN", 409, 413], ["those cytokines", "TEST", 12, 27], ["the proinflammatory cytokines", "TEST", 32, 61], ["IL\u2010", "TEST", 63, 66], ["TNF\u2010\u03b1", "TEST", 73, 78], ["chemokines", "TEST", 153, 163], ["IFN\u2010\u03b3\u2010inducible protein", "TEST", 175, 198], ["IP", "TEST", 203, 205], ["growth\u2010related oncogene proteins", "PROBLEM", 211, 243], ["fractalkine (SCYD1)", "PROBLEM", 249, 268], ["inflammatory responses", "TEST", 314, 336], ["TNF", "TEST", 345, 348], ["protein", "TEST", 359, 366], ["NF\u2010", "TEST", 370, 373], ["mannose\u2010binding lectin", "TEST", 383, 405], ["MBL2", "TEST", 409, 413], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["cytokines", "OBSERVATION", 139, 148], ["inflammatory", "OBSERVATION", 314, 326]]], ["Cytokines use p38 MAPK signaling and notably, its target MK2 to trigger mRNA stabilization.", [["p38 MAPK", "GENE_OR_GENE_PRODUCT", 14, 22], ["MK2", "GENE_OR_GENE_PRODUCT", 57, 60], ["Cytokines", "PROTEIN", 0, 9], ["p38 MAPK", "PROTEIN", 14, 22], ["MK2", "PROTEIN", 57, 60], ["MAPK signaling", "TEST", 18, 32], ["mRNA stabilization", "TREATMENT", 72, 90]]], ["For example, using this pathway, IFN\u2010\u03b3 amplifies immune responses such as increasing NK activity and up\u2010regulating MHC expression [31].", [["NK", "ANATOMY", 85, 87], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 33, 38], ["NK", "CELL", 85, 87], ["IFN\u2010\u03b3", "PROTEIN", 33, 38], ["MHC", "PROTEIN", 115, 118], ["this pathway", "TREATMENT", 19, 31], ["IFN", "TREATMENT", 33, 36], ["immune responses", "TREATMENT", 49, 65], ["increasing NK activity", "TREATMENT", 74, 96]]], ["In several inflammatory conditions, other cytokines can amplify inflammatory responses via post\u2010transcriptional mechanisms.", [["cytokines", "PROTEIN", 42, 51], ["several inflammatory conditions", "PROBLEM", 3, 34], ["other cytokines", "PROBLEM", 36, 51], ["inflammatory responses", "PROBLEM", 64, 86], ["several", "OBSERVATION_MODIFIER", 3, 10], ["inflammatory", "OBSERVATION", 11, 23]]], ["IL\u201017A, in a p38 MAPK\u2010dependent manner, can increase the stability of TNF\u2010\u03b1\u2010induced IL\u20108 mRNA in human airway smooth muscle, a process that is important in development of asthma [32,33].", [["airway smooth muscle", "ANATOMY", 103, 123], ["asthma", "DISEASE", 171, 177], ["IL\u201017A", "GENE_OR_GENE_PRODUCT", 0, 6], ["p38 MAPK\u2010", "GENE_OR_GENE_PRODUCT", 13, 22], ["TNF", "GENE_OR_GENE_PRODUCT", 70, 73], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 84, 88], ["human", "ORGANISM", 97, 102], ["airway smooth muscle", "TISSUE", 103, 123], ["IL\u201017A", "PROTEIN", 0, 6], ["p38 MAPK", "PROTEIN", 13, 21], ["TNF\u2010\u03b1\u2010induced IL\u20108 mRNA", "RNA", 70, 93], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["TNF", "PROBLEM", 70, 73], ["IL\u2010", "TREATMENT", 84, 87], ["asthma", "PROBLEM", 171, 177], ["stability", "OBSERVATION_MODIFIER", 57, 66], ["airway", "ANATOMY", 103, 109], ["smooth muscle", "ANATOMY", 110, 123], ["asthma", "OBSERVATION", 171, 177]]], ["IL\u20101, in addition to activated platelets, triggers stabilization of cyclooxygenase 2 (COX\u20102) mRNA with concomitant cytoplasmic accumulation and increased binding of HuR to the AREs of COX\u20102 mRNA in monocytes [33].", [["platelets", "ANATOMY", 31, 40], ["cytoplasmic", "ANATOMY", 115, 126], ["monocytes", "ANATOMY", 198, 207], ["IL\u20101", "GENE_OR_GENE_PRODUCT", 0, 4], ["platelets", "CELL", 31, 40], ["cyclooxygenase 2", "GENE_OR_GENE_PRODUCT", 68, 84], ["COX\u20102", "GENE_OR_GENE_PRODUCT", 86, 91], ["cytoplasmic", "ORGANISM_SUBSTANCE", 115, 126], ["HuR", "GENE_OR_GENE_PRODUCT", 165, 168], ["COX\u20102", "GENE_OR_GENE_PRODUCT", 184, 189], ["monocytes", "CELL", 198, 207], ["IL\u20101", "PROTEIN", 0, 4], ["activated platelets", "CELL_TYPE", 21, 40], ["cyclooxygenase 2 (COX\u20102) mRNA", "RNA", 68, 97], ["HuR", "PROTEIN", 165, 168], ["AREs", "DNA", 176, 180], ["COX\u20102 mRNA", "RNA", 184, 194], ["monocytes", "CELL_TYPE", 198, 207], ["activated platelets", "TREATMENT", 21, 40], ["triggers stabilization of cyclooxygenase", "TREATMENT", 42, 82], ["COX\u2010", "TEST", 86, 90], ["concomitant cytoplasmic accumulation", "PROBLEM", 103, 139], ["increased binding of HuR", "PROBLEM", 144, 168], ["COX", "TEST", 184, 187], ["mRNA in monocytes", "TEST", 190, 207], ["cytoplasmic accumulation", "OBSERVATION", 115, 139], ["increased", "OBSERVATION_MODIFIER", 144, 153]]], ["In general, stabilization of the mRNA targets seems to occur after translocation of HuR from the nucleus to the cytoplasm upon cellular activation [34].RECOGNITION AND RESPONSE IN INNATE IMMUNITYInnate immunity is the first line of defense against microbes and requires early and rapid gene expression of effector mediators to control infection effectively.", [["nucleus", "ANATOMY", 97, 104], ["cytoplasm", "ANATOMY", 112, 121], ["cellular", "ANATOMY", 127, 135], ["infection", "DISEASE", 335, 344], ["HuR", "GENE_OR_GENE_PRODUCT", 84, 87], ["nucleus", "CELLULAR_COMPONENT", 97, 104], ["cytoplasm", "ORGANISM_SUBSTANCE", 112, 121], ["cellular", "CELL", 127, 135], ["mRNA targets", "RNA", 33, 45], ["HuR", "PROTEIN", 84, 87], ["effector mediators", "PROTEIN", 305, 323], ["effector mediators", "TREATMENT", 305, 323], ["infection", "PROBLEM", 335, 344], ["stabilization", "OBSERVATION", 12, 25], ["nucleus", "ANATOMY", 97, 104]]], ["Recognition and effector mechanisms of innate immunity encompass post\u2010transcriptional gene regulation, which amplifies the much\u2010needed, early response and enforces the transient response.", [["post\u2010transcriptional gene regulation", "TREATMENT", 65, 101]]], ["Efficient recognition of the foreign antigens in microbes, such as bacterial surface molecules and viral dsRNA, is accomplished by cells of the innate immunity, notably macrophages and dendritic cells (DC).", [["surface", "ANATOMY", 77, 84], ["cells", "ANATOMY", 131, 136], ["macrophages", "ANATOMY", 169, 180], ["dendritic cells", "ANATOMY", 185, 200], ["DC", "ANATOMY", 202, 204], ["cells", "CELL", 131, 136], ["macrophages", "CELL", 169, 180], ["dendritic cells", "CELL", 185, 200], ["DC", "CELL", 202, 204], ["foreign antigens", "PROTEIN", 29, 45], ["bacterial surface molecules", "PROTEIN", 67, 94], ["macrophages", "CELL_TYPE", 169, 180], ["dendritic cells", "CELL_TYPE", 185, 200], ["DC", "CELL_TYPE", 202, 204], ["the foreign antigens in microbes", "PROBLEM", 25, 57], ["bacterial surface molecules", "PROBLEM", 67, 94], ["viral dsRNA", "PROBLEM", 99, 110], ["macrophages", "PROBLEM", 169, 180], ["dendritic cells", "PROBLEM", 185, 200], ["foreign antigens", "OBSERVATION", 29, 45], ["viral dsRNA", "OBSERVATION", 99, 110], ["macrophages", "OBSERVATION", 169, 180], ["dendritic cells", "OBSERVATION", 185, 200]]], ["Members of the TLR family [35,36], which have gained considerable attention in recent years, are responsible for triggering the efficient response of the host cell to microbes.RECOGNITION AND RESPONSE IN INNATE IMMUNITYTraditionally, post\u2010transcriptional regulation in innate immunity has been studied in response to the bacterial endotoxin, LPS, which binds CD14 in a complex with TLR4 on the surface of neutrophils and macrophages and initiates a cascade of signals that causes cell activation, the inflammatory response, and phagocytosis [35].", [["cell", "ANATOMY", 159, 163], ["surface", "ANATOMY", 394, 401], ["neutrophils", "ANATOMY", 405, 416], ["macrophages", "ANATOMY", 421, 432], ["cell", "ANATOMY", 480, 484], ["LPS", "CHEMICAL", 342, 345], ["TLR", "GENE_OR_GENE_PRODUCT", 15, 18], ["host cell", "CELL", 154, 163], ["LPS", "SIMPLE_CHEMICAL", 342, 345], ["CD14", "GENE_OR_GENE_PRODUCT", 359, 363], ["TLR4", "GENE_OR_GENE_PRODUCT", 382, 386], ["surface", "CELLULAR_COMPONENT", 394, 401], ["neutrophils", "CELL", 405, 416], ["macrophages", "CELL", 421, 432], ["cell", "CELL", 480, 484], ["TLR family", "PROTEIN", 15, 25], ["bacterial endotoxin", "PROTEIN", 321, 340], ["CD14", "PROTEIN", 359, 363], ["TLR4", "PROTEIN", 382, 386], ["neutrophils", "CELL_TYPE", 405, 416], ["macrophages", "CELL_TYPE", 421, 432], ["the bacterial endotoxin", "TEST", 317, 340], ["macrophages", "PROBLEM", 421, 432], ["cell activation", "PROBLEM", 480, 495], ["the inflammatory response", "PROBLEM", 497, 522], ["phagocytosis", "TEST", 528, 540], ["host cell", "OBSERVATION", 154, 163], ["cell activation", "OBSERVATION", 480, 495], ["inflammatory", "OBSERVATION_MODIFIER", 501, 513]]], ["Recent work gives further insights into LPS\u2010induced pathways.", [["LPS", "CHEMICAL", 40, 43], ["LPS", "SIMPLE_CHEMICAL", 40, 43]]], ["Upon activation of TLR4 by LPS, the adaptor protein MyD88 is recruited to the receptor and couples with IL\u20101 receptor\u2013associated kinase (IRAK)1 and \u20104, causing IRAK activation and recruitment into a complex with TNF receptor\u2010associated factor 6 (TRAF6).", [["LPS", "CHEMICAL", 27, 30], ["TLR4", "GENE_OR_GENE_PRODUCT", 19, 23], ["LPS", "GENE_OR_GENE_PRODUCT", 27, 30], ["MyD88", "GENE_OR_GENE_PRODUCT", 52, 57], ["IL\u20101 receptor\u2013associated kinase (IRAK)1", "GENE_OR_GENE_PRODUCT", 104, 143], ["\u20104", "GENE_OR_GENE_PRODUCT", 148, 150], ["IRAK", "GENE_OR_GENE_PRODUCT", 160, 164], ["TNF receptor\u2010associated factor 6", "GENE_OR_GENE_PRODUCT", 212, 244], ["TRAF6", "GENE_OR_GENE_PRODUCT", 246, 251], ["TLR4", "PROTEIN", 19, 23], ["adaptor protein", "PROTEIN", 36, 51], ["MyD88", "PROTEIN", 52, 57], ["IL\u20101 receptor\u2013associated kinase (IRAK)1", "PROTEIN", 104, 143], ["\u20104", "PROTEIN", 148, 150], ["IRAK", "PROTEIN", 160, 164], ["TNF receptor\u2010associated factor 6", "PROTEIN", 212, 244], ["TRAF6", "PROTEIN", 246, 251], ["the adaptor protein MyD88", "TREATMENT", 32, 57], ["IRAK activation", "PROBLEM", 160, 175], ["TNF receptor\u2010associated factor", "TREATMENT", 212, 242], ["IRAK activation", "OBSERVATION", 160, 175]]], ["This pathway ultimately culminates in a cascade of signaling events including NF\u2010\u03baB activation, MAPK activation, and transcriptional activation of proinflammatory cytokines [37].", [["NF\u2010\u03baB", "GENE_OR_GENE_PRODUCT", 78, 83], ["MAPK", "GENE_OR_GENE_PRODUCT", 96, 100], ["NF\u2010\u03baB", "PROTEIN", 78, 83], ["MAPK", "PROTEIN", 96, 100], ["proinflammatory cytokines", "PROTEIN", 147, 172], ["signaling events", "PROBLEM", 51, 67], ["NF", "PROBLEM", 78, 80], ["MAPK activation", "PROBLEM", 96, 111], ["proinflammatory cytokines", "PROBLEM", 147, 172]]], ["Engagement of LPS with TLR4 can itself lead to stabilization of its own mRNA, resulting in a LPS amplification response.", [["LPS", "CHEMICAL", 14, 17], ["LPS", "CHEMICAL", 93, 96], ["LPS", "GENE_OR_GENE_PRODUCT", 14, 17], ["TLR4", "GENE_OR_GENE_PRODUCT", 23, 27], ["LPS", "SIMPLE_CHEMICAL", 93, 96], ["TLR4", "PROTEIN", 23, 27], ["mRNA", "RNA", 72, 76], ["LPS", "PROBLEM", 14, 17], ["TLR4", "TREATMENT", 23, 27], ["a LPS amplification response", "PROBLEM", 91, 119]]], ["Although this has been shown in the case of vascular smooth muscle cells when exposed to LPS [38], it is likely to occur with cells of the innate immune system.", [["vascular smooth muscle cells", "ANATOMY", 44, 72], ["cells", "ANATOMY", 126, 131], ["LPS", "CHEMICAL", 89, 92], ["vascular smooth muscle cells", "CELL", 44, 72], ["cells", "CELL", 126, 131], ["immune system", "ANATOMICAL_SYSTEM", 146, 159], ["vascular smooth muscle cells", "CELL_TYPE", 44, 72], ["vascular smooth muscle cells", "PROBLEM", 44, 72], ["LPS", "TEST", 89, 92], ["vascular", "ANATOMY", 44, 52], ["smooth muscle", "ANATOMY", 53, 66], ["likely to", "UNCERTAINTY", 105, 114]]], ["TLR4 activation causes HuR translocation to the cytoplasm, enhanced binding of HuR to the 3\u2032UTR, and increased stability of TLR4 mRNA [38].", [["cytoplasm", "ANATOMY", 48, 57], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["HuR", "GENE_OR_GENE_PRODUCT", 23, 26], ["cytoplasm", "ORGANISM_SUBSTANCE", 48, 57], ["HuR", "GENE_OR_GENE_PRODUCT", 79, 82], ["TLR4", "GENE_OR_GENE_PRODUCT", 124, 128], ["TLR4", "PROTEIN", 0, 4], ["HuR", "PROTEIN", 23, 26], ["HuR", "PROTEIN", 79, 82], ["3\u2032UTR", "DNA", 90, 95], ["TLR4 mRNA", "RNA", 124, 133], ["HuR translocation", "PROBLEM", 23, 40], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["stability", "OBSERVATION_MODIFIER", 111, 120]]], ["The adaptor molecule MyD88, which transduces a signal from TLR, causes stabilization of cytokine mRNAs, TNF\u2010\u03b1, IL\u20108, and IP\u201010 in macrophages when stimulated by IFN\u2010\u03b3 [29].", [["macrophages", "ANATOMY", 130, 141], ["MyD88", "GENE_OR_GENE_PRODUCT", 21, 26], ["TLR", "GENE_OR_GENE_PRODUCT", 59, 62], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 104, 109], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 111, 115], ["IP\u201010", "GENE_OR_GENE_PRODUCT", 121, 126], ["macrophages", "CELL", 130, 141], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 161, 166], ["adaptor molecule", "PROTEIN", 4, 20], ["MyD88", "PROTEIN", 21, 26], ["TLR", "PROTEIN", 59, 62], ["cytokine mRNAs", "RNA", 88, 102], ["TNF\u2010\u03b1", "PROTEIN", 104, 109], ["IL\u20108", "PROTEIN", 111, 115], ["macrophages", "CELL_TYPE", 130, 141], ["The adaptor molecule MyD88", "TREATMENT", 0, 26], ["cytokine mRNAs", "TREATMENT", 88, 102], ["TNF", "TEST", 104, 107], ["IL", "TEST", 111, 113], ["IP\u2010", "TREATMENT", 121, 124], ["cytokine mRNAs", "OBSERVATION", 88, 102]]], ["MyD88 bridges IFN\u2010\u03b3 receptor 1 and mixed linkage kinase 3 domains, leading to p38 MAPK activation [31].", [["MyD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN\u2010\u03b3 receptor 1", "GENE_OR_GENE_PRODUCT", 14, 30], ["mixed linkage kinase 3", "GENE_OR_GENE_PRODUCT", 35, 57], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 78, 86], ["MyD88", "PROTEIN", 0, 5], ["IFN\u2010\u03b3 receptor 1", "PROTEIN", 14, 30], ["mixed linkage kinase 3 domains", "PROTEIN", 35, 65], ["p38 MAPK", "PROTEIN", 78, 86], ["MyD88 bridges IFN\u2010\u03b3 receptor", "TREATMENT", 0, 28], ["mixed linkage kinase", "TREATMENT", 35, 55], ["p38 MAPK activation", "TEST", 78, 97]]], ["LPS\u2010induced TLR4 activation can increase formyl peptide receptor 1 (FPR1) mRNA stability via a PI\u20103K pathway in phagocytic leukocytes such as neutrophils and monocytes, leading to infiltration to sites where the invading bacteria possess the formyl peptide ligands [39,40].", [["phagocytic leukocytes", "ANATOMY", 112, 133], ["neutrophils", "ANATOMY", 142, 153], ["monocytes", "ANATOMY", 158, 167], ["sites", "ANATOMY", 196, 201], ["LPS", "CHEMICAL", 0, 3], ["formyl", "CHEMICAL", 41, 47], ["formyl", "CHEMICAL", 242, 248], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["TLR4", "GENE_OR_GENE_PRODUCT", 12, 16], ["formyl peptide receptor 1", "GENE_OR_GENE_PRODUCT", 41, 66], ["FPR1", "GENE_OR_GENE_PRODUCT", 68, 72], ["PI\u20103K", "GENE_OR_GENE_PRODUCT", 95, 100], ["phagocytic leukocytes", "CELL", 112, 133], ["neutrophils", "CELL", 142, 153], ["monocytes", "CELL", 158, 167], ["TLR4", "PROTEIN", 12, 16], ["phagocytic leukocytes", "CELL_TYPE", 112, 133], ["neutrophils", "CELL_TYPE", 142, 153], ["monocytes", "CELL_TYPE", 158, 167], ["LPS", "TEST", 0, 3], ["TLR4 activation", "PROBLEM", 12, 27], ["formyl peptide receptor", "TREATMENT", 41, 64], ["mRNA stability", "TEST", 74, 88], ["a PI\u20103K pathway", "TEST", 93, 108], ["phagocytic leukocytes", "TEST", 112, 133], ["neutrophils", "TEST", 142, 153], ["monocytes", "TEST", 158, 167], ["infiltration to sites", "PROBLEM", 180, 201], ["the invading bacteria", "PROBLEM", 208, 229], ["the formyl peptide ligands", "TEST", 238, 264], ["phagocytic leukocytes", "OBSERVATION", 112, 133], ["infiltration", "OBSERVATION", 180, 192]]], ["Thus, TLR4 activation encompasses several post\u2010transcriptional, positive regulatory events, which lead to amplification of LPS\u2010induced signaling and ultimately, production of proinflammatory cytokines (Fig. 1).", [["LPS", "CHEMICAL", 123, 126], ["TLR4", "GENE_OR_GENE_PRODUCT", 6, 10], ["LPS\u2010", "GENE_OR_GENE_PRODUCT", 123, 127], ["TLR4", "PROTEIN", 6, 10], ["proinflammatory cytokines", "PROTEIN", 175, 200], ["positive regulatory events", "PROBLEM", 64, 90], ["LPS", "PROBLEM", 123, 126], ["proinflammatory cytokines", "PROBLEM", 175, 200], ["proinflammatory cytokines", "OBSERVATION", 175, 200]]], ["These cytokines and other mediators, including vascular endothelial growth factor, the solute carrier family 11 member 1, and NO, can be up\u2010regulated at the level of mRNA stability in LPS\u2010stimulated, monocytic cells [30,41,42,43,44].", [["monocytic cells", "ANATOMY", 200, 215], ["NO", "CHEMICAL", 126, 128], ["LPS", "CHEMICAL", 184, 187], ["NO", "CHEMICAL", 126, 128], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 47, 81], ["solute carrier family 11 member 1", "GENE_OR_GENE_PRODUCT", 87, 120], ["NO", "GENE_OR_GENE_PRODUCT", 126, 128], ["LPS", "SIMPLE_CHEMICAL", 184, 187], ["monocytic cells", "CELL", 200, 215], ["cytokines", "PROTEIN", 6, 15], ["vascular endothelial growth factor", "PROTEIN", 47, 81], ["solute carrier family 11 member 1", "PROTEIN", 87, 120], ["monocytic cells", "CELL_TYPE", 200, 215], ["monocytic cells", "TEST", 200, 215], ["vascular endothelial", "ANATOMY", 47, 67]]], ["Cytokines such as TNF\u2010\u03b1, IL\u20101, IL\u20106, and IL\u20108 not only contribute to effector mechanisms of innate immunity but also help the activation of adaptive immunity.RECOGNITION AND RESPONSE IN INNATE IMMUNITYPost\u2010transcriptional regulation of the inflammatory response as a result of endotoxin also offers a negative\u2010feedback control, as excessive proinflammatory cytokine production, notably, TNF\u2010\u03b1, can lead to deleterious, local and systemic effects including septic shock.", [["endotoxin", "CHEMICAL", 277, 286], ["septic shock", "DISEASE", 456, 468], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 18, 23], ["IL\u20101", "GENE_OR_GENE_PRODUCT", 25, 29], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 31, 35], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 41, 45], ["endotoxin", "SIMPLE_CHEMICAL", 277, 286], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 387, 392], ["Cytokines", "PROTEIN", 0, 9], ["TNF\u2010\u03b1", "PROTEIN", 18, 23], ["IL\u20106", "PROTEIN", 31, 35], ["IL\u20108", "PROTEIN", 41, 45], ["proinflammatory cytokine", "PROTEIN", 341, 365], ["TNF\u2010\u03b1", "PROTEIN", 387, 392], ["Cytokines", "TREATMENT", 0, 9], ["TNF", "TEST", 18, 21], ["IL", "TEST", 25, 27], ["IL", "TREATMENT", 41, 43], ["adaptive immunity", "TREATMENT", 140, 157], ["the inflammatory response", "PROBLEM", 236, 261], ["endotoxin", "TREATMENT", 277, 286], ["a negative\u2010feedback control", "TREATMENT", 299, 326], ["excessive proinflammatory cytokine production", "PROBLEM", 331, 376], ["deleterious, local and systemic effects", "PROBLEM", 406, 445], ["septic shock", "PROBLEM", 456, 468], ["inflammatory", "OBSERVATION_MODIFIER", 240, 252], ["septic shock", "OBSERVATION", 456, 468]]], ["TTP knockout mice having macrophages and neutrophils, which release higher levels of TNF\u2010\u03b1 and GM\u2010CSF, display diseases associated with TNF\u2010\u03b1 over secretion such as inflammatory arthritis [45].", [["macrophages", "ANATOMY", 25, 36], ["neutrophils", "ANATOMY", 41, 52], ["inflammatory arthritis", "DISEASE", 165, 187], ["TTP", "GENE_OR_GENE_PRODUCT", 0, 3], ["mice", "ORGANISM", 13, 17], ["macrophages", "CELL", 25, 36], ["neutrophils", "CELL", 41, 52], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 85, 90], ["GM\u2010CSF", "GENE_OR_GENE_PRODUCT", 95, 101], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 136, 141], ["TTP", "PROTEIN", 0, 3], ["macrophages", "CELL_TYPE", 25, 36], ["neutrophils", "CELL_TYPE", 41, 52], ["TNF\u2010\u03b1", "PROTEIN", 85, 90], ["GM", "PROTEIN", 95, 97], ["CSF", "PROTEIN", 98, 101], ["TNF\u2010\u03b1", "PROTEIN", 136, 141], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["TTP knockout", "TEST", 0, 12], ["macrophages", "PROBLEM", 25, 36], ["neutrophils", "TEST", 41, 52], ["TNF", "TEST", 85, 88], ["GM\u2010CSF", "TEST", 95, 101], ["diseases", "PROBLEM", 111, 119], ["TNF", "PROBLEM", 136, 139], ["inflammatory arthritis", "PROBLEM", 165, 187], ["diseases", "OBSERVATION", 111, 119], ["inflammatory", "OBSERVATION_MODIFIER", 165, 177]]], ["Some of these diseases are similar to mice with genetic knockout of the TNF\u2010\u03b1 ARE region [46,47].RECOGNITION AND RESPONSE IN INNATE IMMUNITYLike TTP, AUF1 acts as another negative\u2010feedback mediator of the innate response to endotoxin; it has been demonstrated recently that LPS challenge in AUF1\u2010knockout mice displays symptoms of severe endotoxic shock as a result of overproduction of TNF\u2010\u03b1 and IL\u20101\u03b2 [48].", [["endotoxin", "CHEMICAL", 224, 233], ["LPS", "CHEMICAL", 274, 277], ["endotoxic shock", "DISEASE", 338, 353], ["mice", "ORGANISM", 38, 42], ["TNF", "GENE_OR_GENE_PRODUCT", 72, 75], ["AUF1", "GENE_OR_GENE_PRODUCT", 150, 154], ["LPS", "SIMPLE_CHEMICAL", 274, 277], ["AUF1", "GENE_OR_GENE_PRODUCT", 291, 295], ["mice", "ORGANISM", 305, 309], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 387, 392], ["IL\u20101\u03b2", "GENE_OR_GENE_PRODUCT", 397, 402], ["TNF\u2010\u03b1 ARE region", "DNA", 72, 88], ["TTP", "PROTEIN", 145, 148], ["AUF1", "PROTEIN", 150, 154], ["endotoxin", "PROTEIN", 224, 233], ["AUF1", "PROTEIN", 291, 295], ["TNF", "PROTEIN", 387, 390], ["\u2010\u03b1", "PROTEIN", 390, 392], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 305, 309], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 305, 309], ["these diseases", "PROBLEM", 8, 22], ["TTP", "PROBLEM", 145, 148], ["endotoxin", "TREATMENT", 224, 233], ["LPS challenge", "TREATMENT", 274, 287], ["symptoms", "PROBLEM", 319, 327], ["severe endotoxic shock", "PROBLEM", 331, 353], ["overproduction of TNF", "PROBLEM", 369, 390], ["diseases", "OBSERVATION", 14, 22], ["severe", "OBSERVATION_MODIFIER", 331, 337], ["endotoxic shock", "OBSERVATION", 338, 353]]], ["This is attributed to the inability to degrade the mRNAs efficiently as a result of absence of AUF1.", [["AUF1", "GENE_OR_GENE_PRODUCT", 95, 99], ["mRNAs", "RNA", 51, 56], ["AUF1", "PROTEIN", 95, 99], ["AUF1", "PROBLEM", 95, 99]]], ["Although HuR is an RNA stabilization protein, it can have a negative modulatory function in specific situations.", [["HuR", "GENE_OR_GENE_PRODUCT", 9, 12], ["HuR", "PROTEIN", 9, 12], ["RNA stabilization protein", "PROTEIN", 19, 44], ["an RNA stabilization protein", "PROBLEM", 16, 44]]], ["This effect has been shown to suppress specific, proinflammatory mRNA targets such as TNF\u2010\u03b1 and COX\u20102, using in vivo models with conditional overexpression in macrophage subpopulations [49].", [["macrophage", "ANATOMY", 159, 169], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 86, 91], ["COX\u20102", "GENE_OR_GENE_PRODUCT", 96, 101], ["macrophage", "CELL", 159, 169], ["proinflammatory mRNA", "RNA", 49, 69], ["TNF\u2010\u03b1", "PROTEIN", 86, 91], ["COX\u20102", "PROTEIN", 96, 101], ["macrophage subpopulations", "CELL_TYPE", 159, 184], ["proinflammatory mRNA targets", "PROBLEM", 49, 77], ["TNF", "TEST", 86, 89], ["COX\u20102", "TEST", 96, 101], ["conditional overexpression in macrophage subpopulations", "PROBLEM", 129, 184]]], ["These three animal models of TTP, AUF1, and HuR offer direct in vivo evidence for the role of post\u2010transcriptional control in innate immunity.RECOGNITION AND RESPONSE IN INNATE IMMUNITYIn addition to LPS, another bacterial component that is an important stimulus of innate immunity is the unmethylated CpG DNA.", [["LPS", "CHEMICAL", 200, 203], ["CpG", "CHEMICAL", 302, 305], ["TTP", "GENE_OR_GENE_PRODUCT", 29, 32], ["AUF1", "GENE_OR_GENE_PRODUCT", 34, 38], ["HuR", "GENE_OR_GENE_PRODUCT", 44, 47], ["LPS", "SIMPLE_CHEMICAL", 200, 203], ["DNA", "CELLULAR_COMPONENT", 306, 309], ["TTP", "PROTEIN", 29, 32], ["AUF1", "PROTEIN", 34, 38], ["HuR", "PROTEIN", 44, 47], ["unmethylated CpG DNA", "DNA", 289, 309], ["TTP", "PROBLEM", 29, 32], ["post\u2010transcriptional control", "TREATMENT", 94, 122], ["LPS", "TREATMENT", 200, 203], ["another bacterial component", "PROBLEM", 205, 232], ["the unmethylated CpG DNA", "TREATMENT", 285, 309], ["TTP", "OBSERVATION", 29, 32]]], ["It binds TLR9 on DC, neutrophils, monocytes, and also, in airway epithelia cells triggering a signal transduction cascade similar to those in response to LPS [50,51,52].", [["DC", "ANATOMY", 17, 19], ["neutrophils", "ANATOMY", 21, 32], ["monocytes", "ANATOMY", 34, 43], ["airway epithelia cells", "ANATOMY", 58, 80], ["LPS", "CHEMICAL", 154, 157], ["TLR9", "GENE_OR_GENE_PRODUCT", 9, 13], ["DC", "CELL", 17, 19], ["neutrophils", "CELL", 21, 32], ["monocytes", "CELL", 34, 43], ["airway epithelia cells", "CELL", 58, 80], ["LPS", "SIMPLE_CHEMICAL", 154, 157], ["TLR9", "PROTEIN", 9, 13], ["DC", "CELL_TYPE", 17, 19], ["neutrophils", "CELL_TYPE", 21, 32], ["monocytes", "CELL_TYPE", 34, 43], ["airway epithelia cells", "CELL_TYPE", 58, 80], ["DC", "TEST", 17, 19], ["neutrophils", "TEST", 21, 32], ["monocytes", "TEST", 34, 43], ["airway epithelia cells", "PROBLEM", 58, 80], ["a signal transduction cascade", "PROBLEM", 92, 121], ["LPS", "TEST", 154, 157], ["TLR9", "OBSERVATION_MODIFIER", 9, 13], ["monocytes", "ANATOMY", 34, 43], ["airway", "ANATOMY", 58, 64], ["epithelia cells", "OBSERVATION", 65, 80]]], ["Cytokines such as IL\u20101\u03b1 and TNF\u2010\u03b1 synergize with CpG DNA to induce IL\u20108 production in airway epithelia, mainly by p38 MAPK activation and stability of IL\u20108 mRNA [51].", [["airway epithelia", "ANATOMY", 86, 102], ["CpG", "CHEMICAL", 49, 52], ["IL\u20101\u03b1", "GENE_OR_GENE_PRODUCT", 18, 23], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 28, 33], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 67, 71], ["airway epithelia", "TISSUE", 86, 102], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 114, 122], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 151, 155], ["Cytokines", "PROTEIN", 0, 9], ["IL\u20101\u03b1", "PROTEIN", 18, 23], ["TNF\u2010\u03b1", "PROTEIN", 28, 33], ["CpG DNA", "DNA", 49, 56], ["IL\u20108", "PROTEIN", 67, 71], ["p38 MAPK", "PROTEIN", 114, 122], ["IL\u20108 mRNA", "RNA", 151, 160], ["Cytokines", "TREATMENT", 0, 9], ["IL\u2010", "TREATMENT", 18, 21], ["TNF\u2010\u03b1 synergize", "TREATMENT", 28, 43], ["CpG DNA", "TREATMENT", 49, 56], ["IL\u2010", "TREATMENT", 67, 70], ["airway epithelia", "PROBLEM", 86, 102], ["MAPK activation", "TEST", 118, 133], ["airway epithelia", "ANATOMY", 86, 102]]], ["CpG DNA can augment DC function and maturation using post\u2010transcriptional mechanisms.", [["DC", "ANATOMY", 20, 22], ["CpG", "CHEMICAL", 0, 3], ["CpG", "CHEMICAL", 0, 3], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["DC", "CELL", 20, 22], ["CpG DNA", "DNA", 0, 7], ["DC", "CELL_TYPE", 20, 22], ["CpG DNA", "TREATMENT", 0, 7], ["post\u2010transcriptional mechanisms", "TREATMENT", 53, 84]]], ["For example, CpG DNA increases MHC I mRNA stability in DC by an IFN\u2010\u03b1/\u03b2\u2010dependent process [52].", [["DC", "ANATOMY", 55, 57], ["CpG", "CHEMICAL", 13, 16], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["MHC I", "GENE_OR_GENE_PRODUCT", 31, 36], ["DC", "CELL", 55, 57], ["IFN\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 64, 69], ["CpG DNA", "DNA", 13, 20], ["MHC I mRNA", "RNA", 31, 41], ["DC", "CELL_TYPE", 55, 57], ["IFN", "PROTEIN", 64, 67], ["CpG DNA", "PROBLEM", 13, 20]]], ["HuR binds to a defined, secondary RNA element in the DC mRNA of CD83 and increases its protein expression [53].", [["DC", "ANATOMY", 53, 55], ["HuR", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD83", "GENE_OR_GENE_PRODUCT", 64, 68], ["HuR", "PROTEIN", 0, 3], ["secondary RNA element", "RNA", 24, 45], ["DC mRNA", "RNA", 53, 60], ["CD83", "PROTEIN", 64, 68], ["HuR binds", "PROBLEM", 0, 9], ["secondary RNA element", "PROBLEM", 24, 45], ["RNA element", "OBSERVATION", 34, 45]]], ["However, this effect does not involve mRNA stabilization, probably as a result of lack of AREs in CD83 3\u2032UTR [1] but most likely because of enhanced, chromosome region maintenance 1\u2010mediated translocation of CD83 mRNA to the cytoplasm by HuR [53].", [["chromosome region", "ANATOMY", 150, 167], ["cytoplasm", "ANATOMY", 225, 234], ["CD83", "GENE_OR_GENE_PRODUCT", 98, 102], ["chromosome", "CELLULAR_COMPONENT", 150, 160], ["CD83", "GENE_OR_GENE_PRODUCT", 208, 212], ["cytoplasm", "ORGANISM_SUBSTANCE", 225, 234], ["HuR", "GENE_OR_GENE_PRODUCT", 238, 241], ["AREs", "DNA", 90, 94], ["CD83 3\u2032UTR", "DNA", 98, 108], ["chromosome region", "DNA", 150, 167], ["CD83 mRNA", "RNA", 208, 217], ["HuR", "PROTEIN", 238, 241], ["mRNA stabilization", "PROBLEM", 38, 56], ["lack of AREs", "PROBLEM", 82, 94], ["CD83", "TEST", 98, 102], ["UTR", "TEST", 105, 108], ["enhanced, chromosome region", "PROBLEM", 140, 167], ["most likely", "UNCERTAINTY", 117, 128]]], ["Mature DC, which express CD83, are efficient in the stimulation of naive CD4+ and CD8+ T cells.", [["DC", "ANATOMY", 7, 9], ["CD4+ and CD8+ T cells", "ANATOMY", 73, 94], ["DC", "CELL", 7, 9], ["CD83", "GENE_OR_GENE_PRODUCT", 25, 29], ["CD4", "GENE_OR_GENE_PRODUCT", 73, 76], ["CD8", "GENE_OR_GENE_PRODUCT", 82, 85], ["DC", "CELL_TYPE", 7, 9], ["CD83", "PROTEIN", 25, 29], ["naive CD4+ and CD8+ T cells", "CELL_TYPE", 67, 94], ["Mature DC", "PROBLEM", 0, 9], ["naive CD4", "TEST", 67, 76]]], ["So, these post\u2010transcriptional, regulation events contribute to the efficient maturation of DC\u2014cells, which are important APCs\u2014and further, aid bridging innate immunity to adaptive immunity.INNATE IMMUNITY TO VIRUS AND dsRNADifferent viruses code for different viral proteins, which can control the cell\u2019s machinery for their growth or to evade immune cells [54].", [["DC\u2014cells", "ANATOMY", 92, 100], ["cell", "ANATOMY", 299, 303], ["immune cells", "ANATOMY", 345, 357], ["DC\u2014cells", "GENE_OR_GENE_PRODUCT", 92, 100], ["dsRNADifferent viruses", "ORGANISM", 219, 241], ["cell", "CELL", 299, 303], ["immune cells", "CELL", 345, 357], ["DC\u2014cells", "CELL_TYPE", 92, 100], ["viral proteins", "PROTEIN", 261, 275], ["immune cells", "CELL_TYPE", 345, 357], ["the efficient maturation of DC\u2014cells", "PROBLEM", 64, 100], ["VIRUS", "PROBLEM", 209, 214], ["dsRNADifferent viruses code", "TREATMENT", 219, 246], ["different viral proteins", "PROBLEM", 251, 275]]], ["Viruses can stabilize mRNAs of gene products that are essential to the virus life cycle.", [["mRNAs", "RNA", 22, 27], ["Viruses", "PROBLEM", 0, 7], ["mRNAs of gene products", "TREATMENT", 22, 44]]], ["HSV infection can lead to stabilization of the ARE\u2010mRNA, termed immediate early response 3 (IEX\u20101), probably by means of its transregulatory protein ICP27, which is essential in HSV early gene expression [55,56].", [["HSV infection", "DISEASE", 0, 13], ["HSV", "ORGANISM", 0, 3], ["immediate early response 3", "GENE_OR_GENE_PRODUCT", 64, 90], ["IEX\u20101", "GENE_OR_GENE_PRODUCT", 92, 97], ["ICP27", "GENE_OR_GENE_PRODUCT", 149, 154], ["HSV", "ORGANISM", 178, 181], ["ARE\u2010mRNA", "DNA", 47, 55], ["transregulatory protein", "PROTEIN", 125, 148], ["ICP27", "PROTEIN", 149, 154], ["HSV", "SPECIES", 0, 3], ["HSV", "SPECIES", 178, 181], ["HSV infection", "PROBLEM", 0, 13], ["its transregulatory protein ICP27", "PROBLEM", 121, 154], ["infection", "OBSERVATION", 4, 13]]], ["The latent membrane protein 1 (LMP1) of EBV is a major player in the induction of cytokines, which in turn, support the growth and survival of the EBV\u2010infected B cells.", [["B cells", "ANATOMY", 160, 167], ["latent membrane protein 1", "GENE_OR_GENE_PRODUCT", 4, 29], ["LMP1", "GENE_OR_GENE_PRODUCT", 31, 35], ["EBV", "ORGANISM", 40, 43], ["EBV", "ORGANISM", 147, 150], ["B cells", "CELL", 160, 167], ["latent membrane protein 1", "PROTEIN", 4, 29], ["LMP1", "PROTEIN", 31, 35], ["cytokines", "PROTEIN", 82, 91], ["EBV\u2010infected B cells", "CELL_LINE", 147, 167], ["The latent membrane protein", "TEST", 0, 27], ["EBV", "PROBLEM", 40, 43], ["the induction of cytokines", "TREATMENT", 65, 91], ["the growth", "PROBLEM", 116, 126], ["the EBV\u2010infected B cells", "PROBLEM", 143, 167], ["latent", "OBSERVATION_MODIFIER", 4, 10], ["membrane protein", "OBSERVATION", 11, 27]]], ["LMP1 activates the p38 MAPK pathway and stabilizes IP\u201010 [57].", [["LMP1", "GENE_OR_GENE_PRODUCT", 0, 4], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 19, 27], ["LMP1", "PROTEIN", 0, 4], ["p38 MAPK", "PROTEIN", 19, 27], ["the p38 MAPK pathway", "TEST", 15, 35]]], ["The Kaposi sarcoma (KS) herpes virus (KSHV or HSV\u20108), which causes angioproliferative regions in immunocompromised patients such as AIDS and transplant patients, promotes the production of proinflammatory cytokines.", [["Kaposi sarcoma (KS) herpes virus", "DISEASE", 4, 36], ["AIDS", "DISEASE", 132, 136], ["Kaposi sarcoma (KS) herpes virus", "ORGANISM", 4, 36], ["KSHV", "ORGANISM", 38, 42], ["HSV\u20108", "ORGANISM", 46, 51], ["patients", "ORGANISM", 115, 123], ["patients", "ORGANISM", 152, 160], ["proinflammatory cytokines", "PROTEIN", 189, 214], ["herpes virus", "SPECIES", 24, 36], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 152, 160], ["Kaposi sarcoma (KS) herpes virus", "SPECIES", 4, 36], ["KSHV", "SPECIES", 38, 42], ["HSV", "SPECIES", 46, 49], ["The Kaposi sarcoma", "PROBLEM", 0, 18], ["herpes virus", "PROBLEM", 24, 36], ["KSHV", "PROBLEM", 38, 42], ["HSV", "TEST", 46, 49], ["angioproliferative regions in immunocompromised patients", "PROBLEM", 67, 123], ["AIDS", "PROBLEM", 132, 136], ["transplant patients", "TREATMENT", 141, 160], ["proinflammatory cytokines", "PROBLEM", 189, 214], ["Kaposi sarcoma", "OBSERVATION", 4, 18], ["immunocompromised", "OBSERVATION", 97, 114], ["proinflammatory cytokines", "OBSERVATION", 189, 214]]], ["Using a two\u2010hybrid system, the KSHV latent protein kaposin B has been shown to interact with the c\u2010lobe of the activation domain of MK2 and requires both of the two proline\u2010rich, 23\u2010amino acid direct repeats in kaposin B [58,59].", [["kaposin B", "CHEMICAL", 211, 220], ["proline\u2010rich", "CHEMICAL", 165, 177], ["\u2010amino acid", "CHEMICAL", 181, 192], ["kaposin B", "CHEMICAL", 211, 220], ["KSHV", "ORGANISM", 31, 35], ["kaposin B", "GENE_OR_GENE_PRODUCT", 51, 60], ["MK2", "GENE_OR_GENE_PRODUCT", 132, 135], ["proline\u2010rich", "GENE_OR_GENE_PRODUCT", 165, 177], ["kaposin B", "GENE_OR_GENE_PRODUCT", 211, 220], ["KSHV latent protein", "PROTEIN", 31, 50], ["kaposin B", "PROTEIN", 51, 60], ["c\u2010lobe", "PROTEIN", 97, 103], ["activation domain", "PROTEIN", 111, 128], ["MK2", "PROTEIN", 132, 135], ["proline\u2010rich, 23\u2010amino acid direct repeats", "PROTEIN", 165, 207], ["kaposin B", "PROTEIN", 211, 220], ["KSHV", "SPECIES", 31, 35], ["a two\u2010hybrid system", "TREATMENT", 6, 25], ["the KSHV latent protein kaposin B", "TREATMENT", 27, 60], ["the two proline\u2010rich", "TREATMENT", 157, 177]]], ["As a result, MK2 becomes phosphorylated, and loss of destabilization of AU\u2010rich mRNAs such as GM\u2010CSF and IL\u20106 occurs [58].", [["GM", "CHEMICAL", 94, 96], ["MK2", "GENE_OR_GENE_PRODUCT", 13, 16], ["AU\u2010rich", "GENE_OR_GENE_PRODUCT", 72, 79], ["GM\u2010CSF", "GENE_OR_GENE_PRODUCT", 94, 100], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 105, 109], ["MK2", "PROTEIN", 13, 16], ["AU\u2010rich mRNAs", "RNA", 72, 85], ["GM", "PROTEIN", 94, 96], ["CSF", "PROTEIN", 97, 100], ["IL\u20106", "PROTEIN", 105, 109], ["phosphorylated", "PROBLEM", 25, 39], ["AU\u2010rich mRNAs", "PROBLEM", 72, 85], ["GM\u2010CSF", "TEST", 94, 100]]], ["IL\u20106 is overexpressed in KS tumors and contributes to its pathogenesis [60].INNATE IMMUNITY TO VIRUS AND dsRNAReplication of hepatitis C virus (HCV) in cultured liver cell lines leads to prolongation of the IL\u20108 mRNA half\u2010life, probably by its nonstructural protein NS5A, and particularly, in the presence of TNF\u2010\u03b1, a potent inducer of IL\u20108 [28].", [["KS tumors", "ANATOMY", 25, 34], ["liver cell lines", "ANATOMY", 161, 177], ["tumors", "DISEASE", 28, 34], ["hepatitis C", "DISEASE", 125, 136], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 0, 4], ["KS tumors", "CANCER", 25, 34], ["hepatitis C virus", "ORGANISM", 125, 142], ["HCV", "ORGANISM", 144, 147], ["liver cell lines", "CELL", 161, 177], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 207, 211], ["NS5A", "GENE_OR_GENE_PRODUCT", 266, 270], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 309, 314], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 336, 340], ["IL\u20106", "PROTEIN", 0, 4], ["cultured liver cell lines", "CELL_LINE", 152, 177], ["IL\u20108 mRNA", "RNA", 207, 216], ["nonstructural protein NS5A", "PROTEIN", 244, 270], ["TNF\u2010\u03b1", "PROTEIN", 309, 314], ["hepatitis C virus", "SPECIES", 125, 142], ["hepatitis C virus", "SPECIES", 125, 142], ["HCV", "SPECIES", 144, 147], ["KS tumors", "PROBLEM", 25, 34], ["its pathogenesis", "PROBLEM", 54, 70], ["hepatitis C virus", "PROBLEM", 125, 142], ["HCV", "PROBLEM", 144, 147], ["cultured liver cell lines", "TREATMENT", 152, 177], ["the IL\u20108 mRNA half\u2010life", "TREATMENT", 203, 226], ["its nonstructural protein NS5A", "PROBLEM", 240, 270], ["a potent inducer of IL", "TREATMENT", 316, 338], ["KS", "ANATOMY", 25, 27], ["tumors", "OBSERVATION", 28, 34], ["hepatitis", "OBSERVATION", 125, 134], ["liver", "ANATOMY", 161, 166], ["cell lines", "OBSERVATION", 167, 177], ["protein NS5A", "OBSERVATION", 258, 270]]], ["A possible mechanism is that HCV, in a similar manner to dsRNA, which is an intermediate viral product, may activate the retinoic acid\u2010inducible gene I (RIG\u2010I) pathway, leading to IL\u20108 mRNA stabilization.", [["HCV", "ORGANISM", 29, 32], ["retinoic acid\u2010inducible gene I", "GENE_OR_GENE_PRODUCT", 121, 151], ["RIG\u2010I", "GENE_OR_GENE_PRODUCT", 153, 158], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 180, 184], ["retinoic acid\u2010inducible gene I", "DNA", 121, 151], ["RIG\u2010I", "DNA", 153, 158], ["IL\u20108 mRNA", "RNA", 180, 189], ["HCV", "SPECIES", 29, 32], ["HCV", "PROBLEM", 29, 32], ["IL\u20108 mRNA stabilization", "TREATMENT", 180, 203], ["possible", "UNCERTAINTY", 2, 10], ["HCV", "OBSERVATION", 29, 32], ["dsRNA", "OBSERVATION", 57, 62], ["viral product", "OBSERVATION", 89, 102], ["mRNA stabilization", "OBSERVATION", 185, 203]]], ["RIG\u2010I along with melanoma differentiation\u2010associated gene 5, which has been a focus of research in recent years, are RNA helicases, recognizing viral dsRNA and triggering IFN response [61].", [["melanoma", "ANATOMY", 17, 25], ["melanoma", "DISEASE", 17, 25], ["RIG\u2010I", "GENE_OR_GENE_PRODUCT", 0, 5], ["melanoma differentiation\u2010associated gene 5", "GENE_OR_GENE_PRODUCT", 17, 59], ["IFN", "GENE_OR_GENE_PRODUCT", 171, 174], ["RIG\u2010I", "PROTEIN", 0, 5], ["melanoma differentiation\u2010associated gene 5", "DNA", 17, 59], ["RNA helicases", "PROTEIN", 117, 130], ["IFN", "PROTEIN", 171, 174], ["melanoma differentiation\u2010associated gene 5", "PROBLEM", 17, 59], ["RNA helicases", "PROBLEM", 117, 130], ["recognizing viral dsRNA", "PROBLEM", 132, 155], ["melanoma", "OBSERVATION", 17, 25], ["focus", "OBSERVATION_MODIFIER", 78, 83], ["viral dsRNA", "OBSERVATION", 144, 155]]], ["Two recent studies have shown that RIG\u2010I can distinguish viral, uncapped ssRNA from cellular mRNAs [62,63].", [["cellular", "ANATOMY", 84, 92], ["RIG", "GENE_OR_GENE_PRODUCT", 35, 38], ["cellular", "CELL", 84, 92], ["RIG", "PROTEIN", 35, 38], ["viral, uncapped ssRNA", "RNA", 57, 78], ["cellular mRNAs", "RNA", 84, 98], ["Two recent studies", "TEST", 0, 18], ["viral", "PROBLEM", 57, 62], ["cellular mRNAs", "TEST", 84, 98], ["viral", "OBSERVATION", 57, 62], ["uncapped ssRNA", "OBSERVATION", 64, 78], ["cellular mRNAs", "OBSERVATION", 84, 98]]], ["These proteins and their adaptors have been explored largely for their transcriptional induction of IFN regulatory factor 3\u2010dependent IFN and NF\u2010\u03baB\u2010mediated proinflammatory cytokines when compared with post\u2010transcriptional effects.", [["IFN regulatory factor 3", "GENE_OR_GENE_PRODUCT", 100, 123], ["IFN", "GENE_OR_GENE_PRODUCT", 134, 137], ["NF\u2010\u03ba", "GENE_OR_GENE_PRODUCT", 142, 146], ["IFN regulatory factor 3", "PROTEIN", 100, 123], ["IFN", "PROTEIN", 134, 137], ["NF\u2010\u03baB\u2010mediated proinflammatory cytokines", "PROTEIN", 142, 182], ["IFN regulatory factor", "PROBLEM", 100, 121], ["dependent IFN", "PROBLEM", 124, 137], ["NF", "PROBLEM", 142, 144], ["B\u2010mediated proinflammatory cytokines", "PROBLEM", 146, 182], ["proinflammatory cytokines", "OBSERVATION", 157, 182]]], ["Recently, it has been shown that a constitutively active RIG\u2010I protein, RIG\u2010N, stabilizes TNF\u2010\u03b1\u2010induced IL\u20108 mRNA and increases reporter activity from a construct that is fused with ARE\u2010bearing, IL\u20108 3\u2032UTR [64].", [["RIG", "GENE_OR_GENE_PRODUCT", 57, 60], ["RIG\u2010N", "GENE_OR_GENE_PRODUCT", 72, 77], ["TNF", "GENE_OR_GENE_PRODUCT", 90, 93], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 104, 108], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 195, 199], ["RIG", "PROTEIN", 57, 60], ["I protein", "PROTEIN", 61, 70], ["RIG\u2010N", "PROTEIN", 72, 77], ["TNF\u2010\u03b1\u2010induced IL\u20108 mRNA", "RNA", 90, 113], ["ARE", "DNA", 182, 185], ["TNF", "TEST", 90, 93], ["IL\u2010", "TREATMENT", 104, 107], ["constitutively", "OBSERVATION_MODIFIER", 35, 49], ["active", "OBSERVATION_MODIFIER", 50, 56]]], ["IL\u20108 is a proinflammatory cytokine, which appears to exaggerate HCV\u2010induced hepatitis.", [["hepatitis", "DISEASE", 76, 85], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 0, 4], ["HCV\u2010induced hepatitis", "ORGANISM", 64, 85], ["IL\u20108", "PROTEIN", 0, 4], ["proinflammatory cytokine", "PROTEIN", 10, 34], ["HCV", "SPECIES", 64, 67], ["a proinflammatory cytokine", "PROBLEM", 8, 34], ["HCV\u2010induced hepatitis", "PROBLEM", 64, 85], ["proinflammatory cytokine", "OBSERVATION", 10, 34], ["HCV", "OBSERVATION", 64, 67], ["hepatitis", "OBSERVATION", 76, 85]]], ["Thus, HCV\u2010driven stabilization of IL\u20108 mRNA may explain, at least in part, the increased IL\u20108 levels seen in the sera of HCV patients and those that are nonresponsive to IFN therapy [65].INNATE IMMUNITY TO VIRUS AND dsRNAFor successful takeover of cell machinery for their own growth, viruses have the ability to shut\u2010off cellular mRNA biogenesis and induce rapid degradation of selected cellular mRNAs, particularly those required for host defense.", [["sera", "ANATOMY", 113, 117], ["cell", "ANATOMY", 248, 252], ["cellular", "ANATOMY", 322, 330], ["cellular", "ANATOMY", 388, 396], ["HCV", "DISEASE", 121, 124], ["IFN", "CHEMICAL", 170, 173], ["HCV\u2010", "ORGANISM", 6, 10], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 34, 38], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 89, 93], ["sera", "ORGANISM_SUBSTANCE", 113, 117], ["HCV", "ORGANISM", 121, 124], ["patients", "ORGANISM", 125, 133], ["cell", "CELL", 248, 252], ["cellular", "CELL", 322, 330], ["cellular", "CELL", 388, 396], ["IL\u20108 mRNA", "RNA", 34, 43], ["IL\u20108", "PROTEIN", 89, 93], ["IFN", "PROTEIN", 170, 173], ["cellular mRNAs", "RNA", 388, 402], ["patients", "SPECIES", 125, 133], ["HCV", "SPECIES", 6, 9], ["HCV", "SPECIES", 121, 124], ["HCV", "PROBLEM", 6, 9], ["stabilization of IL\u2010", "TREATMENT", 17, 37], ["the increased IL\u2010", "TREATMENT", 75, 92], ["IFN therapy", "TREATMENT", 170, 181], ["cell machinery", "TREATMENT", 248, 262], ["viruses", "PROBLEM", 285, 292], ["cellular mRNA biogenesis", "TREATMENT", 322, 346], ["rapid degradation of selected cellular mRNAs", "PROBLEM", 358, 402], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["cellular mRNAs", "OBSERVATION", 388, 402]]], ["For example, the nonstructural protein, nsp1, from the severe acute respiratory syndrome coronavirus, suppresses IFN\u2010\u03b2 production at a post\u2010transcriptional level by increasing its mRNA decay [66].", [["acute respiratory syndrome coronavirus", "DISEASE", 62, 100], ["nsp1", "GENE_OR_GENE_PRODUCT", 40, 44], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 55, 100], ["IFN\u2010\u03b2", "GENE_OR_GENE_PRODUCT", 113, 118], ["nonstructural protein", "PROTEIN", 17, 38], ["nsp1", "PROTEIN", 40, 44], ["IFN", "PROTEIN", 113, 116], ["\u2010\u03b2", "PROTEIN", 116, 118], ["severe acute respiratory syndrome coronavirus", "SPECIES", 55, 100], ["the nonstructural protein", "TEST", 13, 38], ["nsp1", "PROBLEM", 40, 44], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 51, 100], ["IFN\u2010\u03b2 production", "PROBLEM", 113, 129], ["nonstructural protein", "OBSERVATION", 17, 38], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["respiratory syndrome coronavirus", "OBSERVATION", 68, 100]]], ["Cytomegalovirus is able to destabilize IL\u20106 mRNA with concomitant translocation of HuR to the cytoplasmic compartment [67], although this process is usually known to cause up\u2010regulation of ARE and ARE\u2010like\u2010containing mRNA [68].", [["cytoplasmic compartment", "ANATOMY", 94, 117], ["Cytomegalovirus", "ORGANISM", 0, 15], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 39, 43], ["HuR", "GENE_OR_GENE_PRODUCT", 83, 86], ["cytoplasmic", "ORGANISM_SUBSTANCE", 94, 105], ["ARE", "GENE_OR_GENE_PRODUCT", 189, 192], ["ARE\u2010", "GENE_OR_GENE_PRODUCT", 197, 201], ["IL\u20106 mRNA", "RNA", 39, 48], ["HuR", "PROTEIN", 83, 86], ["ARE", "DNA", 189, 192], ["ARE", "DNA", 197, 200], ["Cytomegalovirus", "PROBLEM", 0, 15], ["HuR", "OBSERVATION", 83, 86]]], ["The HSV\u20101 open\u2010reading frame UL41, which encodes virion host shut\u2010off or vhs, can act as an endoRNase or a component of the RNase complex, degrading cellular mRNAs such IEX\u20101 mRNA [69], although this study is in conflict with other reports that HSV\u20101 infection leads to IEX\u20101 mRNA stabilization [55,56].", [["cellular", "ANATOMY", 149, 157], ["infection", "DISEASE", 251, 260], ["HSV\u20101", "ORGANISM", 4, 9], ["UL41", "GENE_OR_GENE_PRODUCT", 29, 33], ["vhs", "GENE_OR_GENE_PRODUCT", 73, 76], ["endoRNase", "GENE_OR_GENE_PRODUCT", 92, 101], ["RNase", "GENE_OR_GENE_PRODUCT", 124, 129], ["cellular", "CELL", 149, 157], ["IEX\u20101", "GENE_OR_GENE_PRODUCT", 169, 174], ["HSV\u20101", "ORGANISM", 245, 250], ["IEX\u20101", "GENE_OR_GENE_PRODUCT", 270, 275], ["HSV\u20101 open\u2010reading frame", "DNA", 4, 28], ["UL41", "DNA", 29, 33], ["vhs", "PROTEIN", 73, 76], ["endoRNase", "PROTEIN", 92, 101], ["RNase complex", "PROTEIN", 124, 137], ["cellular mRNAs", "RNA", 149, 163], ["IEX\u20101 mRNA", "RNA", 169, 179], ["IEX\u20101 mRNA", "RNA", 270, 280], ["HSV\u20101", "SPECIES", 4, 9], ["HSV\u20101", "SPECIES", 245, 250], ["The HSV", "TEST", 0, 7], ["vhs", "PROBLEM", 73, 76], ["the RNase complex", "PROBLEM", 120, 137], ["this study", "TEST", 195, 205], ["HSV", "PROBLEM", 245, 248]]], ["This discrepancy may be a result of the presence of alternative forms of transcripts with different regulatory responses owing to inclusion or exclusion of AREs through alternative splicing and polyadenylation [70].INNATE IMMUNITY TO VIRUS AND dsRNACan the RNA decay\u2010promoting activity of the RNA\u2010binding proteins be harnessed as an antiviral therapeutic strategy?", [["AREs", "GENE_OR_GENE_PRODUCT", 156, 160], ["AREs", "DNA", 156, 160], ["RNA\u2010binding proteins", "PROTEIN", 293, 313], ["exclusion of AREs", "TREATMENT", 143, 160], ["alternative splicing and polyadenylation", "TREATMENT", 169, 209], ["dsRNACan the RNA", "TREATMENT", 244, 260], ["an antiviral therapeutic strategy", "TREATMENT", 330, 363]]], ["KSRP has been tethered to the HIV Type 1 Rev protein, essential in the HIV life cycle, and binds a specific response element in HIV RNA.", [["KSRP", "GENE_OR_GENE_PRODUCT", 0, 4], ["Rev", "GENE_OR_GENE_PRODUCT", 41, 44], ["HIV", "ORGANISM", 128, 131], ["KSRP", "PROTEIN", 0, 4], ["HIV Type 1 Rev protein", "PROTEIN", 30, 52], ["specific response element", "DNA", 99, 124], ["HIV RNA", "RNA", 128, 135], ["HIV", "SPECIES", 128, 131], ["HIV Type 1", "SPECIES", 30, 40], ["HIV", "SPECIES", 71, 74], ["HIV", "SPECIES", 128, 131], ["HIV RNA", "PROBLEM", 128, 135], ["HIV RNA", "OBSERVATION", 128, 135]]], ["The KSRP\u2010Rev is able to bind to HIV RNA and triggers its degradation, leading to a dramatic reduction in HIV replication [9].", [["KSRP", "GENE_OR_GENE_PRODUCT", 4, 8], ["Rev", "GENE_OR_GENE_PRODUCT", 9, 12], ["HIV", "ORGANISM", 32, 35], ["KSRP", "PROTEIN", 4, 8], ["Rev", "PROTEIN", 9, 12], ["HIV RNA", "RNA", 32, 39], ["HIV", "SPECIES", 32, 35], ["HIV", "SPECIES", 105, 108], ["HIV RNA", "PROBLEM", 32, 39], ["a dramatic reduction in HIV replication", "TREATMENT", 81, 120], ["dramatic", "OBSERVATION_MODIFIER", 83, 91], ["reduction", "OBSERVATION_MODIFIER", 92, 101], ["HIV replication", "OBSERVATION", 105, 120]]], ["Likewise, TTP can be used in the same manner, probably with an additional advantage: TTP binds directly to the AU\u2010rich HIV\u20101 RNA and enhances multiple splicing, which leads to a reduction of HIV\u20101 virions [71].T CELL ACTIVATIONActivation of lymphocytes is fundamental to the immune response to antigens and requires two main signals.", [["lymphocytes", "ANATOMY", 241, 252], ["TTP", "GENE_OR_GENE_PRODUCT", 10, 13], ["TTP", "GENE_OR_GENE_PRODUCT", 85, 88], ["HIV\u20101", "ORGANISM", 191, 196], ["lymphocytes", "CELL", 241, 252], ["TTP", "PROTEIN", 10, 13], ["TTP", "PROTEIN", 85, 88], ["AU\u2010rich HIV\u20101 RNA", "RNA", 111, 128], ["lymphocytes", "CELL_TYPE", 241, 252], ["antigens", "PROTEIN", 294, 302], ["HIV\u20101", "SPECIES", 119, 124], ["HIV\u20101", "SPECIES", 191, 196], ["TTP", "PROBLEM", 10, 13], ["TTP binds", "PROBLEM", 85, 94], ["multiple splicing", "PROBLEM", 142, 159], ["lymphocytes", "PROBLEM", 241, 252], ["TTP", "OBSERVATION", 10, 13], ["TTP", "OBSERVATION", 85, 88], ["multiple", "OBSERVATION_MODIFIER", 142, 150], ["splicing", "OBSERVATION", 151, 159], ["CELL ACTIVATIONActivation", "OBSERVATION", 212, 237], ["lymphocytes", "OBSERVATION", 241, 252]]], ["One signal is provided upon the engagement of TcR with the antigen presented with MHC on APCs.", [["APCs", "ANATOMY", 89, 93], ["TcR", "GENE_OR_GENE_PRODUCT", 46, 49], ["APCs", "CELL", 89, 93], ["TcR", "PROTEIN", 46, 49], ["MHC", "PROTEIN", 82, 85], ["APCs", "CELL_TYPE", 89, 93]]], ["The other is delivered by costimulatory molecules, such as lymphocyte function\u2010associated protein 1 (LFA\u20101), CD2, and CD28 on T cells, when they interact with cognate receptors on the APCs.", [["T cells", "ANATOMY", 126, 133], ["APCs", "ANATOMY", 184, 188], ["lymphocyte function\u2010associated protein 1", "GENE_OR_GENE_PRODUCT", 59, 99], ["LFA\u20101", "GENE_OR_GENE_PRODUCT", 101, 106], ["CD2", "GENE_OR_GENE_PRODUCT", 109, 112], ["CD28", "GENE_OR_GENE_PRODUCT", 118, 122], ["T cells", "CELL", 126, 133], ["APCs", "CELL", 184, 188], ["costimulatory molecules", "PROTEIN", 26, 49], ["lymphocyte function\u2010associated protein 1", "PROTEIN", 59, 99], ["LFA\u20101", "PROTEIN", 101, 106], ["CD2", "PROTEIN", 109, 112], ["CD28", "PROTEIN", 118, 122], ["T cells", "CELL_TYPE", 126, 133], ["cognate receptors", "PROTEIN", 159, 176], ["APCs", "CELL_TYPE", 184, 188], ["lymphocyte function\u2010associated protein", "TEST", 59, 97], ["LFA", "TEST", 101, 104], ["CD2", "TEST", 109, 112]]], ["With these two signals, the result is AP\u20101 (c\u2010fos/Jun) induction and commitment production of IL\u20102, the hallmark of T cell activation and differentiation [72].", [["T cell", "ANATOMY", 116, 122], ["AP\u20101", "GENE_OR_GENE_PRODUCT", 38, 42], ["c\u2010fos/Jun", "GENE_OR_GENE_PRODUCT", 44, 53], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 94, 98], ["T cell", "CELL", 116, 122], ["AP\u20101", "PROTEIN", 38, 42], ["c\u2010fos", "PROTEIN", 44, 49], ["Jun", "PROTEIN", 50, 53], ["IL\u20102", "PROTEIN", 94, 98], ["AP\u20101", "TEST", 38, 42], ["c\u2010fos/Jun) induction", "TREATMENT", 44, 64], ["commitment production of IL\u2010", "TREATMENT", 69, 97], ["T cell activation", "OBSERVATION", 116, 133]]], ["Post\u2010transcriptional control plays an important regulatory role in almost all of the events that lead to transcriptional activation (Fig. 2).", [["Post\u2010transcriptional control", "TREATMENT", 0, 28]]], ["A large proportion of genes is regulated by mRNA stability, as revealed with the large\u2010scale, gene\u2010expression profiling in activated T cells [73,74].", [["T cells", "ANATOMY", 133, 140], ["T cells", "CELL", 133, 140], ["activated T cells", "CELL_TYPE", 123, 140], ["mRNA stability", "TEST", 44, 58], ["activated T cells", "PROBLEM", 123, 140], ["large", "OBSERVATION_MODIFIER", 2, 7], ["genes", "OBSERVATION", 22, 27]]], ["One of the most important signaling events in T cell activation that results in stabilization of cytokines, such as IL\u20102, IFN\u2010\u03b3, TNF\u2010\u03b1, and GM\u2010CSF, is induced by the costimulatory CD28 [75].", [["T cell", "ANATOMY", 46, 52], ["T cell", "CELL", 46, 52], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 116, 120], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 122, 127], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 129, 134], ["GM\u2010CSF", "GENE_OR_GENE_PRODUCT", 140, 146], ["CD28", "GENE_OR_GENE_PRODUCT", 180, 184], ["cytokines", "PROTEIN", 97, 106], ["IL\u20102", "PROTEIN", 116, 120], ["IFN\u2010\u03b3", "PROTEIN", 122, 127], ["TNF\u2010\u03b1", "PROTEIN", 129, 134], ["GM", "PROTEIN", 140, 142], ["CSF", "PROTEIN", 143, 146], ["CD28", "PROTEIN", 180, 184], ["T cell activation", "PROBLEM", 46, 63], ["cytokines", "PROBLEM", 97, 106], ["IL", "TEST", 116, 118], ["IFN\u2010\u03b3", "TEST", 122, 127], ["TNF", "TEST", 129, 132], ["GM\u2010CSF", "TEST", 140, 146]]], ["This signaling pathway does not only increase the promoter activity of the cytokines [76] but also stabilizes their mRNAs [75].", [["cytokines", "PROTEIN", 75, 84], ["mRNAs", "RNA", 116, 121]]], ["The increased IL\u20102 mRNA stability is thought to be controlled differently and independent of the PI\u20103K\u2010dependent induction of the IL\u20102 promoter [77,78].", [["IL\u20102", "GENE_OR_GENE_PRODUCT", 14, 18], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 130, 134], ["IL\u20102 mRNA", "RNA", 14, 23], ["IL\u20102 promoter", "DNA", 130, 143], ["The increased IL\u2010", "TREATMENT", 0, 17], ["the PI\u20103K\u2010dependent induction", "TREATMENT", 93, 122], ["the IL\u20102 promoter", "TREATMENT", 126, 143], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["IL", "OBSERVATION_MODIFIER", 14, 16], ["thought to be", "UNCERTAINTY", 37, 50]]], ["Unlike IL\u20102 transcription, CD28\u2010induced stabilization of the IL\u20102 mRNA and possibly other cytokine mRNAs does not require membrane colocalization with the TcR within CD28 in a multimolecular signaling complex, the central supramolecular activation cluster [72,77].", [["membrane", "ANATOMY", 122, 130], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 7, 11], ["CD28", "GENE_OR_GENE_PRODUCT", 27, 31], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 61, 65], ["membrane", "CELLULAR_COMPONENT", 122, 130], ["TcR", "GENE_OR_GENE_PRODUCT", 155, 158], ["CD28", "GENE_OR_GENE_PRODUCT", 166, 170], ["CD28", "PROTEIN", 27, 31], ["IL\u20102 mRNA", "RNA", 61, 70], ["cytokine mRNAs", "RNA", 90, 104], ["TcR", "PROTEIN", 155, 158], ["CD28", "PROTEIN", 166, 170], ["multimolecular signaling complex", "PROTEIN", 176, 208], ["IL\u20102 transcription", "TREATMENT", 7, 25], ["CD28\u2010induced stabilization", "TREATMENT", 27, 53], ["the IL\u20102 mRNA", "TREATMENT", 57, 70], ["other cytokine mRNAs", "PROBLEM", 84, 104], ["membrane colocalization", "TREATMENT", 122, 145]]], ["The role of TTP in IL\u20102 production during T cell activation has been studied in detail [79].", [["T cell", "ANATOMY", 42, 48], ["TTP", "GENE_OR_GENE_PRODUCT", 12, 15], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 19, 23], ["T cell", "CELL", 42, 48], ["TTP", "PROTEIN", 12, 15], ["TTP", "PROBLEM", 12, 15], ["TTP", "OBSERVATION", 12, 15]]], ["The TcR/CD28\u2010engaged or \u2010immobilized, anti\u2010CD3\u2010induced T cells derived from TTP knockout mice have elevated IL\u20102 levels as a result of increased stabilization of the IL\u20102 mRNA [79].", [["T cells", "ANATOMY", 55, 62], ["TcR", "GENE_OR_GENE_PRODUCT", 4, 7], ["CD28", "GENE_OR_GENE_PRODUCT", 8, 12], ["anti\u2010CD3", "GENE_OR_GENE_PRODUCT", 38, 46], ["T cells", "CELL", 55, 62], ["TTP", "GENE_OR_GENE_PRODUCT", 76, 79], ["mice", "ORGANISM", 89, 93], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 108, 112], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 166, 170], ["TcR", "PROTEIN", 4, 7], ["CD28", "PROTEIN", 8, 12], ["anti\u2010CD3\u2010induced T cells", "CELL_LINE", 38, 62], ["TTP", "PROTEIN", 76, 79], ["IL\u20102", "PROTEIN", 108, 112], ["IL\u20102 mRNA", "RNA", 166, 175], ["mice", "SPECIES", 89, 93], ["mice", "SPECIES", 89, 93], ["The TcR/CD28", "TREATMENT", 0, 12], ["anti\u2010CD3", "TREATMENT", 38, 46], ["TTP knockout mice", "PROBLEM", 76, 93], ["elevated IL", "PROBLEM", 99, 110], ["increased", "OBSERVATION_MODIFIER", 135, 144], ["stabilization", "OBSERVATION", 145, 158]]], ["TTP is able to bind 32\u2010base AREs from the IL\u20102 3\u2032UTR and destabilizes reporter mRNA fused with a 3\u2032UTR, which contains the IL\u20102 ARE [79].", [["TTP", "SIMPLE_CHEMICAL", 0, 3], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 123, 127], ["32\u2010base AREs", "DNA", 20, 32], ["IL\u20102 3", "DNA", 42, 48], ["UTR", "DNA", 49, 52], ["reporter mRNA", "RNA", 70, 83], ["UTR", "DNA", 99, 102], ["TTP", "PROBLEM", 0, 3], ["\u2010base AREs", "TEST", 22, 32], ["IL", "OBSERVATION_MODIFIER", 123, 125]]], ["Like CD28, when LFA\u20101 on T cells binds to ICAM\u20101 on APCs, allowing strong adhesion between the two cells and promoting efficient T cell activation [80], it stabilizes certain cytokine mRNAs [81].T CELL ACTIVATIONAlthough it has been reported that HuR translocation occurs in mouse T cells upon CD28\u2010induced signaling, without an effect on IL\u20102 mRNA stabilization [82], LFA\u20101 or CD28 engagement of human\u2010stimulated T cells promoted HuR translocation to the cytoplasm and stabilized TNF\u2010\u03b1 and GM\u2010CSF [81].", [["T cells", "ANATOMY", 25, 32], ["APCs", "ANATOMY", 52, 56], ["cells", "ANATOMY", 99, 104], ["T cell", "ANATOMY", 129, 135], ["T cells", "ANATOMY", 281, 288], ["T cells", "ANATOMY", 414, 421], ["cytoplasm", "ANATOMY", 456, 465], ["CD28", "GENE_OR_GENE_PRODUCT", 5, 9], ["LFA\u20101", "GENE_OR_GENE_PRODUCT", 16, 21], ["T cells", "CELL", 25, 32], ["ICAM\u20101", "GENE_OR_GENE_PRODUCT", 42, 48], ["APCs", "CELL", 52, 56], ["cells", "CELL", 99, 104], ["T cell", "CELL", 129, 135], ["HuR", "GENE_OR_GENE_PRODUCT", 247, 250], ["mouse", "ORGANISM", 275, 280], ["T cells", "CELL", 281, 288], ["CD28", "GENE_OR_GENE_PRODUCT", 294, 298], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 339, 343], ["LFA\u20101", "GENE_OR_GENE_PRODUCT", 369, 374], ["CD28", "GENE_OR_GENE_PRODUCT", 378, 382], ["T cells", "CELL", 414, 421], ["HuR", "GENE_OR_GENE_PRODUCT", 431, 434], ["cytoplasm", "ORGANISM_SUBSTANCE", 456, 465], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 481, 486], ["GM\u2010CSF", "GENE_OR_GENE_PRODUCT", 491, 497], ["CD28", "PROTEIN", 5, 9], ["LFA\u20101", "PROTEIN", 16, 21], ["T cells", "CELL_TYPE", 25, 32], ["ICAM\u20101", "PROTEIN", 42, 48], ["APCs", "CELL_TYPE", 52, 56], ["cytokine mRNAs", "RNA", 175, 189], ["HuR", "PROTEIN", 247, 250], ["mouse T cells", "CELL_TYPE", 275, 288], ["CD28", "PROTEIN", 294, 298], ["IL\u20102 mRNA", "RNA", 339, 348], ["LFA", "PROTEIN", 369, 372], ["CD28", "PROTEIN", 378, 382], ["human\u2010stimulated T cells", "CELL_TYPE", 397, 421], ["HuR", "PROTEIN", 431, 434], ["TNF\u2010\u03b1", "PROTEIN", 481, 486], ["GM", "PROTEIN", 491, 493], ["mouse", "SPECIES", 275, 280], ["mouse", "SPECIES", 275, 280], ["CD28", "TEST", 5, 9], ["LFA", "TEST", 16, 19], ["ICAM", "TEST", 42, 46], ["APCs", "TEST", 52, 56], ["HuR translocation", "PROBLEM", 247, 264], ["mRNA stabilization", "TEST", 344, 362], ["LFA", "TEST", 369, 372], ["HuR translocation", "PROBLEM", 431, 448], ["TNF", "TEST", 481, 484], ["GM\u2010CSF", "TEST", 491, 497]]], ["This discrepancy may be a result of the species source of the lymphocytes used in the two studies.", [["lymphocytes", "ANATOMY", 62, 73], ["lymphocytes", "CELL", 62, 73], ["lymphocytes", "CELL_TYPE", 62, 73], ["the lymphocytes", "PROBLEM", 58, 73], ["the two studies", "TEST", 82, 97], ["lymphocytes", "OBSERVATION", 62, 73]]], ["AREs are evolutionally conserved in mammalian, but the numbers of ARE pentamers may differ slightly among species, allowing differential responses [70].T CELL ACTIVATIONA novel pathway in cytokine mRNA stabilization in T cell activation and differentiation, also occurring during eosinophils activation, has been described recently involving pin1 [83,84].", [["T cell", "ANATOMY", 219, 225], ["eosinophils", "ANATOMY", 280, 291], ["ARE pentamers", "GENE_OR_GENE_PRODUCT", 66, 79], ["T cell", "CELL", 219, 225], ["eosinophils", "CELL", 280, 291], ["pin1", "GENE_OR_GENE_PRODUCT", 342, 346], ["AREs", "DNA", 0, 4], ["ARE pentamers", "PROTEIN", 66, 79], ["cytokine mRNA", "RNA", 188, 201], ["eosinophils", "CELL_TYPE", 280, 291], ["slightly among species", "PROBLEM", 91, 113], ["cytokine mRNA stabilization", "TREATMENT", 188, 215], ["eosinophils activation", "PROBLEM", 280, 302], ["cytokine mRNA", "OBSERVATION", 188, 201], ["T cell", "OBSERVATION", 219, 225]]], ["This protein isomerizes specific peptide bonds and thus, alters protein folding and activity; when it becomes activated in TcR/CD28\u2010stimulated CD4 T cells, it associates concurrently with AUF1 and HuR.", [["CD4 T cells", "ANATOMY", 143, 154], ["TcR", "GENE_OR_GENE_PRODUCT", 123, 126], ["CD28", "GENE_OR_GENE_PRODUCT", 127, 131], ["CD4", "GENE_OR_GENE_PRODUCT", 143, 146], ["AUF1", "GENE_OR_GENE_PRODUCT", 188, 192], ["HuR", "GENE_OR_GENE_PRODUCT", 197, 200], ["TcR", "PROTEIN", 123, 126], ["CD28", "PROTEIN", 127, 131], ["CD4 T cells", "CELL_TYPE", 143, 154], ["AUF1", "PROTEIN", 188, 192], ["HuR", "PROTEIN", 197, 200], ["This protein", "TEST", 0, 12], ["alters protein folding", "PROBLEM", 57, 79], ["peptide bonds", "OBSERVATION", 33, 46]]], ["This results in stabilization of GM\u2010CSF mRNA as a result of the loss of the mRNA decay\u2010promoting activity of AUF1, which is linked to the exosome (Fig. 2) .", [["exosome", "ANATOMY", 138, 145], ["GM", "CHEMICAL", 33, 35], ["GM\u2010CSF", "GENE_OR_GENE_PRODUCT", 33, 39], ["AUF1", "GENE_OR_GENE_PRODUCT", 109, 113], ["exosome", "CELLULAR_COMPONENT", 138, 145], ["GM\u2010CSF mRNA", "RNA", 33, 44], ["AUF1", "PROTEIN", 109, 113], ["exosome", "PROTEIN", 138, 145], ["GM\u2010CSF mRNA", "PROBLEM", 33, 44], ["the loss of the mRNA decay\u2010promoting activity of AUF1", "PROBLEM", 60, 113], ["CSF mRNA", "OBSERVATION", 36, 44]]], ["AUF1 may be isomerized by pin1, allowing the stabilizing action of HuR to predominate [83].", [["AUF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["pin1", "GENE_OR_GENE_PRODUCT", 26, 30], ["HuR", "GENE_OR_GENE_PRODUCT", 67, 70], ["AUF1", "PROTEIN", 0, 4], ["pin1", "PROTEIN", 26, 30], ["HuR", "PROTEIN", 67, 70]]], ["AUF1 is a nucleocytoplasmic\u2010shuttling protein and is associated with stabilization and destabilization activities; this appears to be dependent on the AUF1 isoform generated from four alternative\u2010spliced mRNAs and the cell type in question.", [["cell", "ANATOMY", 218, 222], ["AUF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["AUF1", "GENE_OR_GENE_PRODUCT", 151, 155], ["cell", "CELL", 218, 222], ["AUF1", "PROTEIN", 0, 4], ["nucleocytoplasmic\u2010shuttling protein", "PROTEIN", 10, 45], ["AUF1 isoform", "PROTEIN", 151, 163], ["\u2010spliced mRNAs", "RNA", 195, 209], ["a nucleocytoplasmic\u2010shuttling protein", "PROBLEM", 8, 45], ["destabilization activities", "PROBLEM", 87, 113], ["nucleocytoplasmic\u2010shuttling protein", "OBSERVATION", 10, 45], ["stabilization", "OBSERVATION", 69, 82]]], ["For example, when AUF1 p37 and p42 isoforms are overexpressed, they bind to IL\u20106 3\u2032UTR, facilitated by a putative RNA stem\u2010loop structure; this process promotes the stabilization of IL\u20106 mRNA [85].T CELL ACTIVATIONTTP plays a significant role in regulating mRNA stability of cytokines such as IL\u20102 during T cell activation.", [["T cell", "ANATOMY", 305, 311], ["AUF1", "GENE_OR_GENE_PRODUCT", 18, 22], ["p37", "GENE_OR_GENE_PRODUCT", 23, 26], ["p42", "GENE_OR_GENE_PRODUCT", 31, 34], ["IL\u20106 3", "GENE_OR_GENE_PRODUCT", 76, 82], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 182, 186], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 293, 297], ["T cell", "CELL", 305, 311], ["AUF1", "PROTEIN", 18, 22], ["p37", "PROTEIN", 23, 26], ["p42 isoforms", "PROTEIN", 31, 43], ["IL", "PROTEIN", 76, 78], ["UTR", "DNA", 83, 86], ["IL\u20106 mRNA", "RNA", 182, 191], ["cytokines", "PROTEIN", 275, 284], ["IL\u20102", "PROTEIN", 293, 297], ["AUF1 p37", "TEST", 18, 26], ["a putative RNA stem\u2010loop structure", "PROBLEM", 103, 137], ["significant", "OBSERVATION_MODIFIER", 226, 237]]], ["Thus, one can envision that for CD28\u2010 or LFA\u20101\u2010induced stabilization to occur following T cell activation, TTP destabilization action must cease.", [["T cell", "ANATOMY", 88, 94], ["CD28", "GENE_OR_GENE_PRODUCT", 32, 36], ["LFA\u20101", "GENE_OR_GENE_PRODUCT", 41, 46], ["T cell", "CELL", 88, 94], ["TTP", "GENE_OR_GENE_PRODUCT", 107, 110], ["CD28", "PROTEIN", 32, 36], ["LFA", "PROTEIN", 41, 44], ["\u20101", "PROTEIN", 44, 46], ["CD28\u2010", "TREATMENT", 32, 37], ["T cell activation", "TREATMENT", 88, 105], ["TTP destabilization action", "TREATMENT", 107, 133]]], ["This can happen by either or both of two scenarios: coordinated stabilization\u2010destabilization kinetics and TTP phosphorylation (Fig. 2) .", [["TTP", "PROTEIN", 107, 110], ["coordinated stabilization\u2010destabilization kinetics", "TREATMENT", 52, 102], ["TTP phosphorylation (Fig", "TREATMENT", 107, 131]]], ["With the coordinated kinetics model, stabilizing RNA\u2010binding proteins such as HuR can occur initially following immune cell activation, allowing rapid and early response of cytokine production.", [["immune cell", "ANATOMY", 112, 123], ["HuR", "GENE_OR_GENE_PRODUCT", 78, 81], ["immune cell", "CELL", 112, 123], ["RNA\u2010binding proteins", "PROTEIN", 49, 69], ["HuR", "PROTEIN", 78, 81], ["cytokine", "PROTEIN", 173, 181], ["stabilizing RNA\u2010binding proteins", "PROBLEM", 37, 69], ["immune cell activation", "TREATMENT", 112, 134], ["cytokine production", "PROBLEM", 173, 192], ["cytokine production", "OBSERVATION", 173, 192]]], ["This is followed by the action of mRNA\u2010destabilizing proteins such as TTP, resulting in transient cytokine production.", [["TTP", "GENE_OR_GENE_PRODUCT", 70, 73], ["mRNA", "RNA", 34, 38], ["TTP", "PROTEIN", 70, 73], ["cytokine", "PROTEIN", 98, 106], ["mRNA\u2010destabilizing proteins", "PROBLEM", 34, 61], ["TTP", "PROBLEM", 70, 73], ["transient cytokine production", "PROBLEM", 88, 117], ["transient", "OBSERVATION_MODIFIER", 88, 97], ["cytokine production", "OBSERVATION", 98, 117]]], ["HuR translocation following TcR/CD28 engagement is seen, first within 1 h, and TTP is induced in activated T cells in a later time [86].", [["T cells", "ANATOMY", 107, 114], ["HuR", "GENE_OR_GENE_PRODUCT", 0, 3], ["TcR", "GENE_OR_GENE_PRODUCT", 28, 31], ["CD28", "GENE_OR_GENE_PRODUCT", 32, 36], ["TTP", "GENE_OR_GENE_PRODUCT", 79, 82], ["T cells", "CELL", 107, 114], ["HuR", "PROTEIN", 0, 3], ["TcR", "PROTEIN", 28, 31], ["CD28", "PROTEIN", 32, 36], ["TTP", "PROTEIN", 79, 82], ["activated T cells", "CELL_TYPE", 97, 114], ["HuR translocation", "PROBLEM", 0, 17], ["TcR/CD28 engagement", "TREATMENT", 28, 47], ["TTP", "PROBLEM", 79, 82], ["TTP", "OBSERVATION", 79, 82]]], ["There is also the potential for interesting reciprocal regulation, which helps to amplify this \u201ccycle\u201d; HuR may stabilize TTP mRNA itself, thus helping to prime TTP for its destabilizing action on cytokine mRNAs.", [["HuR", "GENE_OR_GENE_PRODUCT", 104, 107], ["TTP", "GENE_OR_GENE_PRODUCT", 122, 125], ["TTP", "GENE_OR_GENE_PRODUCT", 161, 164], ["HuR", "PROTEIN", 104, 107], ["TTP mRNA", "RNA", 122, 130], ["TTP", "PROTEIN", 161, 164], ["cytokine mRNAs", "RNA", 197, 211], ["interesting reciprocal regulation", "PROBLEM", 32, 65], ["TTP mRNA itself", "PROBLEM", 122, 137], ["prime TTP", "PROBLEM", 155, 164], ["cytokine mRNAs", "TREATMENT", 197, 211]]], ["TTP has also been suggested to regulate the stability of its own mRNA in different cell types [20,21], although this has not been proved conclusively [4]; it is also possible that this regulation extends to activated T cells.", [["cell", "ANATOMY", 83, 87], ["T cells", "ANATOMY", 217, 224], ["TTP", "CHEMICAL", 0, 3], ["TTP", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 83, 87], ["T cells", "CELL", 217, 224], ["TTP", "PROTEIN", 0, 3], ["mRNA", "RNA", 65, 69], ["activated T cells", "CELL_TYPE", 207, 224], ["TTP", "PROBLEM", 0, 3], ["activated T cells", "PROBLEM", 207, 224], ["stability", "OBSERVATION_MODIFIER", 44, 53], ["different cell types", "OBSERVATION", 73, 93]]], ["The second scenario is that TTP becomes transiently phosphorylated by one of the kinases following CD28 or LFA\u20101 engagement.", [["TTP", "GENE_OR_GENE_PRODUCT", 28, 31], ["CD28", "GENE_OR_GENE_PRODUCT", 99, 103], ["LFA\u20101", "GENE_OR_GENE_PRODUCT", 107, 112], ["TTP", "PROTEIN", 28, 31], ["kinases", "PROTEIN", 81, 88], ["CD28", "PROTEIN", 99, 103], ["LFA", "PROTEIN", 107, 110], ["TTP", "PROBLEM", 28, 31], ["transiently phosphorylated", "PROBLEM", 40, 66], ["TTP", "OBSERVATION", 28, 31]]], ["The ultimate outcome is a transient immune response and controlled cytokine production.T CELL ACTIVATIONDuring restimulation of Th2 cells, as opposed to priming of na\u00efve T cells with APC, rapid dephosphorylation of eIF2\u03b1 occurs and results in derepression of translational arrest of cytokine mRNAs such as IL\u20104 mRNA [87].", [["Th2 cells", "ANATOMY", 128, 137], ["na\u00efve T cells", "ANATOMY", 164, 177], ["Th2 cells", "CELL", 128, 137], ["na\u00efve T cells", "CELL", 164, 177], ["APC", "GENE_OR_GENE_PRODUCT", 183, 186], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 215, 220], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 306, 310], ["cytokine", "PROTEIN", 67, 75], ["Th2 cells", "CELL_LINE", 128, 137], ["na\u00efve T cells", "CELL_TYPE", 164, 177], ["APC", "CELL_TYPE", 183, 186], ["eIF2\u03b1", "PROTEIN", 215, 220], ["cytokine mRNAs", "RNA", 283, 297], ["IL\u20104 mRNA", "RNA", 306, 315], ["a transient immune response", "PROBLEM", 24, 51], ["controlled cytokine production", "PROBLEM", 56, 86], ["Th2 cells", "PROBLEM", 128, 137], ["APC", "PROBLEM", 183, 186], ["rapid dephosphorylation of eIF2", "TREATMENT", 188, 219], ["translational arrest", "PROBLEM", 259, 279], ["cytokine mRNAs", "TREATMENT", 283, 297], ["transient", "OBSERVATION_MODIFIER", 26, 35], ["immune response", "OBSERVATION", 36, 51], ["cytokine production", "OBSERVATION", 67, 86], ["Th2 cells", "OBSERVATION", 128, 137]]], ["This process involves translation repressor proteins, TIA\u20101, and TIA\u20101\u2010related protein, which operate during priming and restrict T cell function by recruiting untranslated mRNAs into stress granules, discrete cytoplasmic foci triggered by eIF2\u03b1 phosphorylation [88].", [["T cell", "ANATOMY", 130, 136], ["stress granules", "ANATOMY", 184, 199], ["cytoplasmic foci", "ANATOMY", 210, 226], ["TIA", "DISEASE", 54, 57], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 54, 59], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 65, 70], ["T cell", "CELL", 130, 136], ["stress granules", "CELLULAR_COMPONENT", 184, 199], ["cytoplasmic foci", "CELLULAR_COMPONENT", 210, 226], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 240, 245], ["translation repressor proteins", "PROTEIN", 22, 52], ["TIA\u20101", "PROTEIN", 54, 59], ["TIA\u20101", "PROTEIN", 65, 70], ["\u2010related protein", "PROTEIN", 70, 86], ["untranslated mRNAs", "RNA", 160, 178], ["eIF2\u03b1", "PROTEIN", 240, 245], ["translation repressor proteins", "PROBLEM", 22, 52], ["TIA", "PROBLEM", 54, 57], ["TIA\u20101\u2010related protein", "PROBLEM", 65, 86], ["recruiting untranslated mRNAs into stress granules", "PROBLEM", 149, 199], ["discrete cytoplasmic foci", "PROBLEM", 201, 226], ["discrete", "OBSERVATION_MODIFIER", 201, 209], ["cytoplasmic", "OBSERVATION_MODIFIER", 210, 221], ["foci", "OBSERVATION", 222, 226]]], ["Also, the p38 activity, which leads to IL\u20104 mRNA stabilization, modulates differentiation of naive precursor T cells to Th2 direction [89].NEGATIVE REGULATION OF THE IMMUNE SYSTEM AND ROLE OF microRNA (miRNA)Post\u2010transcriptional control plays a significant part in specific pathways that regulate T cell activation and involves several types of modulators, including suppressive cytokines, miRNA, and adaptors.", [["precursor T cells", "ANATOMY", 99, 116], ["T cell", "ANATOMY", 297, 303], ["p38", "GENE_OR_GENE_PRODUCT", 10, 13], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 39, 43], ["T cells", "CELL", 109, 116], ["T cell", "CELL", 297, 303], ["p38", "PROTEIN", 10, 13], ["naive precursor T cells", "CELL_TYPE", 93, 116], ["cytokines", "PROTEIN", 379, 388], ["miRNA", "PROTEIN", 390, 395], ["adaptors", "PROTEIN", 401, 409], ["IL\u20104 mRNA stabilization", "TREATMENT", 39, 62], ["microRNA (miRNA)Post\u2010transcriptional control", "TREATMENT", 192, 236], ["modulators", "TREATMENT", 345, 355], ["suppressive cytokines", "TREATMENT", 367, 388], ["miRNA", "TREATMENT", 390, 395], ["IMMUNE SYSTEM", "OBSERVATION", 166, 179]]], ["When cytokines such as IFN\u2010\u03b1/\u03b2, IL\u20104, and IL\u201010 dampen the immune response, they tend to destabilize mRNAs involved.", [["IFN\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 23, 28], ["\u03b2", "GENE_OR_GENE_PRODUCT", 29, 30], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 32, 36], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 42, 47], ["cytokines", "PROTEIN", 5, 14], ["IFN\u2010\u03b1", "PROTEIN", 23, 28], ["\u03b2", "PROTEIN", 29, 30], ["IL\u20104", "PROTEIN", 32, 36], ["IL\u201010", "PROTEIN", 42, 47], ["mRNAs", "RNA", 101, 106], ["cytokines", "TREATMENT", 5, 14], ["IFN\u2010\u03b1", "TREATMENT", 23, 28], ["IL\u2010", "TREATMENT", 32, 35], ["IL\u2010", "TREATMENT", 42, 45]]], ["IFN such as IFN\u2010\u03b2 or \u2010\u03b3, when in combination with LPS, induces TTP transcription and thereby reduces proinflammatory cytokines, namely, TNF\u2010\u03b1 and IL\u20106 and the chemokines CCL2 (MCP\u20101) and CCL3 (MIP\u20101\u03b1) [90].", [["LPS", "CHEMICAL", 50, 53], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["IFN\u2010\u03b2", "GENE_OR_GENE_PRODUCT", 12, 17], ["\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 21, 23], ["LPS", "SIMPLE_CHEMICAL", 50, 53], ["TTP", "GENE_OR_GENE_PRODUCT", 63, 66], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 136, 141], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 146, 150], ["CCL2", "GENE_OR_GENE_PRODUCT", 170, 174], ["MCP\u20101", "GENE_OR_GENE_PRODUCT", 176, 181], ["CCL3", "GENE_OR_GENE_PRODUCT", 187, 191], ["MIP\u20101\u03b1", "GENE_OR_GENE_PRODUCT", 193, 199], ["IFN", "PROTEIN", 0, 3], ["IFN\u2010\u03b2", "PROTEIN", 12, 17], ["\u2010\u03b3", "PROTEIN", 21, 23], ["TTP", "PROTEIN", 63, 66], ["proinflammatory cytokines", "PROTEIN", 101, 126], ["TNF\u2010\u03b1", "PROTEIN", 136, 141], ["IL\u20106", "PROTEIN", 146, 150], ["chemokines", "PROTEIN", 159, 169], ["CCL2", "PROTEIN", 170, 174], ["MCP\u20101", "PROTEIN", 176, 181], ["CCL3", "PROTEIN", 187, 191], ["MIP", "PROTEIN", 193, 196], ["IFN", "PROBLEM", 0, 3], ["LPS", "TREATMENT", 50, 53], ["TTP transcription", "PROBLEM", 63, 80], ["proinflammatory cytokines", "TEST", 101, 126], ["TNF", "TEST", 136, 139], ["IL", "TEST", 146, 148], ["the chemokines CCL2", "TEST", 155, 174], ["MCP", "TEST", 176, 179], ["CCL3", "TEST", 187, 191], ["MIP", "TEST", 193, 196]]], ["This happens in a p38 MAPK\u2010dependent manner, as revealed with TTP\u2010knockout mouse embryo fibroblasts [90].", [["embryo fibroblasts", "ANATOMY", 81, 99], ["p38 MAPK\u2010", "GENE_OR_GENE_PRODUCT", 18, 27], ["TTP", "GENE_OR_GENE_PRODUCT", 62, 65], ["mouse", "ORGANISM", 75, 80], ["embryo fibroblasts", "CELL", 81, 99], ["p38 MAPK", "PROTEIN", 18, 26], ["TTP\u2010knockout mouse embryo fibroblasts", "CELL_LINE", 62, 99], ["mouse", "SPECIES", 75, 80], ["mouse", "SPECIES", 75, 80], ["TTP", "PROBLEM", 62, 65], ["knockout mouse embryo fibroblasts", "PROBLEM", 66, 99]]], ["The TTP transcription appears to require a functional, IFN\u2010\u03b3\u2010activated sequence, which recruits STAT1 onto the TTP promoter.", [["TTP", "GENE_OR_GENE_PRODUCT", 4, 7], ["STAT1", "GENE_OR_GENE_PRODUCT", 96, 101], ["TTP", "GENE_OR_GENE_PRODUCT", 111, 114], ["TTP", "PROTEIN", 4, 7], ["IFN\u2010\u03b3\u2010activated sequence", "DNA", 55, 79], ["STAT1", "PROTEIN", 96, 101], ["TTP promoter", "DNA", 111, 123], ["The TTP transcription", "PROBLEM", 0, 21], ["a functional, IFN\u2010\u03b3\u2010activated sequence", "PROBLEM", 41, 79], ["TTP", "OBSERVATION", 4, 7], ["appears to require", "UNCERTAINTY", 22, 40]]], ["As TTP is considered an anti\u2010inflammatory mediator and suppresses proinflammatory cytokines, it is possible that at least some of the molecules with anti\u2010inflammatory action induce TTP or its activity.", [["TTP", "GENE_OR_GENE_PRODUCT", 3, 6], ["TTP", "GENE_OR_GENE_PRODUCT", 181, 184], ["TTP", "PROTEIN", 3, 6], ["proinflammatory cytokines", "PROTEIN", 66, 91], ["TTP", "PROTEIN", 181, 184], ["TTP", "PROBLEM", 3, 6], ["an anti\u2010inflammatory mediator", "PROBLEM", 21, 50], ["suppresses proinflammatory cytokines", "PROBLEM", 55, 91], ["anti\u2010inflammatory action", "TREATMENT", 149, 173], ["TTP", "PROBLEM", 181, 184]]], ["Indeed, glucocorticoids can induce the transcription of TTP in the A549 lung epithelial cell line; small interfering RNA to TTP prevented dexamethasone\u2010induced reduction of TNF\u2010\u03b1 mRNA stability and activity of reporter fused with TNF\u2010\u03b1 3\u2032UTR [91].", [["A549 lung epithelial cell line", "ANATOMY", 67, 97], ["glucocorticoids", "CHEMICAL", 8, 23], ["TTP", "CHEMICAL", 124, 127], ["glucocorticoids", "SIMPLE_CHEMICAL", 8, 23], ["TTP", "GENE_OR_GENE_PRODUCT", 56, 59], ["A549 lung epithelial cell line", "CELL", 67, 97], ["TTP", "GENE_OR_GENE_PRODUCT", 124, 127], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 173, 178], ["TNF\u2010\u03b1 3", "GENE_OR_GENE_PRODUCT", 230, 237], ["TTP", "PROTEIN", 56, 59], ["A549 lung epithelial cell line", "CELL_LINE", 67, 97], ["small interfering RNA", "RNA", 99, 120], ["TNF", "PROTEIN", 173, 176], ["TNF", "PROTEIN", 230, 233], ["glucocorticoids", "TREATMENT", 8, 23], ["TTP", "PROBLEM", 56, 59], ["the A549 lung epithelial cell line", "TREATMENT", 63, 97], ["small interfering RNA", "PROBLEM", 99, 120], ["TTP", "PROBLEM", 124, 127], ["dexamethasone\u2010induced reduction", "TREATMENT", 138, 169], ["TNF", "PROBLEM", 173, 176], ["mRNA stability", "PROBLEM", 179, 193], ["reporter fused", "TEST", 210, 224], ["TNF", "TEST", 230, 233], ["UTR", "TEST", 238, 241], ["TTP", "OBSERVATION", 56, 59], ["lung", "ANATOMY", 72, 76], ["epithelial cell line", "OBSERVATION", 77, 97], ["small", "OBSERVATION_MODIFIER", 99, 104], ["interfering RNA", "OBSERVATION", 105, 120]]], ["On the contrary, this action may be tissue\u2010type\u2010specific, as dexamethasone may inhibit rather than induce TTP in activated macrophages [92].NEGATIVE REGULATION OF THE IMMUNE SYSTEM AND ROLE OF microRNA (miRNA)IL\u201010 is a potent, suppressive cytokine, which can inhibit macrophage action and generation of Th2 lymphocytes.", [["macrophages", "ANATOMY", 123, 134], ["macrophage", "ANATOMY", 268, 278], ["Th2 lymphocytes", "ANATOMY", 304, 319], ["dexamethasone", "CHEMICAL", 61, 74], ["dexamethasone", "CHEMICAL", 61, 74], ["dexamethasone", "SIMPLE_CHEMICAL", 61, 74], ["TTP", "GENE_OR_GENE_PRODUCT", 106, 109], ["macrophages", "CELL", 123, 134], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 209, 214], ["macrophage", "CELL", 268, 278], ["Th2 lymphocytes", "CELL", 304, 319], ["TTP", "PROTEIN", 106, 109], ["activated macrophages", "CELL_TYPE", 113, 134], ["microRNA (miRNA)IL\u201010", "PROTEIN", 193, 214], ["cytokine", "PROTEIN", 240, 248], ["Th2 lymphocytes", "CELL_TYPE", 304, 319], ["dexamethasone", "TREATMENT", 61, 74], ["TTP in activated macrophages", "PROBLEM", 106, 134], ["microRNA (miRNA)IL\u2010", "TEST", 193, 212], ["suppressive cytokine", "TREATMENT", 228, 248], ["Th2 lymphocytes", "PROBLEM", 304, 319], ["IMMUNE SYSTEM", "OBSERVATION", 167, 180], ["Th2 lymphocytes", "OBSERVATION", 304, 319]]], ["It is capable of inhibiting proinflammatory cytokines and Th1 cytokines, such as TNF\u2010\u03b1, IFN\u2010\u03b3, IL\u20102, IL\u20103, and GM\u2010CSF.", [["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 81, 86], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 88, 93], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 95, 99], ["IL\u20103", "GENE_OR_GENE_PRODUCT", 101, 105], ["GM\u2010CSF", "GENE_OR_GENE_PRODUCT", 111, 117], ["proinflammatory cytokines", "PROTEIN", 28, 53], ["Th1 cytokines", "PROTEIN", 58, 71], ["TNF\u2010\u03b1", "PROTEIN", 81, 86], ["IFN\u2010\u03b3", "PROTEIN", 88, 93], ["IL\u20102", "PROTEIN", 95, 99], ["IL\u20103", "PROTEIN", 101, 105], ["GM", "PROTEIN", 111, 113], ["CSF", "PROTEIN", 114, 117], ["inhibiting proinflammatory cytokines", "PROBLEM", 17, 53], ["Th1 cytokines", "TEST", 58, 71], ["TNF", "TEST", 81, 84], ["IFN\u2010\u03b3", "TEST", 88, 93], ["IL", "TEST", 95, 97], ["CSF", "ANATOMY", 114, 117]]], ["IL\u201010 destabilizes TNF\u2010\u03b1 mRNA and probably others by inhibiting the binding of HuR to the AREs in the 3\u2032UTR; this effect appears also to be dependent on the p38 MAPK pathway [93].", [["IL\u201010", "GENE_OR_GENE_PRODUCT", 0, 5], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 19, 24], ["HuR", "GENE_OR_GENE_PRODUCT", 79, 82], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 157, 165], ["IL\u201010", "PROTEIN", 0, 5], ["TNF\u2010\u03b1 mRNA", "RNA", 19, 29], ["HuR", "PROTEIN", 79, 82], ["AREs", "DNA", 90, 94], ["UTR", "DNA", 104, 107], ["p38 MAPK", "PROTEIN", 157, 165], ["UTR", "PROBLEM", 104, 107], ["the p38 MAPK pathway", "TEST", 153, 173]]], ["Another anti\u2010inflammatory cytokine, IL\u20104, can suppress FPR1 mRNA expression via a mechanism, which acts on primary transcripts prior to maturation and depends on the constitutive instability of pre\u2010existing mRNA [94].NEGATIVE REGULATION OF THE IMMUNE SYSTEM AND ROLE OF microRNA (miRNA)A possible pathway, which may involve mRNA stability changes as a result of negative regulation of TcR/CD28\u2010induced T cell activation, is the association between adaptor in lymphocytes of unknown function (ALX) and membrane\u2010associated adaptor protein (LAX) adaptors.", [["T cell", "ANATOMY", 402, 408], ["lymphocytes", "ANATOMY", 459, 470], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 36, 40], ["FPR1", "GENE_OR_GENE_PRODUCT", 55, 59], ["TcR", "GENE_OR_GENE_PRODUCT", 385, 388], ["CD28", "GENE_OR_GENE_PRODUCT", 389, 393], ["T cell", "CELL", 402, 408], ["lymphocytes", "CELL", 459, 470], ["ALX", "GENE_OR_GENE_PRODUCT", 492, 495], ["membrane\u2010associated adaptor protein", "GENE_OR_GENE_PRODUCT", 501, 536], ["LAX", "GENE_OR_GENE_PRODUCT", 538, 541], ["anti\u2010inflammatory cytokine", "PROTEIN", 8, 34], ["IL\u20104", "PROTEIN", 36, 40], ["FPR1 mRNA", "RNA", 55, 64], ["pre\u2010existing mRNA", "RNA", 194, 211], ["TcR", "PROTEIN", 385, 388], ["CD28", "PROTEIN", 389, 393], ["lymphocytes", "CELL_TYPE", 459, 470], ["ALX", "PROTEIN", 492, 495], ["membrane\u2010associated adaptor protein (LAX) adaptors", "PROTEIN", 501, 551], ["Another anti\u2010inflammatory cytokine, IL\u2010", "TREATMENT", 0, 39], ["mRNA stability changes", "PROBLEM", 324, 346], ["TcR/CD28\u2010induced T cell activation", "PROBLEM", 385, 419], ["membrane\u2010associated adaptor protein (LAX) adaptors", "TREATMENT", 501, 551], ["IMMUNE SYSTEM", "OBSERVATION", 244, 257], ["microRNA", "OBSERVATION", 270, 278], ["cell activation", "OBSERVATION", 404, 419]]], ["Work with ALX\u2010deficient knockout mice suggested that the ALX/LAX association may inhibit the p38 MAPK pathway and IL\u20102 production [95].", [["ALX\u2010", "GENE_OR_GENE_PRODUCT", 10, 14], ["mice", "ORGANISM", 33, 37], ["ALX", "GENE_OR_GENE_PRODUCT", 57, 60], ["LAX", "GENE_OR_GENE_PRODUCT", 61, 64], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 93, 101], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 114, 118], ["ALX", "PROTEIN", 10, 13], ["ALX", "PROTEIN", 57, 60], ["LAX", "PROTEIN", 61, 64], ["p38 MAPK", "PROTEIN", 93, 101], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["the ALX/LAX association", "TREATMENT", 53, 76], ["the p38 MAPK pathway", "TEST", 89, 109]]], ["Specifically, the upstream, regulatory MAPKs, MKK3/6, have been found to be constitutively activated in ALX\u2010deficient mice [95].", [["MAPKs", "GENE_OR_GENE_PRODUCT", 39, 44], ["MKK3/6", "GENE_OR_GENE_PRODUCT", 46, 52], ["ALX", "GENE_OR_GENE_PRODUCT", 104, 107], ["mice", "ORGANISM", 118, 122], ["regulatory MAPKs", "PROTEIN", 28, 44], ["MKK3/6", "PROTEIN", 46, 52], ["ALX", "PROTEIN", 104, 107], ["mice", "SPECIES", 118, 122], ["MKK3", "TEST", 46, 50]]], ["As p38 MAPK is involved in IL\u20102 mRNA stabilization, it is possible that negative regulation by ALX occurs via a post\u2010transcriptional mechanism as well.NEGATIVE REGULATION OF THE IMMUNE SYSTEM AND ROLE OF microRNA (miRNA)Negative regulation of T cell activation and cytokine production can also occur by a miRNA\u2010processing pathway.", [["T cell", "ANATOMY", 243, 249], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 3, 11], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 27, 31], ["ALX", "GENE_OR_GENE_PRODUCT", 95, 98], ["T cell", "CELL", 243, 249], ["p38 MAPK", "PROTEIN", 3, 11], ["IL\u20102 mRNA", "RNA", 27, 36], ["ALX", "PROTEIN", 95, 98], ["cytokine", "PROTEIN", 265, 273], ["p38 MAPK", "TEST", 3, 11], ["mRNA stabilization", "TREATMENT", 32, 50], ["microRNA (miRNA", "TEST", 204, 219], ["T cell activation", "PROBLEM", 243, 260], ["cytokine production", "PROBLEM", 265, 284], ["negative", "OBSERVATION", 72, 80], ["IMMUNE SYSTEM", "OBSERVATION", 178, 191], ["cell activation", "OBSERVATION", 245, 260]]], ["In general, miRNAs are considered post\u2010transcriptional, negative regulatory elements, which have the ability to dampen many biological processes including innate and adaptive immunity.", [["post\u2010transcriptional, negative regulatory elements", "DNA", 34, 84], ["innate and adaptive immunity", "TREATMENT", 155, 183]]], ["A role in the regulation of T cell development has been proposed recently in a few studies [96,97,98,99].", [["T cell", "ANATOMY", 28, 34], ["T cell", "CELL", 28, 34], ["T cell development", "TREATMENT", 28, 46]]], ["Specific deletion of the dicer\u2010coding gene, dcr\u20101, in mouse T cell lineage resulted in aberrant Th cell differentiation and failure to suppress IFN\u2010\u03b3 expression under Th2\u2010polarizing conditions [98].", [["T cell lineage", "ANATOMY", 60, 74], ["Th cell", "ANATOMY", 96, 103], ["dcr\u20101", "GENE_OR_GENE_PRODUCT", 44, 49], ["mouse", "ORGANISM", 54, 59], ["T cell lineage", "CELL", 60, 74], ["Th cell", "CELL", 96, 103], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 144, 149], ["dicer\u2010coding gene", "DNA", 25, 42], ["dcr\u20101", "DNA", 44, 49], ["mouse T cell lineage", "CELL_TYPE", 54, 74], ["IFN", "PROTEIN", 144, 147], ["\u2010\u03b3", "PROTEIN", 147, 149], ["mouse", "SPECIES", 54, 59], ["mouse", "SPECIES", 54, 59], ["the dicer\u2010coding gene", "TREATMENT", 21, 42], ["aberrant Th cell differentiation", "PROBLEM", 87, 119], ["failure", "PROBLEM", 124, 131], ["aberrant Th cell differentiation", "OBSERVATION", 87, 119]]], ["Although no mechanism is discussed in this study, it is possible that miRNA targets the IFN\u2010\u03b3 mRNA, which harbors an ARE, which may in turn be a target for miR16 by a process in which TTP promotes mRNA decay.", [["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 88, 93], ["ARE", "GENE_OR_GENE_PRODUCT", 117, 120], ["miR16", "GENE_OR_GENE_PRODUCT", 156, 161], ["TTP", "GENE_OR_GENE_PRODUCT", 184, 187], ["IFN\u2010\u03b3 mRNA", "RNA", 88, 98], ["ARE", "DNA", 117, 120], ["miR16", "PROTEIN", 156, 161], ["TTP", "PROTEIN", 184, 187], ["this study", "TEST", 38, 48], ["no", "UNCERTAINTY", 9, 11]]], ["Involvement of miRNA in ARE\u2010mediated instability has been documented by demonstrating that dicer and miR16 are required in epithelial cells [100].", [["epithelial cells", "ANATOMY", 123, 139], ["ARE", "GENE_OR_GENE_PRODUCT", 24, 27], ["dicer", "GENE_OR_GENE_PRODUCT", 91, 96], ["miR16", "GENE_OR_GENE_PRODUCT", 101, 106], ["epithelial cells", "CELL", 123, 139], ["ARE", "DNA", 24, 27], ["dicer", "PROTEIN", 91, 96], ["miR16", "PROTEIN", 101, 106], ["epithelial cells", "CELL_TYPE", 123, 139], ["mediated instability", "PROBLEM", 28, 48], ["miRNA", "OBSERVATION", 15, 20], ["instability", "OBSERVATION", 37, 48]]], ["This TTP involvement would be an attractive option in explaining the IFN\u2010\u03b3 mRNA dysregulation in dicer\u2010deficient Th cells.", [["Th cells", "ANATOMY", 113, 121], ["TTP", "GENE_OR_GENE_PRODUCT", 5, 8], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 69, 74], ["Th cells", "CELL", 113, 121], ["IFN\u2010\u03b3 mRNA", "RNA", 69, 79], ["Th cells", "CELL_LINE", 113, 121], ["This TTP involvement", "PROBLEM", 0, 20], ["the IFN\u2010\u03b3 mRNA dysregulation", "PROBLEM", 65, 93]]], ["Another important role of dicer in T cell development has been shown to occur in the development of regulatory T cells (Treg); absence of dicer leads to a reduced number of Treg and immunopathological disorders such as splenomegaly [97].", [["T cell", "ANATOMY", 35, 41], ["regulatory T cells", "ANATOMY", 100, 118], ["Treg", "ANATOMY", 120, 124], ["Treg", "ANATOMY", 173, 177], ["immunopathological disorders", "DISEASE", 182, 210], ["splenomegaly", "DISEASE", 219, 231], ["dicer", "GENE_OR_GENE_PRODUCT", 26, 31], ["T cell", "CELL", 35, 41], ["regulatory T cells", "CELL", 100, 118], ["Treg", "CELL", 120, 124], ["dicer", "GENE_OR_GENE_PRODUCT", 138, 143], ["Treg", "CELL", 173, 177], ["dicer", "PROTEIN", 26, 31], ["regulatory T cells", "CELL_TYPE", 100, 118], ["Treg", "CELL_TYPE", 120, 124], ["dicer leads", "PROBLEM", 138, 149], ["immunopathological disorders", "PROBLEM", 182, 210], ["splenomegaly", "PROBLEM", 219, 231], ["splenomegaly", "OBSERVATION", 219, 231]]], ["This study concludes that dicer facilitates the development of Treg in the thymus and the efficient induction of the necessary forkhead transcription factor, Foxp3, by TGF\u2010\u03b2 in naive CD4 T cells [97].", [["Treg", "ANATOMY", 63, 67], ["thymus", "ANATOMY", 75, 81], ["CD4 T cells", "ANATOMY", 183, 194], ["dicer", "GENE_OR_GENE_PRODUCT", 26, 31], ["Treg", "CELL", 63, 67], ["thymus", "ORGAN", 75, 81], ["Foxp3", "GENE_OR_GENE_PRODUCT", 158, 163], ["TGF\u2010\u03b2", "GENE_OR_GENE_PRODUCT", 168, 173], ["Treg", "CELL_TYPE", 63, 67], ["forkhead transcription factor", "PROTEIN", 127, 156], ["Foxp3", "PROTEIN", 158, 163], ["TGF\u2010\u03b2", "PROTEIN", 168, 173], ["naive CD4 T cells", "CELL_TYPE", 177, 194], ["This study", "TEST", 0, 10], ["Treg in the thymus", "PROBLEM", 63, 81], ["TGF", "TEST", 168, 171], ["Treg", "OBSERVATION", 63, 67], ["thymus", "ANATOMY", 75, 81]]], ["Several miRNAs, miR146a/b, miR132, and miR155, are LPS\u2010responsive genes in human monocytes [99,101].", [["monocytes", "ANATOMY", 81, 90], ["miR146a", "GENE_OR_GENE_PRODUCT", 16, 23], ["b", "GENE_OR_GENE_PRODUCT", 24, 25], ["miR132", "GENE_OR_GENE_PRODUCT", 27, 33], ["miR155", "GENE_OR_GENE_PRODUCT", 39, 45], ["LPS\u2010", "GENE_OR_GENE_PRODUCT", 51, 55], ["human", "ORGANISM", 75, 80], ["monocytes", "CELL", 81, 90], ["miRNAs", "DNA", 8, 14], ["miR146a", "DNA", 16, 23], ["miR132", "DNA", 27, 33], ["miR155", "DNA", 39, 45], ["LPS\u2010responsive genes", "DNA", 51, 71], ["human monocytes", "CELL_TYPE", 75, 90], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["Several miRNAs", "TEST", 0, 14], ["miR146a", "TEST", 16, 23], ["miR132", "TEST", 27, 33], ["miR155", "TEST", 39, 45], ["LPS", "TEST", 51, 54], ["human monocytes", "TEST", 75, 90]]], ["The miR155 is inducible in a human primary macrophage in response to different types of inflammatory mediators [101], but its effects on the immune cell function remain to be elucidated.", [["primary macrophage", "ANATOMY", 35, 53], ["immune cell", "ANATOMY", 141, 152], ["miR155", "GENE_OR_GENE_PRODUCT", 4, 10], ["human", "ORGANISM", 29, 34], ["macrophage", "CELL", 43, 53], ["immune cell", "CELL", 141, 152], ["miR155", "PROTEIN", 4, 10], ["human primary macrophage", "CELL_TYPE", 29, 53], ["inflammatory mediators", "PROTEIN", 88, 110], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["a human primary macrophage", "PROBLEM", 27, 53], ["inflammatory mediators", "PROBLEM", 88, 110], ["the immune cell function", "TEST", 137, 161], ["inducible", "OBSERVATION_MODIFIER", 14, 23], ["primary macrophage", "OBSERVATION", 35, 53], ["inflammatory", "OBSERVATION_MODIFIER", 88, 100], ["immune cell", "OBSERVATION", 141, 152]]], ["The miR146a/b bind sequences in the 3\u2032UTRs of two important adaptor molecules involved in LPS signaling, TRAF6 and IRAK1, and these UTRs inhibit expression of reporter constructs [99].NEGATIVE REGULATION OF THE IMMUNE SYSTEM AND ROLE OF microRNA (miRNA)The role of miRNA silencing machinery in not limited to negative control of the immune system as described in the above examples but itself, has a direct innate immunity function.", [["immune system", "ANATOMY", 333, 346], ["miR146a", "GENE_OR_GENE_PRODUCT", 4, 11], ["b", "GENE_OR_GENE_PRODUCT", 12, 13], ["LPS", "GENE_OR_GENE_PRODUCT", 90, 93], ["TRAF6", "GENE_OR_GENE_PRODUCT", 105, 110], ["IRAK1", "GENE_OR_GENE_PRODUCT", 115, 120], ["miR146a", "PROTEIN", 4, 11], ["UTRs", "DNA", 38, 42], ["adaptor molecules", "PROTEIN", 60, 77], ["TRAF6", "PROTEIN", 105, 110], ["IRAK1", "PROTEIN", 115, 120], ["UTRs", "DNA", 132, 136], ["reporter constructs", "DNA", 159, 178], ["The miR146a/b bind sequences", "TREATMENT", 0, 28], ["LPS signaling", "TEST", 90, 103], ["TRAF6", "TEST", 105, 110], ["IRAK1", "TREATMENT", 115, 120], ["reporter constructs", "TEST", 159, 178], ["miRNA silencing machinery", "TREATMENT", 265, 290], ["adaptor molecules", "OBSERVATION", 60, 77], ["IMMUNE SYSTEM", "OBSERVATION", 211, 224], ["microRNA", "OBSERVATION", 237, 245], ["immune system", "OBSERVATION", 333, 346]]], ["Drosha and dicer can act as intracellular, antiviral enzymes against HIV human monocytic cells, and the HIV Tat can act as a suppressor of the host RNA silencing [102,103].OVERVIEW AND FINAL REMARKSAlthough many recent studies emphasize protein\u2013protein and the adaptor interactions on signaling events, which lead to transcriptional activation, it is expected that more studies will focus on post\u2010transcriptional mechanisms.", [["intracellular", "ANATOMY", 28, 41], ["monocytic cells", "ANATOMY", 79, 94], ["Drosha", "GENE_OR_GENE_PRODUCT", 0, 6], ["dicer", "GENE_OR_GENE_PRODUCT", 11, 16], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 41], ["HIV", "ORGANISM", 69, 72], ["human", "ORGANISM", 73, 78], ["monocytic cells", "CELL", 79, 94], ["HIV", "ORGANISM", 104, 107], ["Tat", "GENE_OR_GENE_PRODUCT", 108, 111], ["Drosha", "PROTEIN", 0, 6], ["antiviral enzymes", "PROTEIN", 43, 60], ["HIV human monocytic cells", "CELL_TYPE", 69, 94], ["HIV Tat", "PROTEIN", 104, 111], ["HIV", "SPECIES", 69, 72], ["human", "SPECIES", 73, 78], ["HIV", "SPECIES", 69, 72], ["human", "SPECIES", 73, 78], ["HIV", "SPECIES", 104, 107], ["Drosha", "PROBLEM", 0, 6], ["intracellular, antiviral enzymes", "TEST", 28, 60], ["HIV human monocytic cells", "PROBLEM", 69, 94], ["the HIV Tat", "PROBLEM", 100, 111], ["recent studies", "TEST", 212, 226], ["the adaptor interactions", "PROBLEM", 257, 281], ["signaling events", "PROBLEM", 285, 301]]], ["The array of intracellular RNA\u2010protein interactions is manifested by the large number of ARE\u2010mRNAs and RNA\u2010binding proteins.", [["intracellular", "ANATOMY", 13, 26], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 26], ["ARE\u2010mRNAs", "GENE_OR_GENE_PRODUCT", 89, 98], ["RNA\u2010binding proteins", "GENE_OR_GENE_PRODUCT", 103, 123], ["ARE\u2010mRNAs", "PROTEIN", 89, 98], ["RNA\u2010binding proteins", "PROTEIN", 103, 123], ["intracellular RNA\u2010protein interactions", "PROBLEM", 13, 51], ["ARE\u2010mRNAs", "PROBLEM", 89, 98], ["RNA\u2010binding proteins", "PROBLEM", 103, 123], ["intracellular RNA", "OBSERVATION", 13, 30], ["large", "OBSERVATION_MODIFIER", 73, 78], ["number", "OBSERVATION_MODIFIER", 79, 85]]], ["Given that many mRNAs of the immune response contain AREs, and multiple signaling pathways are operative such as p38 MAPK and PI\u20103K/AKT, one can imagine the vast probability of post\u2010transcriptional interactions in the immune system.", [["immune system", "ANATOMY", 218, 231], ["AREs", "GENE_OR_GENE_PRODUCT", 53, 57], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 113, 121], ["PI\u20103K", "GENE_OR_GENE_PRODUCT", 126, 131], ["AKT", "GENE_OR_GENE_PRODUCT", 132, 135], ["mRNAs", "RNA", 16, 21], ["AREs", "DNA", 53, 57], ["p38 MAPK", "PROTEIN", 113, 121], ["PI\u20103K", "PROTEIN", 126, 131], ["AKT", "PROTEIN", 132, 135], ["p38 MAPK", "TEST", 113, 121], ["PI", "TEST", 126, 128], ["AKT", "TEST", 132, 135], ["post\u2010transcriptional interactions in the immune system", "PROBLEM", 177, 231]]], ["Additional types of post\u2010transcriptional mechanisms, such as alternative splicing and post\u2010translational regulatory events, although not within the focus of this review, also contribute to the intricate and complex regulation of the immune system.OVERVIEW AND FINAL REMARKSAs cities cope with the rapid entry of people by using rapid transit systems, post\u2010transcriptional control of immune system helps in rapid activation of immune cells by mechanisms that involve rapid translocation of mRNA stabilization proteins such as HuR to effector cellular compartments and/or temporal inactivation, e.g., by phosphorylation or proteolysis of RNA decay proteins such as TTP or KSRP.", [["immune system", "ANATOMY", 233, 246], ["immune system", "ANATOMY", 383, 396], ["immune cells", "ANATOMY", 426, 438], ["cellular compartments", "ANATOMY", 541, 562], ["people", "ORGANISM", 312, 318], ["immune system", "ANATOMICAL_SYSTEM", 383, 396], ["immune cells", "CELL", 426, 438], ["HuR", "GENE_OR_GENE_PRODUCT", 525, 528], ["TTP", "GENE_OR_GENE_PRODUCT", 663, 666], ["KSRP", "GENE_OR_GENE_PRODUCT", 670, 674], ["immune cells", "CELL_TYPE", 426, 438], ["mRNA stabilization proteins", "PROTEIN", 489, 516], ["HuR", "PROTEIN", 525, 528], ["RNA decay proteins", "PROTEIN", 636, 654], ["TTP", "PROTEIN", 663, 666], ["KSRP", "PROTEIN", 670, 674], ["people", "SPECIES", 312, 318], ["post\u2010transcriptional mechanisms", "PROBLEM", 20, 51], ["alternative splicing", "TREATMENT", 61, 81], ["post\u2010translational regulatory events", "PROBLEM", 86, 122], ["rapid transit systems", "TREATMENT", 328, 349], ["immune system", "TREATMENT", 383, 396], ["immune cells", "PROBLEM", 426, 438], ["mRNA stabilization proteins", "PROBLEM", 489, 516], ["HuR to effector cellular compartments", "PROBLEM", 525, 562], ["temporal inactivation", "PROBLEM", 570, 591], ["RNA decay proteins", "PROBLEM", 636, 654], ["TTP", "PROBLEM", 663, 666], ["KSRP", "TEST", 670, 674], ["immune cells", "OBSERVATION", 426, 438], ["cellular compartments", "OBSERVATION", 541, 562]]], ["Also, when people move out quickly from the transits at the point of exit, mechanisms in the immune system ensure a swift shut\u2010off and recovery.", [["immune system", "ANATOMY", 93, 106], ["people", "ORGANISM", 11, 17], ["people", "SPECIES", 11, 17]]], ["This happens by the reversal of events that led to mRNA stabilization, activation of decay\u2010promoting proteins, and translational arrest (Fig. 3).", [["decay\u2010promoting proteins", "PROTEIN", 85, 109], ["mRNA stabilization", "TREATMENT", 51, 69], ["decay\u2010promoting proteins", "PROBLEM", 85, 109], ["translational arrest", "PROBLEM", 115, 135]]], ["These temporal and spatial events culminate in a transiently regulated immune system, which is able to cope with external and internal insults to the body without deleterious effects on the host.", [["immune system", "ANATOMY", 71, 84], ["body", "ANATOMY", 150, 154], ["body", "ORGANISM_SUBDIVISION", 150, 154], ["These temporal and spatial events", "PROBLEM", 0, 33], ["a transiently regulated immune system", "PROBLEM", 47, 84], ["external and internal insults", "PROBLEM", 113, 142], ["deleterious effects on the host", "PROBLEM", 163, 194], ["temporal", "OBSERVATION_MODIFIER", 6, 14], ["spatial events", "OBSERVATION", 19, 33], ["immune system", "OBSERVATION", 71, 84]]], ["Specific abnormal situations may arise if the transient response of the immune system becomes prolonged, such as those that occur in chronic inflammatory and autoimmune diseases.", [["immune system", "ANATOMY", 72, 85], ["autoimmune diseases", "DISEASE", 158, 177], ["Specific abnormal situations", "PROBLEM", 0, 28], ["chronic inflammatory and autoimmune diseases", "PROBLEM", 133, 177], ["chronic", "OBSERVATION_MODIFIER", 133, 140], ["inflammatory", "OBSERVATION", 141, 153], ["autoimmune diseases", "OBSERVATION", 158, 177]]]], "8080c6182b0f339d7ee0cbcb035217e4d7dad10e": [["Emerging diseases include outbreaks of previously unknown diseases or known diseases whose incidence in humans has significantly increased in the past two decades.", [["humans", "ORGANISM", 104, 110], ["humans", "SPECIES", 104, 110], ["humans", "SPECIES", 104, 110], ["Emerging diseases", "PROBLEM", 0, 17], ["previously unknown diseases", "PROBLEM", 39, 66], ["known diseases", "PROBLEM", 70, 84], ["diseases", "OBSERVATION", 9, 17], ["diseases", "OBSERVATION", 58, 66], ["diseases", "OBSERVATION", 76, 84], ["significantly", "OBSERVATION_MODIFIER", 115, 128], ["increased", "OBSERVATION_MODIFIER", 129, 138]]], ["Re-emerging diseases are known diseases that have reappeared after a significant decline in incidence (http://www3.niaid.nih.gov/research/topics/emerging).", [["Re-emerging diseases", "PROBLEM", 0, 20], ["known diseases", "PROBLEM", 25, 39], ["a significant decline in incidence (http://www3.niaid.nih.gov/research/topics/emerging", "PROBLEM", 67, 153], ["significant", "OBSERVATION_MODIFIER", 69, 80], ["decline", "OBSERVATION_MODIFIER", 81, 88]]]], "59b5aa15ad789505ef2ee719bf0d7ce21ca8ac21": [["There are many studies documenting outcomes of Pediatric intensive care units (PICU) from western countries l~s but very few such studies are available from the developing countries.", [["such studies", "TEST", 125, 137]]], ["9-12 Parikh et al outlined significant issues in quality, cost and outcomes from an adult Intensive care unit (ICU) in India. ~~ Current status of information regarding a variety of clinical conditions,and outcomes from Indian PICUs is unknown with the exception of a few studies retrospectively looking at specific issues such as incidence and outcome of acute respiratory distress syndrome (ARDS) in children, u A retrospective study reviewing the admission records from 1986-93 docttmemted the profile and outcomes of patients admitted to a six bedded pediatric intensive care unit.", [["respiratory", "ANATOMY", 362, 373], ["9-12", "CHEMICAL", 0, 4], ["acute respiratory distress syndrome", "DISEASE", 356, 391], ["ARDS", "DISEASE", 393, 397], ["children", "ORGANISM", 402, 410], ["patients", "ORGANISM", 521, 529], ["children", "SPECIES", 402, 410], ["patients", "SPECIES", 521, 529], ["a few studies", "TEST", 266, 279], ["acute respiratory distress syndrome", "PROBLEM", 356, 391], ["ARDS", "PROBLEM", 393, 397], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["issues", "OBSERVATION", 39, 45], ["acute", "OBSERVATION_MODIFIER", 356, 361], ["respiratory distress", "OBSERVATION", 362, 382]]], ["9 The present prospective observational study attempts to characterize the profile of children admitted to a tertiary PICU in India over a period of three years with various disease entities, their mangement in the PICU, adjusted mortality according to PRISMIII scores, iatrogenic and other complications, morbidity and overall outcomes.Study PICU ProfileStudy PICU is a 10 bed ded Pediatric Intensive care unit of a private tertiary care hospital located in New Delhi, India Reprint requests : Dr. Praveen Khilnani, B42, Panchsheel Enclave, New Delhi-110017.", [["Delhi-110017", "CHEMICAL", 546, 558], ["children", "ORGANISM", 86, 94], ["children", "SPECIES", 86, 94], ["prospective observational study", "TEST", 14, 45], ["various disease entities", "PROBLEM", 166, 190], ["PRISMIII scores", "TEST", 253, 268], ["iatrogenic", "PROBLEM", 270, 280], ["other complications", "PROBLEM", 285, 304], ["morbidity", "PROBLEM", 306, 315]]], ["Total number of beds for Pediatric patients is 52.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43]]], ["The multidisciplinary PICU receives patients from Pediatric ward, direct transfers from other hospitals, patients brought from other hospitals by the pediatric critical care transport team, as well as post operative patients requiring PICU care.", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 105, 113], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 216, 224], ["PICU care", "TREATMENT", 235, 244]]], ["The hospital, in most part, caters to self paying middle class and higher socioeconomic groups of patients from India and neighbouring Asian and Middle eastern countries.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106]]], ["The hospital has an active pediatric congenital heart surgery program as well as active pediatric liver and kidney transplant programs.Study PICU ProfileThe study unit is staffed by two full time pediatric intensivists (one with formal fellowship training and American board certification in pediatric critical care medicine, and other with British training in pediatric intensive care), supported by referring pediatricians and various pediatric subspecialists.", [["heart", "ANATOMY", 48, 53], ["liver", "ANATOMY", 98, 103], ["kidney", "ANATOMY", 108, 114], ["heart", "ORGAN", 48, 53], ["liver", "ORGAN", 98, 103], ["kidney", "ORGAN", 108, 114], ["an active pediatric congenital heart surgery program", "TREATMENT", 17, 69], ["active pediatric liver and kidney transplant programs", "TREATMENT", 81, 134], ["formal fellowship training", "TREATMENT", 229, 255], ["heart", "ANATOMY", 48, 53], ["surgery", "OBSERVATION", 54, 61], ["liver", "ANATOMY", 98, 103], ["kidney", "ANATOMY", 108, 114], ["transplant", "OBSERVATION", 115, 125]]], ["There is an active pediatric residency training (DNB) program with pediatric residents involved with supervised patient care.Study PICU Profile'For ventilated patients, nurse to patients ratio is 2 : I or 1:1 as needed and for other patients it is I : 2.", [["patient", "ORGANISM", 112, 119], ["patients", "ORGANISM", 159, 167], ["patients", "ORGANISM", 178, 186], ["patients", "ORGANISM", 233, 241], ["patient", "SPECIES", 112, 119], ["patients", "SPECIES", 159, 167], ["patients", "SPECIES", 178, 186], ["patients", "SPECIES", 233, 241], ["active", "OBSERVATION_MODIFIER", 12, 18]]], ["Ventilators are h a n d l e d by pediatric registrars and pediatric intensivists with back u p s u p p o r t of biomedical engineers for correction of any technical faults.", [["Ventilators", "DISEASE", 0, 11], ["r t of biomedical engineers", "TREATMENT", 105, 132]]], ["Suction and nebulizer therapy is routinely handled by PICU nurses.", [["Suction", "TREATMENT", 0, 7], ["nebulizer therapy", "TREATMENT", 12, 29]]], ["Physiotherapists and nurses provide chest physiotherapy as instructed by the attending pediatrc intensivist.Study PICU ProfileThe hospital does not have a separate laboratory for the PICU but a central emergency laboratory is operative 24 hours with one hour turn around time for laboratory results.", [["chest", "ANATOMY", 36, 41], ["chest", "ORGANISM_SUBDIVISION", 36, 41], ["chest physiotherapy", "TREATMENT", 36, 55], ["chest", "ANATOMY", 36, 41]]], ["Results of arterial blood gas analysis, electrolytes, and ionized calcium are available on immediate basis round the clock .Pediatric critical care transport team consists of a pediatric registrar ,a nurse and a paramedic available 24 hours with 30 min response time (time elapsed from the time of receiving a transport request to the time that transport team leaves to get the patient).", [["arterial blood", "ANATOMY", 11, 25], ["calcium", "CHEMICAL", 66, 73], ["calcium", "CHEMICAL", 66, 73], ["arterial", "MULTI-TISSUE_STRUCTURE", 11, 19], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["electrolytes", "SIMPLE_CHEMICAL", 40, 52], ["calcium", "SIMPLE_CHEMICAL", 66, 73], ["patient", "ORGANISM", 378, 385], ["patient", "SPECIES", 378, 385], ["arterial blood gas analysis", "TEST", 11, 38], ["electrolytes", "TEST", 40, 52], ["ionized calcium", "TEST", 58, 73]]], ["Ambulance is equipped with e m e r g e n c y drugs, ventilators, monitors, suction equipment and adequate oxygen supply.", [["oxygen", "CHEMICAL", 106, 112], ["oxygen", "CHEMICAL", 106, 112], ["oxygen", "SIMPLE_CHEMICAL", 106, 112], ["y drugs", "TREATMENT", 43, 50], ["ventilators", "TREATMENT", 52, 63], ["suction equipment", "TREATMENT", 75, 92], ["adequate oxygen supply", "TREATMENT", 97, 119]]], ["Pediatric intensivist accompanies the transport team for a few selected patients upon request of the transport team or upon the discretion of the pediatric intensivist if the patient is very critical requiring multiple interventions.Study PICU ProfileAt the time of the study, admission age in Our PICU was 12 years and under due to the then existing hospital rules.", [["patients", "ORGANISM", 72, 80], ["patient", "ORGANISM", 175, 182], ["patients", "SPECIES", 72, 80], ["patient", "SPECIES", 175, 182], ["multiple interventions", "TREATMENT", 210, 232], ["the study", "TEST", 266, 275]]], ["Patients of ages 16 years and under can be admitted to PICU if they need PICU admission.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Standard admission criteria were used for admission to the PICU as per PICU protocol established in 1998 and published recently as consensus guidelines for Pediatric intensive care units in India23MATERIALS AND METHODSAfter obtaining approval from the hospital review board (Ethics committee), all patients admitted to the PICU between Jan'1998 to Dec'2000 (Age 12 years and under) were prospectively studied till discharge, transfer or death.", [["death", "DISEASE", 437, 442], ["patients", "ORGANISM", 298, 306], ["patients", "SPECIES", 298, 306]]], ["Data collected on patients included : age, gender, admission and discharge diagnosis classified by system and etiology of the disease, elective or emergency status, admission source (same hospital, referral hospital, home), transportation to the hospital by an organized transport system and critical care mangement during the PICU stay, average length of the PICU stay, and duration of mechanical ventilation, as applicable.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["the disease", "PROBLEM", 122, 133], ["critical care mangement", "TREATMENT", 292, 315], ["mechanical ventilation", "TREATMENT", 387, 409], ["disease", "OBSERVATION", 126, 133], ["mechanical ventilation", "OBSERVATION", 387, 409]]], ["All patients u n d e r w e n t PRISM-III scoring (most abnormal value within 24 hours of admission was used) .", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["abnormal value", "PROBLEM", 55, 69]]], ["Overall outcomes including all iatrogenic and other complications including nosocomial infections, m o r b i d i t y and mortality rates adjusted according to PRISMm scores were recorded.RESULTSDuring the 36 months study period, 948 children were admitted to the 10 bedded PICU (270, 310, and 368 each year in 3 years).", [["nosocomial infections", "DISEASE", 76, 97], ["children", "ORGANISM", 233, 241], ["children", "SPECIES", 233, 241], ["all iatrogenic and other complications", "PROBLEM", 27, 65], ["nosocomial infections", "PROBLEM", 76, 97], ["mortality rates", "TEST", 121, 136], ["PRISMm scores", "TEST", 159, 172]]], ["480 patients had received treatment in a smaller community hospital for at least 24 hours before admission to our hospital.175 children were transported from the referring hospital by our pediatric critical care transport team.", [["patients", "ORGANISM", 4, 12], ["children", "ORGANISM", 127, 135], ["patients", "SPECIES", 4, 12], ["children", "SPECIES", 127, 135], ["treatment", "TREATMENT", 26, 35]]], ["Out of 948 children 134 (14.14%) had congenital disorders and rest had acquired disorders.Various disease categories encountered are shown in Table 1DISCUSSIONThe concept of pediatric critical care is relatively new in India.", [["congenital disorders", "DISEASE", 37, 57], ["children", "ORGANISM", 11, 19], ["children", "SPECIES", 11, 19], ["congenital disorders", "PROBLEM", 37, 57], ["acquired disorders", "PROBLEM", 71, 89], ["Various disease categories", "PROBLEM", 90, 116], ["disease", "OBSERVATION", 98, 105], ["new", "OBSERVATION_MODIFIER", 212, 215]]], ["Due to rapid growth in population and, general lack of education and health awareness, inability to adequately control infectious diseases is a major public health issue.", [["infectious diseases", "DISEASE", 119, 138], ["rapid growth in population", "PROBLEM", 7, 33], ["inability to adequately control infectious diseases", "PROBLEM", 87, 138], ["rapid", "OBSERVATION_MODIFIER", 7, 12], ["growth", "OBSERVATION_MODIFIER", 13, 19]]], ["A gradual rise in incidence of m o d e r n epidemiological diseases (such as multiple trauma); i m p r o v i n g socioeconomic status and increasing a w a r e n e s s of health related issues a m o n g u r b a n population have led to increasing demand for pediatric critical care in India.", [["trauma", "DISEASE", 86, 92], ["epidemiological diseases", "PROBLEM", 43, 67], ["multiple trauma", "PROBLEM", 77, 92], ["pediatric critical care", "TREATMENT", 257, 280], ["gradual", "OBSERVATION_MODIFIER", 2, 9], ["rise", "OBSERVATION_MODIFIER", 10, 14], ["diseases", "OBSERVATION", 59, 67]]], ["Only a few major centers run by state medical colleges have tertiary level PICUs, in addition to even fewer privately run tertiary level institutions.Various previously published studies have reported significant variability between PICUs in age, percentage of surgical or trauma patients, morbidity, and mortality.", [["trauma", "DISEASE", 273, 279], ["patients", "ORGANISM", 280, 288], ["patients", "SPECIES", 280, 288], ["Various previously published studies", "TEST", 150, 186], ["surgical or trauma patients", "PROBLEM", 261, 288], ["morbidity", "PROBLEM", 290, 299], ["few", "OBSERVATION_MODIFIER", 7, 10], ["significant", "OBSERVATION_MODIFIER", 201, 212], ["variability", "OBSERVATION_MODIFIER", 213, 224], ["surgical", "OBSERVATION", 261, 269]]], ["1619 Although many scoring systems exist for different illnesses for assessing severity.", [["different illnesses", "PROBLEM", 45, 64]]], ["7,8,19-23 a foolproof qualitative and unbiased assessment of severity of illness is difficult, and controversy continues regarding the accuracy of prediction of mortality due to significantly different mortality rates reported in different studies.", [["illness", "DISEASE", 73, 80], ["unbiased assessment", "TEST", 38, 57], ["illness", "PROBLEM", 73, 80], ["significantly different mortality rates", "PROBLEM", 178, 217], ["different studies", "TEST", 230, 247]]], ["2~,22DISCUSSIONICUs with higher mortality rates m a y be caring for patients with more severe illnesses and vice versa.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["more severe illnesses", "PROBLEM", 82, 103]]], ["In addition, lower m o r t a l i t y rates do not necessarily translate into better long term patient outcomes.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101]]], ["PRISMIII may be inaccurate in predicting mortality in multiple trauma patients.DISCUSSIONIn the present study we encountered a wide spectrum of cases including respiratory, cardiac,neurological, trauma patients, as well as patients with septic shock, dengue, malaria, ARDS and multiorgan failure requiring mechanical ventilation, inotropes, and various critical care treatment modalities such as renal replacement therapy and hepatic support.", [["respiratory", "ANATOMY", 160, 171], ["cardiac", "ANATOMY", 173, 180], ["neurological", "ANATOMY", 181, 193], ["multiorgan", "ANATOMY", 277, 287], ["renal", "ANATOMY", 396, 401], ["hepatic", "ANATOMY", 426, 433], ["trauma", "DISEASE", 63, 69], ["respiratory, cardiac,neurological, trauma", "DISEASE", 160, 201], ["septic shock", "DISEASE", 237, 249], ["dengue", "DISEASE", 251, 257], ["malaria", "DISEASE", 259, 266], ["ARDS", "DISEASE", 268, 272], ["multiorgan failure", "DISEASE", 277, 295], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 202, 210], ["patients", "ORGANISM", 223, 231], ["renal", "ORGAN", 396, 401], ["hepatic", "ORGAN", 426, 433], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 202, 210], ["patients", "SPECIES", 223, 231], ["the present study", "TEST", 92, 109], ["septic shock", "PROBLEM", 237, 249], ["dengue", "PROBLEM", 251, 257], ["malaria", "PROBLEM", 259, 266], ["ARDS", "PROBLEM", 268, 272], ["multiorgan failure", "PROBLEM", 277, 295], ["mechanical ventilation", "TREATMENT", 306, 328], ["inotropes", "TREATMENT", 330, 339], ["various critical care treatment modalities", "TREATMENT", 345, 387], ["renal replacement therapy", "TREATMENT", 396, 421], ["hepatic support", "TREATMENT", 426, 441], ["multiple", "OBSERVATION_MODIFIER", 54, 62], ["trauma", "OBSERVATION", 63, 69], ["cardiac", "ANATOMY", 173, 180], ["septic shock", "OBSERVATION", 237, 249], ["malaria", "OBSERVATION", 259, 266], ["ARDS", "OBSERVATION", 268, 272], ["multiorgan failure", "OBSERVATION", 277, 295], ["mechanical ventilation", "OBSERVATION", 306, 328], ["renal", "ANATOMY", 396, 401], ["replacement", "OBSERVATION", 402, 413], ["hepatic", "ANATOMY", 426, 433]]], ["We found a general trend towards direct proportionality of PRISMIII scores with respect to increasing mortality in our patient population.", [["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 119, 126], ["PRISMIII scores", "TEST", 59, 74], ["increasing mortality", "PROBLEM", 91, 111], ["increasing", "OBSERVATION_MODIFIER", 91, 101], ["mortality", "OBSERVATION_MODIFIER", 102, 111]]], ["Despite some discrepancies PRISMIII remains the most practical predictor of mortality in critically ill children.DISCUSSIONDue to scanty published data of PICU profile within India, an adequate comparison of relative incidences and outcomes is not possible within the country.", [["critically ill", "DISEASE", 89, 103], ["children", "ORGANISM", 104, 112], ["children", "SPECIES", 104, 112], ["some discrepancies", "PROBLEM", 8, 26]]], ["A retrospective study performed at the All India Institute of Medical Sciences (AIIMS study) reviewed PICU(from a 6 bedded PICU established in 1986) patient data over a period of six years (1986-93), published in 1993.", [["patient", "ORGANISM", 149, 156], ["patient", "SPECIES", 149, 156], ["A retrospective study", "TEST", 0, 21]]], ["9 In this study 69.2% of patients were males.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["this study", "TEST", 5, 15]]], ["We found a similar male prepoderence in our PICU population for almost every 3 boys admitted, there was only 1 girl ,possibly reflecting the social bias still prevailing against the girl child in India In the 1993 AIIMS study, 9 septicemia was found to be the most common cause of admission (14.8%), compared to respiratory failure (19.73%) being the most common cause in the present study.", [["respiratory", "ANATOMY", 312, 323], ["septicemia", "DISEASE", 229, 239], ["respiratory failure", "DISEASE", 312, 331], ["girl", "SPECIES", 111, 115], ["girl", "SPECIES", 182, 186], ["AIIMS study", "TEST", 214, 225], ["9 septicemia", "PROBLEM", 227, 239], ["respiratory failure", "PROBLEM", 312, 331], ["the present study", "TEST", 372, 389], ["similar", "OBSERVATION_MODIFIER", 11, 18], ["septicemia", "OBSERVATION", 229, 239], ["respiratory failure", "OBSERVATION", 312, 331], ["most common", "OBSERVATION_MODIFIER", 351, 362]]], ["Septicemia as an isolated entity was not looked at in the present study,but could have been coexistent in patients with respiratory distress due to respiratory tract infections, ARDS, other infections and multiorgan failure.DISCUSSIONOverall mortality was 23.5%, with age related mortality being highest (32.1%) in 1-5 years in AIIMS study.", [["respiratory", "ANATOMY", 120, 131], ["respiratory tract", "ANATOMY", 148, 165], ["multiorgan", "ANATOMY", 205, 215], ["Septicemia", "DISEASE", 0, 10], ["respiratory distress", "DISEASE", 120, 140], ["respiratory tract infections", "DISEASE", 148, 176], ["ARDS", "DISEASE", 178, 182], ["infections", "DISEASE", 190, 200], ["multiorgan failure", "DISEASE", 205, 223], ["patients", "ORGANISM", 106, 114], ["tract", "ORGANISM_SUBDIVISION", 160, 165], ["patients", "SPECIES", 106, 114], ["Septicemia", "PROBLEM", 0, 10], ["respiratory distress", "PROBLEM", 120, 140], ["respiratory tract infections", "PROBLEM", 148, 176], ["ARDS", "PROBLEM", 178, 182], ["other infections", "PROBLEM", 184, 200], ["multiorgan failure", "PROBLEM", 205, 223], ["AIIMS study", "TEST", 328, 339], ["respiratory distress", "OBSERVATION", 120, 140], ["respiratory tract", "ANATOMY", 148, 165], ["infections", "OBSERVATION", 166, 176], ["ARDS", "OBSERVATION", 178, 182], ["infections", "OBSERVATION", 190, 200], ["multiorgan failure", "OBSERVATION", 205, 223]]], ["9 Mortality due to fulminant hepatic failure was 10.16% in our study compared to the AIIMS study (51.3%).", [["hepatic", "ANATOMY", 29, 36], ["fulminant hepatic failure", "DISEASE", 19, 44], ["hepatic", "ORGAN", 29, 36], ["fulminant hepatic failure", "PROBLEM", 19, 44], ["our study", "TEST", 59, 68], ["the AIIMS study", "TEST", 81, 96], ["fulminant", "OBSERVATION_MODIFIER", 19, 28], ["hepatic", "ANATOMY", 29, 36], ["failure", "OBSERVATION", 37, 44]]], ["Severity of illness scores were not documented in the AIIMS study probably due to non availability of established scoring systems such as PRISM untill late 80s, therefore an adequate comparison of mortality based on severity of illness to AIIMS study is not possible Overall mortality in the present study was lower (6.72%) compared to the AIIMS study.", [["illness scores", "PROBLEM", 12, 26], ["the AIIMS study", "TEST", 50, 65], ["PRISM", "TEST", 138, 143], ["illness", "PROBLEM", 228, 235], ["AIIMS study", "TEST", 239, 250], ["the present study", "TEST", 288, 305], ["the AIIMS study", "TEST", 336, 351], ["illness", "OBSERVATION", 12, 19], ["not possible", "UNCERTAINTY", 254, 266]]], ["This could possibly be due to significant improvement in pediatric critical care in the last decade, earlier referral to the PICU, as well as a difference in the case mix.DISCUSSIONBased on our observations,it appears that Pediatric Intensive Care in our center is somewhat similar to the western world in terms of severity of illness and prediction of mortality, PRISMIII adjusted mortality, average days of ventilation required and length of PICU stay.", [["illness", "DISEASE", 327, 334], ["illness", "PROBLEM", 327, 334], ["ventilation", "TREATMENT", 409, 420], ["could possibly be due to", "UNCERTAINTY", 5, 29], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["improvement", "OBSERVATION_MODIFIER", 42, 53]]], ["25 Observed PRISMIIt adjusted mortality rate seems directly proportional to PRISMIII scores as expected.DISCUSSIONIn the present study 119 children (12.55%) were admitted for infectious diseases and significant number of which were due to dengue hemorrhagic fever (54 cases :5.5% of total admission).", [["infectious diseases", "DISEASE", 175, 194], ["dengue hemorrhagic fever", "DISEASE", 239, 263], ["children", "ORGANISM", 139, 147], ["children", "SPECIES", 139, 147], ["dengue hemorrhagic fever", "SPECIES", 239, 263], ["PRISMIII scores", "TEST", 76, 91], ["infectious diseases", "PROBLEM", 175, 194], ["dengue hemorrhagic fever", "PROBLEM", 239, 263]]], ["Other important tropical infectious diseases that required admission included cerebral malaria, pulmonary tuberculosis and tubercular meningitis.", [["cerebral", "ANATOMY", 78, 86], ["pulmonary", "ANATOMY", 96, 105], ["infectious diseases", "DISEASE", 25, 44], ["cerebral malaria", "DISEASE", 78, 94], ["pulmonary tuberculosis", "DISEASE", 96, 118], ["tubercular meningitis", "DISEASE", 123, 144], ["cerebral", "ORGAN", 78, 86], ["pulmonary", "ORGAN", 96, 105], ["cerebral malaria", "PROBLEM", 78, 94], ["pulmonary tuberculosis", "PROBLEM", 96, 118], ["tubercular meningitis", "PROBLEM", 123, 144], ["tropical", "OBSERVATION_MODIFIER", 16, 24], ["infectious", "OBSERVATION", 25, 35], ["cerebral", "ANATOMY", 78, 86], ["malaria", "OBSERVATION", 87, 94], ["pulmonary", "ANATOMY", 96, 105], ["tuberculosis", "OBSERVATION", 106, 118], ["tubercular", "OBSERVATION_MODIFIER", 123, 133], ["meningitis", "OBSERVATION", 134, 144]]], ["Some of the infectious diseases that required admission included vaccine preventable diseasess (Hemophilus influenzae meningits, fulminant measles and fulminant Hepatitis due to Hepatitis A and Hepatitis B Viruses).", [["infectious diseases", "DISEASE", 12, 31], ["Hemophilus influenzae meningits", "DISEASE", 96, 127], ["fulminant measles", "DISEASE", 129, 146], ["fulminant Hepatitis", "DISEASE", 151, 170], ["Hepatitis A and Hepatitis B Viruses", "DISEASE", 178, 213], ["Hemophilus influenzae meningits", "ORGANISM", 96, 127], ["Hepatitis A", "ORGANISM", 178, 189], ["Hepatitis B Viruses", "ORGANISM", 194, 213], ["Hemophilus influenzae", "SPECIES", 96, 117], ["Hemophilus influenzae meningits", "SPECIES", 96, 127], ["Hepatitis A", "SPECIES", 178, 189], ["the infectious diseases", "PROBLEM", 8, 31], ["vaccine preventable diseasess", "PROBLEM", 65, 94], ["Hemophilus influenzae meningits", "PROBLEM", 96, 127], ["fulminant measles", "PROBLEM", 129, 146], ["fulminant Hepatitis", "PROBLEM", 151, 170], ["Hepatitis A", "PROBLEM", 178, 189], ["Hepatitis B Viruses", "PROBLEM", 194, 213], ["infectious", "OBSERVATION", 12, 22]]], ["Above findings regarding different infectious diseases, although not common in the West, are common in this part of the world.DISCUSSIONThe incidence of ARDS was somewhat higher than reported in other studies.", [["infectious diseases", "DISEASE", 35, 54], ["ARDS", "DISEASE", 153, 157], ["different infectious diseases", "PROBLEM", 25, 54], ["ARDS", "PROBLEM", 153, 157], ["other studies", "TEST", 195, 208], ["different", "OBSERVATION_MODIFIER", 25, 34], ["infectious", "OBSERVATION", 35, 45], ["ARDS", "OBSERVATION", 153, 157], ["somewhat", "OBSERVATION_MODIFIER", 162, 170], ["higher", "OBSERVATION_MODIFIER", 171, 177]]], ["26' 27 This finding may be explained by the fact that a significant number of our ARDS cases were secondry to dengue shock syndrome which is not very common in other countries.", [["ARDS", "DISEASE", 82, 86], ["dengue shock syndrome", "DISEASE", 110, 131], ["our ARDS cases", "PROBLEM", 78, 92], ["dengue shock syndrome", "PROBLEM", 110, 131], ["may be explained", "UNCERTAINTY", 20, 36], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["number", "OBSERVATION_MODIFIER", 68, 74], ["ARDS", "OBSERVATION", 82, 86], ["shock syndrome", "OBSERVATION", 117, 131]]], ["The incidence of nosocomial infections was 16.86%.", [["nosocomial infections", "DISEASE", 17, 38], ["nosocomial infections", "PROBLEM", 17, 38], ["nosocomial", "OBSERVATION_MODIFIER", 17, 27], ["infections", "OBSERVATION", 28, 38]]], ["This is somewhat higher than that reported in literature from developed countries, expected to be 5 to 15 %,2s but similar to that of other developing countries.", [["somewhat", "OBSERVATION_MODIFIER", 8, 16], ["higher", "OBSERVATION_MODIFIER", 17, 23]]], ["29,3~ A relatively high rate of nosocomial infections could be related to factors such as personal hygiene, noncompliance of PICU visitation policies and infection control measures such as strict hand washing before and after patient contact.", [["hand", "ANATOMY", 196, 200], ["nosocomial infections", "DISEASE", 32, 53], ["infection", "DISEASE", 154, 163], ["hand", "ORGANISM_SUBDIVISION", 196, 200], ["patient", "ORGANISM", 226, 233], ["patient", "SPECIES", 226, 233], ["nosocomial infections", "PROBLEM", 32, 53], ["PICU visitation policies", "TREATMENT", 125, 149], ["infection control measures", "TREATMENT", 154, 180], ["strict hand washing", "TREATMENT", 189, 208], ["nosocomial infections", "OBSERVATION", 32, 53]]], ["Authors acknowledge the limitation of this study as being representative for only a subgroup of hospitals catering to a relatively higher socioeconomic group, rather than rural areas of India or even medical school (university) affiliated city hospitals run by various state governments.", [["this study", "TEST", 38, 48]]], ["With more PICUs coming up in India in state governments run institutions catering to the poor population, perhaps a multicenter outcome analysis from PICUs would establish the profiles and outcomes more firmly and present a more realistic picture of the status of pediatric intensive care in thedeveloping countries like India.CONCLUSIONPediatric intensive care in our center appears to be largely similar to the western world in terms of severity of illness and prediction of mortality, PRISMIII adjusted mortality, average days of ventilation required and length of PICU stay.", [["illness", "DISEASE", 451, 458], ["a multicenter outcome analysis", "TEST", 114, 144], ["pediatric intensive care", "TREATMENT", 264, 288], ["illness", "PROBLEM", 451, 458], ["ventilation", "TREATMENT", 533, 544]]], ["The profile of children admitted mainly differs from western countries in terms of some of the demographic profile, spectrum of diseases and incidence of nosocomial infections: as expected, diseases such as tuberculosis, cerebral malaria, dengue hemorrhagic fever are more common.", [["cerebral", "ANATOMY", 221, 229], ["nosocomial infections", "DISEASE", 154, 175], ["tuberculosis", "DISEASE", 207, 219], ["cerebral malaria", "DISEASE", 221, 237], ["dengue hemorrhagic fever", "DISEASE", 239, 263], ["children", "ORGANISM", 15, 23], ["children", "SPECIES", 15, 23], ["dengue hemorrhagic fever", "SPECIES", 239, 263], ["diseases", "PROBLEM", 128, 136], ["nosocomial infections", "PROBLEM", 154, 175], ["diseases", "PROBLEM", 190, 198], ["tuberculosis", "PROBLEM", 207, 219], ["cerebral malaria", "PROBLEM", 221, 237], ["dengue hemorrhagic fever", "PROBLEM", 239, 263], ["diseases", "OBSERVATION", 128, 136], ["nosocomial", "OBSERVATION_MODIFIER", 154, 164], ["infections", "OBSERVATION", 165, 175], ["tuberculosis", "OBSERVATION", 207, 219], ["cerebral", "ANATOMY", 221, 229], ["malaria", "OBSERVATION", 230, 237], ["hemorrhagic", "OBSERVATION_MODIFIER", 246, 257]]], ["Male children are more likely to be admitted in PICU compared to female children (2.95:1) probably related to gender bias still prevailing in India.", [["children", "ORGANISM", 5, 13], ["children", "ORGANISM", 72, 80], ["children", "SPECIES", 5, 13], ["children", "SPECIES", 72, 80]]], ["There is somwhat high incidence of nosocomial infections (16.86%) compared to available western data, necessitating a need for better compliance with infection control policies.", [["nosocomial infections", "DISEASE", 35, 56], ["infection", "DISEASE", 150, 159], ["nosocomial infections", "PROBLEM", 35, 56], ["infection control policies", "TREATMENT", 150, 176], ["high", "OBSERVATION_MODIFIER", 17, 21], ["nosocomial", "OBSERVATION_MODIFIER", 35, 45], ["infections", "OBSERVATION", 46, 56], ["infection", "OBSERVATION", 150, 159]]]], "a57cb00ca369247dabfbe07abd19496d106cc867": [["activation; however, MHC-dependent, T cell receptor (TCR)-mimic CARs that enable the recognition of intracellular tumour-associated antigens (TAAs) have also been described [11] [12] [13] [14] .", [["T cell", "ANATOMY", 36, 42], ["intracellular tumour", "ANATOMY", 100, 120], ["tumour", "DISEASE", 114, 120], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 36, 51], ["TCR", "GENE_OR_GENE_PRODUCT", 53, 56], ["intracellular tumour", "CANCER", 100, 120], ["TAAs", "GENE_OR_GENE_PRODUCT", 142, 146], ["[11] [12] [13] [14]", "SIMPLE_CHEMICAL", 173, 192], ["MHC", "PROTEIN", 21, 24], ["T cell receptor", "PROTEIN", 36, 51], ["TCR", "PROTEIN", 53, 56], ["CARs", "PROTEIN", 64, 68], ["intracellular tumour-associated antigens", "PROTEIN", 100, 140], ["TAAs", "PROTEIN", 142, 146], ["intracellular tumour", "PROBLEM", 100, 120], ["intracellular tumour", "OBSERVATION", 100, 120]]], ["CARs have also been engineered with scFvs that bind to soluble ligands present in the tumour microenvironment (TME), such as transforming growth factor-\u03b2 (TGF\u03b2) 15 , in order to convert an immunosuppressive signal often present in solid tumours into a potent T cell activator.", [["tumour", "ANATOMY", 86, 92], ["solid tumours", "ANATOMY", 231, 244], ["T cell", "ANATOMY", 259, 265], ["tumour", "DISEASE", 86, 92], ["CARs", "GENE_OR_GENE_PRODUCT", 0, 4], ["scFvs", "GENE_OR_GENE_PRODUCT", 36, 41], ["tumour", "CANCER", 86, 92], ["transforming growth factor-\u03b2", "GENE_OR_GENE_PRODUCT", 125, 153], ["TGF\u03b2) 15", "GENE_OR_GENE_PRODUCT", 155, 163], ["solid tumours", "CANCER", 231, 244], ["T cell", "CELL", 259, 265], ["CARs", "PROTEIN", 0, 4], ["scFvs", "PROTEIN", 36, 41], ["transforming growth factor-\u03b2", "PROTEIN", 125, 153], ["TGF\u03b2) 15", "PROTEIN", 155, 163], ["T cell activator", "PROTEIN", 259, 275], ["scFvs", "TREATMENT", 36, 41], ["transforming growth factor", "TEST", 125, 151], ["an immunosuppressive signal", "PROBLEM", 186, 213], ["solid tumours", "PROBLEM", 231, 244], ["a potent T cell activator", "TREATMENT", 250, 275]]]], "PMC7407434": [["HighlightsAbout one-tenths of patients with COVID-19 in Jiangsu had severe or critically ill presentationAll patients were discharged and no patients died by the end of studyRisk of severe or critically ill COVID-19 patients increased with ageLow lymphocyte count and high pulmonary opacity score in CT on admission were associated with high risk of severe or critically ill COVID-19BackgroundCoronavirus Disease 2019 (COVID-19), caused by the etiological agent Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), was first reported from Wuhan, Hubei province, China, in December 2019.", [["lymphocyte", "ANATOMY", 247, 257], ["pulmonary", "ANATOMY", 273, 282], ["COVID-19", "CHEMICAL", 419, 427], ["Acute Respiratory Syndrome", "DISEASE", 469, 495], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 141, 149], ["patients", "ORGANISM", 216, 224], ["lymphocyte", "CELL", 247, 257], ["pulmonary", "ORGAN", 273, 282], ["SARS-CoV-2", "ORGANISM", 511, 521], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 216, 224], ["Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2", "SPECIES", 462, 521], ["COVID", "TEST", 44, 49], ["critically ill presentation", "PROBLEM", 78, 105], ["critically ill COVID", "PROBLEM", 192, 212], ["ageLow lymphocyte count", "PROBLEM", 240, 263], ["high pulmonary opacity score", "PROBLEM", 268, 296], ["CT", "TEST", 300, 302], ["critically ill COVID", "PROBLEM", 360, 380], ["19BackgroundCoronavirus Disease", "PROBLEM", 381, 412], ["COVID", "TEST", 419, 424], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 462, 507], ["SARS", "PROBLEM", 511, 515], ["CoV", "TEST", 516, 519], ["severe", "OBSERVATION_MODIFIER", 182, 188], ["lymphocyte count", "OBSERVATION", 247, 263], ["high", "OBSERVATION_MODIFIER", 268, 272], ["pulmonary", "ANATOMY", 273, 282], ["opacity", "OBSERVATION", 283, 290], ["severe", "OBSERVATION_MODIFIER", 350, 356], ["Severe", "OBSERVATION_MODIFIER", 462, 468], ["Acute", "OBSERVATION_MODIFIER", 469, 474], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 475, 507]]], ["The COVID-19 pandemic have spread quickly from a focal outbreak to over 7410, 000 cases with more than 400, 000 deaths affecting more than 140 countries by the 12th June 2020 [2].BackgroundChina had reported over 80, 000 confirmed cases by the 13th March 2020 [2].", [["deaths", "DISEASE", 112, 118], ["The COVID", "TEST", 0, 9], ["pandemic", "PROBLEM", 13, 21], ["focal", "OBSERVATION_MODIFIER", 49, 54]]], ["In a case series of the first 44,672 confirmed cases, 1023 patients had died, with a crude case fatality rate (CFR) of 2.3%, and mortality was higher among critically ill patients, who had a CFR of 49% [3].", [["critically ill", "DISEASE", 156, 170], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 171, 179], ["CFR", "TEST", 111, 114], ["a CFR", "TEST", 189, 194]]], ["In Hubei, the proportion of health workers with severe or critical ill COVID-19 was higher than in other provinces (10.4 and 7.0%, respectively) [3].", [["severe or critical ill COVID", "PROBLEM", 48, 76]]], ["Compared to China, the crude CFR in South Korea is lower among both males (1.1%) and females (0.4%) [4], and the crude CFR in Australia (1.4%) [5] and in countries of the European Union (EU) and European Economic Area (EEA) was also lower (1.5%) [6], while the crude CFR in Italy was much higher (7.2%) [7].BackgroundCOVID-19 initial symptoms are not specific, presenting with fever, and cough, which can then resolve spontaneously or progress to shortness of breath, dyspnoea, and pneumonia, leading to acute respiratory distress syndrome (ARDS), renal failure, coagulation dysfunction, multiple organ failure and death [8\u201313].", [["respiratory", "ANATOMY", 510, 521], ["renal", "ANATOMY", 548, 553], ["organ", "ANATOMY", 597, 602], ["fever", "DISEASE", 377, 382], ["cough", "DISEASE", 388, 393], ["shortness of breath", "DISEASE", 447, 466], ["dyspnoea", "DISEASE", 468, 476], ["pneumonia", "DISEASE", 482, 491], ["acute respiratory distress syndrome", "DISEASE", 504, 539], ["ARDS", "DISEASE", 541, 545], ["renal failure", "DISEASE", 548, 561], ["coagulation dysfunction", "DISEASE", 563, 586], ["multiple organ failure", "DISEASE", 588, 610], ["death", "DISEASE", 615, 620], ["renal", "ORGAN", 548, 553], ["organ", "ORGAN", 597, 602], ["the crude CFR", "TEST", 19, 32], ["females", "TEST", 85, 92], ["the crude CFR", "TEST", 109, 122], ["the crude CFR", "TEST", 257, 270], ["BackgroundCOVID", "TEST", 307, 322], ["initial symptoms", "PROBLEM", 326, 342], ["fever", "PROBLEM", 377, 382], ["cough", "PROBLEM", 388, 393], ["shortness of breath", "PROBLEM", 447, 466], ["dyspnoea", "PROBLEM", 468, 476], ["pneumonia", "PROBLEM", 482, 491], ["acute respiratory distress syndrome", "PROBLEM", 504, 539], ["ARDS)", "PROBLEM", 541, 546], ["renal failure", "PROBLEM", 548, 561], ["coagulation dysfunction", "PROBLEM", 563, 586], ["multiple organ failure", "PROBLEM", 588, 610], ["death", "PROBLEM", 615, 620], ["lower", "OBSERVATION_MODIFIER", 51, 56], ["cough", "OBSERVATION", 388, 393], ["pneumonia", "OBSERVATION", 482, 491], ["acute", "OBSERVATION_MODIFIER", 504, 509], ["respiratory distress", "OBSERVATION", 510, 530], ["ARDS", "OBSERVATION", 541, 545], ["renal", "ANATOMY", 548, 553], ["failure", "OBSERVATION", 554, 561], ["coagulation dysfunction", "OBSERVATION", 563, 586], ["multiple", "OBSERVATION_MODIFIER", 588, 596], ["organ", "ANATOMY", 597, 602], ["failure", "OBSERVATION", 603, 610]]], ["Demographic features (eg age and gender); epidemiological features (eg smoking and comorbidities); laboratory parameters (eg C-reactive protein, albumin, cytokine, lactate dehydrogenase, D-dimer, platelet, lymphocyte, and neutrophil); clinical manifestations (eg cough, expectoration, chest pain, and dyspnea); computer tomography (CT) image test results; and others, have been reported to be associated with the severity of COVID-19 in some small studies in China [14\u201320], and other countires [13, 21, 22].BackgroundUnderstanding the factors associated with COVID-19 disease severity could support the early identification of patients with high risk for severe/critically ill COVID-19 presentation and inform prevention and control activities and reduce mortality.", [["platelet", "ANATOMY", 196, 204], ["lymphocyte", "ANATOMY", 206, 216], ["neutrophil", "ANATOMY", 222, 232], ["chest", "ANATOMY", 285, 290], ["lactate", "CHEMICAL", 164, 171], ["cough", "DISEASE", 263, 268], ["expectoration", "DISEASE", 270, 283], ["chest pain", "DISEASE", 285, 295], ["dyspnea", "DISEASE", 301, 308], ["lactate", "CHEMICAL", 164, 171], ["eg C-reactive protein", "GENE_OR_GENE_PRODUCT", 122, 143], ["albumin", "GENE_OR_GENE_PRODUCT", 145, 152], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 164, 185], ["D-dimer", "GENE_OR_GENE_PRODUCT", 187, 194], ["platelet", "CELL", 196, 204], ["lymphocyte", "CELL", 206, 216], ["neutrophil", "CELL", 222, 232], ["patients", "ORGANISM", 627, 635], ["C-reactive protein", "PROTEIN", 125, 143], ["albumin", "PROTEIN", 145, 152], ["cytokine", "PROTEIN", 154, 162], ["lactate dehydrogenase", "PROTEIN", 164, 185], ["D-dimer", "PROTEIN", 187, 194], ["platelet", "CELL_TYPE", 196, 204], ["lymphocyte", "CELL_TYPE", 206, 216], ["neutrophil", "CELL_TYPE", 222, 232], ["patients", "SPECIES", 627, 635], ["epidemiological features", "PROBLEM", 42, 66], ["comorbidities", "PROBLEM", 83, 96], ["laboratory parameters", "TEST", 99, 120], ["C-reactive protein", "TEST", 125, 143], ["albumin", "TEST", 145, 152], ["cytokine", "TEST", 154, 162], ["lactate dehydrogenase", "TEST", 164, 185], ["D-dimer", "TEST", 187, 194], ["platelet", "TEST", 196, 204], ["lymphocyte", "TEST", 206, 216], ["neutrophil", "TEST", 222, 232], ["clinical manifestations (eg cough", "PROBLEM", 235, 268], ["expectoration", "PROBLEM", 270, 283], ["chest pain", "PROBLEM", 285, 295], ["dyspnea", "PROBLEM", 301, 308], ["computer tomography", "TEST", 311, 330], ["CT) image test", "TEST", 332, 346], ["COVID", "TEST", 425, 430], ["COVID-19 disease severity", "PROBLEM", 559, 584], ["severe/critically ill COVID", "PROBLEM", 655, 682], ["chest", "ANATOMY", 285, 290]]], ["Hubei was the COVID-19 epicentre of China at the time of data collection for this study (from the 10th January 2020 to the 15th March 2020), so patients in other parts of China, outside Hubei, may have different profiles of demographic, epidemiological, clinical characteristics, laboratory parameters, and image test results.", [["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["this study", "TEST", 77, 87], ["laboratory parameters", "TEST", 280, 301], ["image test", "TEST", 307, 317]]], ["Knowing those profiles may help predict the severity of COVID-19.BackgroundJiangsu, a province in China over 600 km from Hubei without common geographical borders and 80 million population, reported over 600 patients infected with COVID-19.", [["COVID-19", "CHEMICAL", 56, 64], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["COVID", "TEST", 56, 61], ["COVID", "TEST", 231, 236]]], ["We report here an analysis of nearly all cases in Jiangsu province from the 10th January 2020 to the 15th March 2020 to describe the demographic, epidemiological, clinical, laboratory, and imaging characteristics of cases and to identify risk factors for severe/critically ill COVID-19 presentation.", [["an analysis", "TEST", 15, 26], ["severe/critically ill COVID", "PROBLEM", 255, 282]]], ["Previous studies were mostly small and descriptive in nature.", [["Previous studies", "TEST", 0, 16], ["small", "OBSERVATION_MODIFIER", 29, 34]]], ["Our study will use data from the whole Jiangsu province and make inferential statistical analyses by means of multivariate regression model to control for possible confounding factors and identify independent risk factors of becoming a severe/critically ill case.Study design and population ::: MethodsThis is a multicentre retrospective cohort study.", [["critically ill", "DISEASE", 243, 257], ["Our study", "TEST", 0, 9], ["multivariate regression model", "TREATMENT", 110, 139], ["confounding factors", "PROBLEM", 164, 183], ["a severe/critically ill case", "PROBLEM", 234, 262], ["Methods", "TREATMENT", 295, 302], ["a multicentre retrospective cohort study", "TEST", 310, 350]]], ["All patients were included if they (1) were clinically diagnosed and then confirmed to have COVID-19 in Jiangsu province from the 10th January 2020 up to the 15th March 2020, and (2) fulfilled the diagnostic criteria for the \u201cDiagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)\u201d released by National Health Commission & National Administration of Traditional Chinese Medicine of China [23].", [["Coronavirus Pneumonia", "DISEASE", 269, 290], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["COVID", "TEST", 92, 97], ["Treatment Protocol", "TREATMENT", 240, 258], ["Novel Coronavirus Pneumonia", "PROBLEM", 263, 290], ["Pneumonia", "OBSERVATION", 281, 290]]], ["The diagnosis of COVID-19 was based on epidemiological history, clinical manifestations, imaging manifestations of pneumonia in CT scans, and laboratory confirmation [23, 24].", [["pneumonia", "DISEASE", 115, 124], ["COVID", "TEST", 17, 22], ["clinical manifestations", "PROBLEM", 64, 87], ["imaging manifestations", "TEST", 89, 111], ["pneumonia", "PROBLEM", 115, 124], ["CT scans", "TEST", 128, 136], ["laboratory confirmation", "TEST", 142, 165], ["pneumonia", "OBSERVATION", 115, 124]]], ["Patients without medical records were excluded.Study design and population ::: MethodsThe Ethics Committee of Zhongda Hospital, Affiliated to Southeast University, approved the study protocols (2020ZDSYLL013\u2013P01 and 2020ZDSYLL019\u2013P01).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Methods", "TREATMENT", 79, 86], ["the study protocols", "TEST", 173, 192]]], ["Patient informed consent was waived due to the retrospective study design.Data measures ::: MethodsThe primary outcome was severe or critically ill within the follow up period.", [["Patient", "SPECIES", 0, 7], ["the retrospective study", "TEST", 43, 66], ["Methods", "TREATMENT", 92, 99], ["critically ill", "PROBLEM", 133, 147], ["severe", "OBSERVATION_MODIFIER", 123, 129]]], ["Patients were categorised by disease severity into (1) asymptomatic or mild, or moderate, and (2) severe or critically ill, according to \u201cDiagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)\u201d [23].", [["critically ill", "DISEASE", 108, 122], ["Coronavirus Pneumonia", "DISEASE", 181, 202], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["asymptomatic or mild, or moderate, and (2) severe or critically ill", "PROBLEM", 55, 122], ["Treatment Protocol", "TREATMENT", 152, 170], ["Novel Coronavirus Pneumonia", "PROBLEM", 175, 202], ["mild", "OBSERVATION_MODIFIER", 71, 75], ["moderate", "OBSERVATION_MODIFIER", 80, 88], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["Pneumonia", "OBSERVATION", 193, 202]]], ["Asymptomatic infections were defined as the absence of clinical symptoms with a positive nucleic acid test (real-time reverse transcriptase\u2013polymerase chain reaction assay, RT-PCR, for SARS-CoV-2).", [["infections", "DISEASE", 13, 23], ["nucleic acid", "CHEMICAL", 89, 101], ["SARS-CoV", "SPECIES", 185, 193], ["Asymptomatic infections", "PROBLEM", 0, 23], ["clinical symptoms", "PROBLEM", 55, 72], ["a positive nucleic acid test", "PROBLEM", 78, 106], ["assay", "TEST", 166, 171], ["RT", "TEST", 173, 175], ["PCR", "TEST", 176, 179], ["SARS", "PROBLEM", 185, 189], ["CoV", "TEST", 190, 193], ["infections", "OBSERVATION", 13, 23]]], ["Mild COVID-19 disease was defined as the presence of mild clinical symptoms without respiratory distress and the absence of imaging manifestations of pneumonia.", [["respiratory", "ANATOMY", 84, 95], ["respiratory distress", "DISEASE", 84, 104], ["pneumonia", "DISEASE", 150, 159], ["Mild COVID-19 disease", "PROBLEM", 0, 21], ["mild clinical symptoms", "PROBLEM", 53, 75], ["respiratory distress", "PROBLEM", 84, 104], ["pneumonia", "PROBLEM", 150, 159], ["19 disease", "OBSERVATION", 11, 21], ["mild", "OBSERVATION_MODIFIER", 53, 57], ["pneumonia", "OBSERVATION", 150, 159]]], ["Moderate disease was defined as the presence of fever, with respiratory symptoms and an image of pneumonia in CT scans.", [["respiratory", "ANATOMY", 60, 71], ["fever", "DISEASE", 48, 53], ["respiratory symptoms", "DISEASE", 60, 80], ["pneumonia", "DISEASE", 97, 106], ["Moderate disease", "PROBLEM", 0, 16], ["fever", "PROBLEM", 48, 53], ["respiratory symptoms", "PROBLEM", 60, 80], ["pneumonia", "PROBLEM", 97, 106], ["CT scans", "TEST", 110, 118], ["disease", "OBSERVATION", 9, 16], ["fever", "OBSERVATION", 48, 53], ["pneumonia", "OBSERVATION", 97, 106]]], ["Severe disease was defined as the presence of at least one of the three conditions: respiratory distress, a respiratory rate \u2265 30 beats / min; oxygen saturation in resting state \u226493%; or an arterial blood oxygen partial pressure / oxygen concentration \u2264 300 mmHg (1 mmHg = 0.133 kPa).", [["respiratory", "ANATOMY", 84, 95], ["respiratory", "ANATOMY", 108, 119], ["arterial", "ANATOMY", 190, 198], ["blood", "ANATOMY", 199, 204], ["respiratory distress", "DISEASE", 84, 104], ["oxygen", "CHEMICAL", 143, 149], ["oxygen", "CHEMICAL", 205, 211], ["oxygen", "CHEMICAL", 231, 237], ["oxygen", "CHEMICAL", 143, 149], ["oxygen", "CHEMICAL", 205, 211], ["oxygen", "CHEMICAL", 231, 237], ["oxygen", "SIMPLE_CHEMICAL", 143, 149], ["blood", "ORGANISM_SUBSTANCE", 199, 204], ["oxygen", "SIMPLE_CHEMICAL", 205, 211], ["oxygen", "SIMPLE_CHEMICAL", 231, 237], ["Severe disease", "PROBLEM", 0, 14], ["respiratory distress", "PROBLEM", 84, 104], ["a respiratory rate", "TEST", 106, 124], ["oxygen saturation", "TEST", 143, 160], ["resting state", "TEST", 164, 177], ["an arterial blood oxygen partial pressure", "TEST", 187, 228], ["oxygen concentration", "TEST", 231, 251], ["disease", "OBSERVATION", 7, 14], ["respiratory distress", "OBSERVATION", 84, 104]]], ["Critically ill was defined as having respiratory failure requiring mechanical ventilation, shock or combined organ failure requiring intensive care unit (ICU) monitoring and treatment.", [["respiratory", "ANATOMY", 37, 48], ["organ", "ANATOMY", 109, 114], ["Critically ill", "DISEASE", 0, 14], ["respiratory failure", "DISEASE", 37, 56], ["shock", "DISEASE", 91, 96], ["organ failure", "DISEASE", 109, 122], ["organ", "ORGAN", 109, 114], ["Critically ill", "PROBLEM", 0, 14], ["respiratory failure", "PROBLEM", 37, 56], ["mechanical ventilation", "TREATMENT", 67, 89], ["shock", "PROBLEM", 91, 96], ["combined organ failure", "PROBLEM", 100, 122], ["treatment", "TREATMENT", 174, 183], ["respiratory failure", "OBSERVATION", 37, 56], ["mechanical ventilation", "OBSERVATION", 67, 89], ["shock", "OBSERVATION", 91, 96], ["organ", "ANATOMY", 109, 114], ["failure", "OBSERVATION", 115, 122]]], ["A clustering onset was defined as the occurrence of two or more confirmed COVID-19 cases in the same cluster/group within 14 days, such as family, community, hospital, working place or public place, etc. A clustering onset could occur due to interpersonal transmission via close contact with or joint exposure to a confirmed COVID-19 case.", [["COVID", "DNA", 325, 330], ["A clustering onset", "PROBLEM", 0, 18], ["A clustering onset", "PROBLEM", 204, 222], ["joint", "ANATOMY", 295, 300]]], ["All patients were followed up to the 15th March 2020.Data measures ::: MethodsData were collected using case record forms and electronic medical record systems and included demographic, epidemiological, clinical, laboratory, and imaging information provided by the Data Center of Jiangsu Provincial Health Commission without any patient\u2019s personal information.", [["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 329, 336], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 329, 336]]], ["The severity of illness was assessed by two physicians.", [["illness", "DISEASE", 16, 23], ["illness", "PROBLEM", 16, 23], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["illness", "OBSERVATION", 16, 23]]], ["Severity was assessed at days 1, 2, 3, 4, 5, 6, 7 and 14 after admission and patients were followed for up to discharge.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85]]], ["Imaging grading was performed by two independent radiologists with more than 5 years\u2019 experience in pulmonary imaging.", [["pulmonary", "ANATOMY", 100, 109], ["pulmonary", "ORGAN", 100, 109], ["Imaging grading", "TEST", 0, 15], ["pulmonary imaging", "TEST", 100, 117], ["pulmonary", "ANATOMY", 100, 109]]], ["Chest CT axial sections were divided into quadrants (left and right, anterior and posterior) by drawing horizontal and vertical lines through the centre of the chest.", [["Chest CT axial sections", "ANATOMY", 0, 23], ["left", "ANATOMY", 53, 57], ["right", "ANATOMY", 62, 67], ["anterior", "ANATOMY", 69, 77], ["chest", "ANATOMY", 160, 165], ["anterior", "MULTI-TISSUE_STRUCTURE", 69, 77], ["chest", "ORGAN", 160, 165], ["Chest CT axial sections", "TEST", 0, 23], ["left", "ANATOMY_MODIFIER", 53, 57], ["right", "ANATOMY_MODIFIER", 62, 67], ["anterior", "ANATOMY_MODIFIER", 69, 77], ["posterior", "ANATOMY_MODIFIER", 82, 91], ["vertical lines", "OBSERVATION", 119, 133], ["chest", "ANATOMY", 160, 165]]], ["Quadrant scores were estimated as the sum of quadrants with pulmonary opacities extending from the proximal to the distal end of the chest and ranged from 0 to 4.", [["pulmonary", "ANATOMY", 60, 69], ["chest", "ANATOMY", 133, 138], ["pulmonary", "ORGAN", 60, 69], ["chest", "ORGAN", 133, 138], ["Quadrant scores", "TEST", 0, 15], ["pulmonary opacities", "PROBLEM", 60, 79], ["quadrants", "ANATOMY_MODIFIER", 45, 54], ["pulmonary", "ANATOMY", 60, 69], ["opacities", "OBSERVATION", 70, 79], ["proximal", "ANATOMY_MODIFIER", 99, 107], ["distal", "ANATOMY_MODIFIER", 115, 121], ["end", "ANATOMY_MODIFIER", 122, 125], ["chest", "ANATOMY", 133, 138]]], ["Pulmonary opacity was visually estimated and assigned a percentage of pulmonary opacity area in the area of bilateral lungs, rounded to the nearest 5%.Variables ::: Statistical analysis ::: MethodsPrimary outcome variable was the occurrence of severe/critically ill case.", [["Pulmonary", "ANATOMY", 0, 9], ["pulmonary opacity area", "ANATOMY", 70, 92], ["area", "ANATOMY", 100, 104], ["lungs", "ANATOMY", 118, 123], ["critically ill", "DISEASE", 251, 265], ["Pulmonary", "ORGAN", 0, 9], ["pulmonary", "ORGAN", 70, 79], ["lungs", "ORGAN", 118, 123], ["Pulmonary opacity", "PROBLEM", 0, 17], ["pulmonary opacity", "PROBLEM", 70, 87], ["severe/critically ill case", "PROBLEM", 244, 270], ["opacity", "OBSERVATION", 10, 17], ["percentage", "OBSERVATION_MODIFIER", 56, 66], ["pulmonary", "ANATOMY", 70, 79], ["opacity", "OBSERVATION", 80, 87], ["area", "ANATOMY_MODIFIER", 100, 104], ["bilateral", "ANATOMY_MODIFIER", 108, 117], ["lungs", "ANATOMY", 118, 123], ["rounded", "OBSERVATION_MODIFIER", 125, 132], ["severe", "OBSERVATION_MODIFIER", 244, 250]]], ["Predictive variables included sex, age, exposure type, types of disease onset, initial symptoms, medical history, vital signs (including body temperature, heart rate (HR), respiratory rate, and peripheral capillary oxygen saturation (SpO2)), CT image parameters (including quadrant score and pulmonary opacity), and laboratory parameters (including white blood cells count, neutrophil, lymphocyte, platelet, albumin, creatinine, C-reactive protein, activated partial thromboplastin time, fibrinogen, and D-dimer).", [["body", "ANATOMY", 137, 141], ["heart", "ANATOMY", 155, 160], ["respiratory", "ANATOMY", 172, 183], ["peripheral capillary", "ANATOMY", 194, 214], ["pulmonary", "ANATOMY", 292, 301], ["white blood cells", "ANATOMY", 349, 366], ["neutrophil", "ANATOMY", 374, 384], ["lymphocyte", "ANATOMY", 386, 396], ["platelet", "ANATOMY", 398, 406], ["oxygen", "CHEMICAL", 215, 221], ["creatinine", "CHEMICAL", 417, 427], ["oxygen", "CHEMICAL", 215, 221], ["creatinine", "CHEMICAL", 417, 427], ["body", "ORGANISM_SUBDIVISION", 137, 141], ["heart", "ORGAN", 155, 160], ["peripheral capillary", "TISSUE", 194, 214], ["oxygen", "SIMPLE_CHEMICAL", 215, 221], ["pulmonary", "ORGAN", 292, 301], ["white blood cells", "CELL", 349, 366], ["neutrophil", "CELL", 374, 384], ["lymphocyte", "CELL", 386, 396], ["platelet", "CELL", 398, 406], ["albumin", "GENE_OR_GENE_PRODUCT", 408, 415], ["creatinine", "SIMPLE_CHEMICAL", 417, 427], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 429, 447], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 467, 481], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 488, 498], ["D-dimer", "SIMPLE_CHEMICAL", 504, 511], ["white blood cells count, neutrophil, lymphocyte, platelet, albumin, creatinine, C-reactive protein", "PROTEIN", 349, 447], ["fibrinogen", "PROTEIN", 488, 498], ["D-dimer", "PROTEIN", 504, 511], ["disease onset", "PROBLEM", 64, 77], ["initial symptoms", "PROBLEM", 79, 95], ["vital signs", "TEST", 114, 125], ["body temperature", "TEST", 137, 153], ["heart rate", "TEST", 155, 165], ["HR", "TEST", 167, 169], ["respiratory rate", "TEST", 172, 188], ["peripheral capillary oxygen saturation", "TEST", 194, 232], ["SpO2", "TEST", 234, 238], ["CT image parameters", "TEST", 242, 261], ["quadrant score", "TEST", 273, 287], ["pulmonary opacity", "PROBLEM", 292, 309], ["laboratory parameters", "TEST", 316, 337], ["white blood cells count", "TEST", 349, 372], ["neutrophil", "TEST", 374, 384], ["lymphocyte", "TEST", 386, 396], ["platelet", "TEST", 398, 406], ["albumin", "TEST", 408, 415], ["creatinine", "TEST", 417, 427], ["C", "TEST", 429, 430], ["reactive protein", "TEST", 431, 447], ["activated partial thromboplastin time", "TEST", 449, 486], ["fibrinogen", "TEST", 488, 498], ["disease", "OBSERVATION", 64, 71], ["heart", "ANATOMY", 155, 160], ["respiratory rate", "OBSERVATION", 172, 188], ["peripheral", "ANATOMY_MODIFIER", 194, 204], ["capillary", "ANATOMY_MODIFIER", 205, 214], ["pulmonary", "ANATOMY", 292, 301], ["opacity", "OBSERVATION", 302, 309]]], ["The other variables including supportive treatments and medical drugs were collected during the follow-up period.Statistical analysis ::: Statistical analysis ::: MethodsContinuous variables were described using means (standard deviations, SD) or medians (with inter-quartile range, IQR) by disease severity and were compared using ANOVA or Kruskal-Wallis tests as appropriate.", [["supportive treatments", "TREATMENT", 30, 51], ["medical drugs", "TREATMENT", 56, 69], ["MethodsContinuous variables", "PROBLEM", 163, 190], ["disease severity", "PROBLEM", 291, 307], ["Kruskal-Wallis tests", "TEST", 341, 361]]], ["Categorical variables were summarised using frequencies and percentages and compared using Fisher exact tests.Statistical analysis ::: Statistical analysis ::: MethodsLogistic regression models were used to identify the risk factors for having a severe or critically ill status.", [["critically ill", "DISEASE", 256, 270], ["Categorical variables", "TEST", 0, 21], ["percentages", "TEST", 60, 71], ["Fisher exact tests", "TEST", 91, 109], ["MethodsLogistic regression models", "TREATMENT", 160, 193], ["a severe or critically ill status", "PROBLEM", 244, 277], ["severe", "OBSERVATION_MODIFIER", 246, 252]]], ["Analysis was performed in 2 steps.", [["Analysis", "TEST", 0, 8]]], ["Firstly, a univariate logistic regression model was fitted for each variable based on completed cases.", [["a univariate logistic regression model", "TREATMENT", 9, 47]]], ["As there are many potential predictors, we chose the variables for univariate regression analysis if a variable is significant at 5%.", [["univariate regression analysis", "TEST", 67, 97], ["significant", "OBSERVATION_MODIFIER", 115, 126]]], ["Respiratory rate and SpO2 were not included in the regression analyses since they were part of criterion for classifying the disease severity.", [["Respiratory rate", "TEST", 0, 16], ["SpO2", "TEST", 21, 25], ["the regression analyses", "TEST", 47, 70], ["the disease severity", "PROBLEM", 121, 141], ["disease", "OBSERVATION", 125, 132]]], ["All variables selected for univariate regression analysis were also included in the second stage of the multivariate logistic regression.", [["univariate regression analysis", "TEST", 27, 57]]], ["Missing covariates at admission were imputed with multiple imputation using a Markov Chain Monte Carlo simulation method with 10 iterations.", [["Missing covariates", "PROBLEM", 0, 18], ["multiple imputation", "TREATMENT", 50, 69], ["a Markov Chain Monte Carlo simulation method", "TREATMENT", 76, 120]]], ["In the logistic regression analysis, odds ratios (ORs) for having a severe or critically ill status for each variable were calculated along with 95% confidence intervals (CIs).", [["critically ill", "DISEASE", 78, 92], ["a severe or critically ill status", "PROBLEM", 66, 99], ["severe", "OBSERVATION_MODIFIER", 68, 74]]], ["A sensitivity analysis was performed on the completed cases.", [["A sensitivity analysis", "TEST", 0, 22]]], ["The analyses were performed using SAS 9.4 (SAS Institute).ResultsFrom the 10th January 2020 to 15th March 2020, 721 suspected cases with possible COVID-19 were admitted in 24 hospitals in Jiangsu province, China, while 90 cases were excluded because of negative reverse transcriptase\u2013polymerase chain reaction assay.", [["The analyses", "TEST", 0, 12], ["SAS", "TEST", 34, 37], ["COVID", "TEST", 146, 151], ["reverse transcriptase\u2013polymerase chain reaction assay", "PROBLEM", 262, 315]]], ["Six hundred thirty-one cases were diagnosed with COVID-19 totally.", [["COVID", "TEST", 49, 54]]], ["Of these, 625 (99.0%) had retrievable medical records and were included in the analysis (Fig. 1).", [["the analysis", "TEST", 75, 87]]]], "PMC7407441": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 4012,000 infections and > 32,000 deaths in New York State alone [1].", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["SARS-CoV-2", "CHEMICAL", 61, 71], ["infections", "DISEASE", 98, 108], ["deaths", "DISEASE", 122, 128], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45]]], ["Due to delay in testing and asymptomatic infections the true number of cases are unknown.", [["infections", "DISEASE", 41, 51], ["delay in testing", "TEST", 7, 23], ["asymptomatic infections", "PROBLEM", 28, 51], ["asymptomatic", "OBSERVATION_MODIFIER", 28, 40], ["infections", "OBSERVATION", 41, 51]]], ["Few reports have characterized the prevalence of seroconversion in community populations [2, 3].", [["seroconversion", "PROBLEM", 49, 63]]], ["Seroconversion, the process in which a patient accumulates antigen-specific antibodies against an epitope, is the first step towards the development of adaptive immunity against pathogens.", [["patient", "ORGANISM", 39, 46], ["antigen", "GENE_OR_GENE_PRODUCT", 59, 66], ["antigen-specific antibodies", "PROTEIN", 59, 86], ["patient", "SPECIES", 39, 46], ["Seroconversion", "TREATMENT", 0, 14], ["an epitope", "PROBLEM", 95, 105], ["pathogens", "PROBLEM", 178, 187]]], ["Although it is not an assurance of protection against future infections, positive seroconversion is an informative measure of previous viral infectivity within the population.", [["infections", "DISEASE", 61, 71], ["future infections", "PROBLEM", 54, 71], ["positive seroconversion", "PROBLEM", 73, 96], ["previous viral infectivity", "PROBLEM", 126, 152], ["viral infectivity", "OBSERVATION", 135, 152]]], ["To assess the seroconversion of a community, antibody testing with high sensitivity and specificity that is also easily available is necessary.IntroductionHowever, a crucial step in understanding the test characteristics is to ensure the assay detects antibodies in individuals with a previous documented disease.", [["antibodies", "PROTEIN", 252, 262], ["a community, antibody testing", "TEST", 32, 61], ["the assay", "TEST", 234, 243], ["a previous documented disease", "PROBLEM", 283, 312], ["disease", "OBSERVATION", 305, 312]]], ["One study suggests that 75% of patients with a confirmed PCR test had a positive antibody IgG and 20% were weakly positive [4].", [["patients", "ORGANISM", 31, 39], ["positive antibody IgG", "PROTEIN", 72, 93], ["patients", "SPECIES", 31, 39], ["One study", "TEST", 0, 9], ["PCR test", "TEST", 57, 65], ["antibody IgG", "TEST", 81, 93]]], ["Another study showed 100% seroconversion in COVID19 patients and three patterns of IgM and IgG responses: synchronous seroconversion of IgG and IgM, IgM seroconversion earlier than that of IgG, and IgM seroconversion later than that of IgG [3].", [["patients", "ORGANISM", 52, 60], ["IgM", "GENE_OR_GENE_PRODUCT", 83, 86], ["IgG", "GENE_OR_GENE_PRODUCT", 91, 94], ["IgG", "GENE_OR_GENE_PRODUCT", 136, 139], ["IgM", "GENE_OR_GENE_PRODUCT", 144, 147], ["IgM", "GENE_OR_GENE_PRODUCT", 149, 152], ["IgG", "GENE_OR_GENE_PRODUCT", 189, 192], ["IgM", "GENE_OR_GENE_PRODUCT", 198, 201], ["IgM", "PROTEIN", 83, 86], ["IgG", "PROTEIN", 91, 94], ["IgG", "PROTEIN", 136, 139], ["IgM", "PROTEIN", 144, 147], ["IgM", "PROTEIN", 149, 152], ["IgG", "PROTEIN", 189, 192], ["IgM", "PROTEIN", 198, 201], ["IgG", "PROTEIN", 236, 239], ["patients", "SPECIES", 52, 60], ["Another study", "TEST", 0, 13], ["IgM", "TEST", 83, 86], ["IgG responses", "TEST", 91, 104], ["synchronous seroconversion", "PROBLEM", 106, 132], ["IgG", "TEST", 136, 139], ["IgM", "TEST", 144, 147], ["IgM seroconversion", "PROBLEM", 149, 167], ["IgG", "TEST", 189, 192], ["IgM seroconversion", "PROBLEM", 198, 216]]], ["In addition, assay characteristics such as antigen target (nucleocapsid and/or spike glycoprotein), total (IgG and IgM) versus IgG only, and their sensitivity and specificity are important in defining seroconversion rates [5].", [["nucleocapsid", "GENE_OR_GENE_PRODUCT", 59, 71], ["IgG", "GENE_OR_GENE_PRODUCT", 107, 110], ["IgM", "GENE_OR_GENE_PRODUCT", 115, 118], ["IgG", "GENE_OR_GENE_PRODUCT", 127, 130], ["antigen target", "PROTEIN", 43, 57], ["nucleocapsid and/or spike glycoprotein", "PROTEIN", 59, 97], ["IgG", "PROTEIN", 107, 110], ["IgM", "PROTEIN", 115, 118], ["IgG", "PROTEIN", 127, 130], ["assay characteristics", "TEST", 13, 34], ["antigen target", "TEST", 43, 57], ["nucleocapsid", "TEST", 59, 71], ["spike glycoprotein", "PROBLEM", 79, 97], ["total (IgG", "TEST", 100, 110], ["IgM", "TEST", 115, 118], ["IgG", "TEST", 127, 130]]], ["Thus, more studies with various antibody tests are needed to understand seroconversion of an infected population.IntroductionIn response to this need for antibody testing, a lateral flow assay (LFA) was developed to provide rapid point of care diagnostic testing of COVID19 antibodies.", [["COVID19 antibodies", "GENE_OR_GENE_PRODUCT", 266, 284], ["COVID19 antibodies", "PROTEIN", 266, 284], ["various antibody tests", "TEST", 24, 46], ["an infected population", "PROBLEM", 90, 112], ["antibody testing", "TEST", 154, 170], ["a lateral flow assay", "TEST", 172, 192], ["diagnostic testing", "TEST", 244, 262], ["COVID19 antibodies", "PROBLEM", 266, 284], ["infected", "OBSERVATION", 93, 101]]], ["The LFA test is able to detect specific SARS-CoV-2 antibodies and differentiate between IgG and IgM immunoglobin classes in a rapid, point of care test using either whole blood, plasma or serum [6].", [["whole blood", "ANATOMY", 165, 176], ["plasma", "ANATOMY", 178, 184], ["serum", "ANATOMY", 188, 193], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["IgG", "GENE_OR_GENE_PRODUCT", 88, 91], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["plasma", "ORGANISM_SUBSTANCE", 178, 184], ["serum", "ORGANISM_SUBSTANCE", 188, 193], ["LFA", "PROTEIN", 4, 7], ["SARS-CoV-2 antibodies", "PROTEIN", 40, 61], ["IgG", "PROTEIN", 88, 91], ["IgM", "PROTEIN", 96, 99], ["SARS-CoV", "SPECIES", 40, 48], ["The LFA test", "TEST", 0, 12], ["specific SARS", "TEST", 31, 44], ["CoV", "TEST", 45, 48], ["antibodies", "TEST", 51, 61], ["IgG", "TEST", 88, 91], ["IgM immunoglobin classes", "TEST", 96, 120], ["care test", "TEST", 142, 151], ["whole blood", "TEST", 165, 176], ["serum", "TEST", 188, 193]]], ["The test principle is based on the receptor-binding domain (RBD) of the spike and nucleocapsid proteins.", [["receptor-binding domain", "PROTEIN", 35, 58], ["RBD", "PROTEIN", 60, 63], ["spike and nucleocapsid proteins", "PROTEIN", 72, 103], ["the spike", "PROBLEM", 68, 77], ["nucleocapsid proteins", "PROBLEM", 82, 103]]], ["The cassette has both a dye pad which contains colloidal gold coupled with Recombinant 2019-novel coronavirus nucleocapsid protein and a dye pad which contains colloidal gold coupled with Recombinant 2019-novel coronavirus Spike Protein (Si Subunit).", [["colloidal gold", "SIMPLE_CHEMICAL", 47, 61], ["coronavirus", "ORGANISM", 98, 109], ["colloidal gold", "SIMPLE_CHEMICAL", 160, 174], ["coronavirus", "ORGANISM", 211, 222], ["Si Subunit", "GENE_OR_GENE_PRODUCT", 238, 248], ["Recombinant 2019-novel coronavirus nucleocapsid protein", "PROTEIN", 75, 130], ["Recombinant 2019-novel coronavirus Spike Protein", "PROTEIN", 188, 236], ["Si Subunit", "PROTEIN", 238, 248], ["coronavirus", "SPECIES", 98, 109], ["a dye pad", "TREATMENT", 22, 31], ["novel coronavirus nucleocapsid protein", "PROBLEM", 92, 130], ["a dye pad", "TREATMENT", 135, 144], ["novel coronavirus Spike Protein (Si Subunit", "TREATMENT", 205, 248]]], ["Thus, LFAs are potentially useful assays that require low sample input and minimum processivity.", [["LFAs", "GENE_OR_GENE_PRODUCT", 6, 10], ["LFAs", "PROTEIN", 6, 10], ["low sample input", "TREATMENT", 54, 70]]], ["In this study, we report the sensitivity and specificity of Clungene\u00ae SARS-CoV-2 IgG/IgM Rapid Test Cassettes in determining the presence of binding antibodies in convalescent plasma (CP) donor samples with previously documented COVID19.Methods ::: Main textConvalescent donor plasma was collected by the New York Blood Center (NYBC) with written consent from patients in accordance with NYBC Institutional Review Board protocols.", [["plasma", "ANATOMY", 176, 182], ["CP", "ANATOMY", 184, 186], ["samples", "ANATOMY", 194, 201], ["plasma", "ANATOMY", 277, 283], ["plasma", "ORGANISM_SUBSTANCE", 176, 182], ["plasma", "ORGANISM_SUBSTANCE", 277, 283], ["patients", "ORGANISM", 360, 368], ["Clungene\u00ae SARS-CoV-2 IgG", "PROTEIN", 60, 84], ["IgM", "PROTEIN", 85, 88], ["binding antibodies", "PROTEIN", 141, 159], ["COVID19", "PROTEIN", 229, 236], ["patients", "SPECIES", 360, 368], ["this study", "TEST", 3, 13], ["the sensitivity", "TEST", 25, 40], ["Clungene", "TEST", 60, 68], ["SARS", "TEST", 70, 74], ["CoV", "TEST", 75, 78], ["IgG", "TEST", 81, 84], ["binding antibodies", "TEST", 141, 159], ["donor samples", "TEST", 188, 201], ["previously documented COVID19", "TREATMENT", 207, 236]]], ["All donors had self-reported documented COVID19 disease by positive SARS-CoV-2 RT-PCR test (manufacturer and documentation not provided from referring institution of CP donors), had complete resolution of symptoms at least 14 days prior to donation, and otherwise met all criteria for donating blood consistent with FDA\u2019s policy on the Collection of COVID-19 Convalescent Plasma [1].", [["blood", "ANATOMY", 294, 299], ["donors", "ORGANISM", 4, 10], ["donors", "ORGANISM", 169, 175], ["blood", "ORGANISM_SUBSTANCE", 294, 299], ["COVID19 disease", "PROBLEM", 40, 55], ["positive SARS", "PROBLEM", 59, 72], ["CoV", "TEST", 73, 76], ["PCR test", "TEST", 82, 90], ["CP donors", "PROBLEM", 166, 175], ["symptoms", "PROBLEM", 205, 213], ["COVID", "TEST", 350, 355]]], ["As a negative control, fresh frozen plasma was used that was collected prior to the beginning of the epidemic.", [["plasma", "ANATOMY", 36, 42], ["plasma", "ORGANISM_SUBSTANCE", 36, 42], ["fresh frozen plasma", "TREATMENT", 23, 42]]], ["Clungene\u00ae SARS-CoV-2 (COVID-19) IgG/IgM Rapid Test Cassettes were used to determine the presence of SARS-CoV-2-specific IgG and IgM.", [["IgG", "ORGANISM", 32, 35], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 100, 110], ["IgG", "GENE_OR_GENE_PRODUCT", 120, 123], ["IgM.", "SIMPLE_CHEMICAL", 128, 132], ["IgG", "PROTEIN", 32, 35], ["IgM", "PROTEIN", 36, 39], ["SARS-CoV-2-specific IgG", "PROTEIN", 100, 123], ["SARS-CoV", "SPECIES", 100, 108], ["CoV", "TEST", 15, 18], ["COVID", "TEST", 22, 27], ["IgG", "TEST", 32, 35], ["Rapid Test Cassettes", "TREATMENT", 40, 60], ["SARS", "PROBLEM", 100, 104], ["CoV", "TEST", 105, 108], ["specific IgG", "TEST", 111, 123]]], ["The manufacturer of the Cassette (Hangzhou Clongene Biotech Co., Ltd., Hangzhou, China) validated this immunoassay for the qualitative detection of IgG and IgM antibodies to SARS-CoV-2 and these data were submitted to FDA as part of their Emergency Use Authorization [7].Methods ::: Main textTo perform assays, 20 mL of human plasma was applied to the sample pad followed by two drops of proprietary running buffer.", [["plasma", "ANATOMY", 326, 332], ["SARS", "DISEASE", 174, 178], ["IgG", "GENE_OR_GENE_PRODUCT", 148, 151], ["human", "ORGANISM", 320, 325], ["plasma", "ORGANISM_SUBSTANCE", 326, 332], ["IgG", "PROTEIN", 148, 151], ["IgM antibodies", "PROTEIN", 156, 170], ["human", "SPECIES", 320, 325], ["SARS-CoV", "SPECIES", 174, 182], ["human", "SPECIES", 320, 325], ["this immunoassay", "TEST", 98, 114], ["the qualitative detection", "TEST", 119, 144], ["IgG", "TEST", 148, 151], ["IgM antibodies", "TEST", 156, 170], ["SARS", "TEST", 174, 178], ["CoV", "TEST", 179, 182], ["these data", "TEST", 189, 199], ["assays", "TEST", 303, 309], ["human plasma", "TREATMENT", 320, 332], ["the sample pad", "TREATMENT", 348, 362], ["proprietary running buffer", "TREATMENT", 388, 414]]], ["Tests were analyzed after 15 min.", [["Tests", "TEST", 0, 5]]], ["Following incubation, high resolution images were taken of detection zone and saved as JPEG for reference and analysis.", [["high resolution images", "TEST", 22, 44], ["JPEG", "TEST", 87, 91], ["analysis", "TEST", 110, 118]]], ["Positive and negative IgG/IgM band determinations were made by visual inspection with accordance to manufacturer instructions (Fig. 1a, b).", [["IgG", "GENE_OR_GENE_PRODUCT", 22, 25], ["IgM", "GENE_OR_GENE_PRODUCT", 26, 29], ["IgG", "PROTEIN", 22, 25], ["IgM", "PROTEIN", 26, 29], ["IgG/IgM band determinations", "TEST", 22, 49], ["visual inspection", "TEST", 63, 80]]], ["All tests were performed under a NYBC IRB approved protocol using four independently trained operators.Results ::: Main textConvalescent donor plasma contains SARS-CoV-2 specific antibodies.", [["plasma", "ANATOMY", 143, 149], ["plasma", "ORGANISM_SUBSTANCE", 143, 149], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 159, 169], ["SARS-CoV-2 specific antibodies", "PROTEIN", 159, 189], ["All tests", "TEST", 0, 9], ["a NYBC IRB", "TREATMENT", 31, 41], ["Main textConvalescent donor plasma", "TEST", 115, 149], ["SARS", "TEST", 159, 163], ["CoV", "TEST", 164, 167]]], ["Using CP donors as a prospectively positive population, we tested 63 NYBC CP donor samples for the presence of SARS-CoV-2 specific IgG and IgM.", [["samples", "ANATOMY", 83, 90], ["donors", "ORGANISM", 9, 15], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 111, 121], ["IgG", "GENE_OR_GENE_PRODUCT", 131, 134], ["IgM.", "GENE_OR_GENE_PRODUCT", 139, 143], ["SARS-CoV-2 specific IgG", "PROTEIN", 111, 134], ["SARS-CoV", "SPECIES", 111, 119], ["CP donors", "TREATMENT", 6, 15], ["donor samples", "TEST", 77, 90], ["SARS", "PROBLEM", 111, 115], ["CoV", "TEST", 116, 119], ["IgG", "TEST", 131, 134]]], ["CP donors showed diverse antibody result profiles with the LFA test, including strong and weak bands as compared to FFP negative control (Fig. 1c, Table 1).", [["LFA", "PROTEIN", 59, 62], ["FFP", "PROTEIN", 116, 119], ["CP donors", "TEST", 0, 9], ["diverse antibody result profiles", "PROBLEM", 17, 49], ["the LFA test", "TEST", 55, 67], ["weak bands", "PROBLEM", 90, 100], ["FFP", "TEST", 116, 119], ["diverse", "OBSERVATION_MODIFIER", 17, 24], ["antibody", "OBSERVATION", 25, 33]]], ["All samples yielded an interpretable result with no invalid results.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11]]], ["Overall, 88.9% (56/63) of CP donors were considered positive.", [["donors", "ORGANISM", 29, 35], ["Overall", "TEST", 0, 7], ["CP donors", "PROBLEM", 26, 35], ["positive", "PROBLEM", 52, 60]]], ["87.3% (55/63) of CP donors were positive for IgG and 50.8% (32/63) of CP donors were positive for IgM (Fig. 2a, b).Results ::: Main textWith regard to negative samples, 11.1% (7/63) of CP donors were IgGNeg and IgMNeg, 1.6% (1/63) were IgGNeg and IgMPos and 38.1% (24/63) were IgGPos and IgMNeg (Fig. 2c).", [["samples", "ANATOMY", 160, 167], ["donors", "ORGANISM", 20, 26], ["IgG", "GENE_OR_GENE_PRODUCT", 45, 48], ["donors", "ORGANISM", 73, 79], ["IgM", "GENE_OR_GENE_PRODUCT", 98, 101], ["donors", "ORGANISM", 188, 194], ["IgGNeg", "GENE_OR_GENE_PRODUCT", 200, 206], ["IgMNeg", "GENE_OR_GENE_PRODUCT", 211, 217], ["IgGNeg", "GENE_OR_GENE_PRODUCT", 236, 242], ["IgMPos", "CANCER", 247, 253], ["IgGPos", "GENE_OR_GENE_PRODUCT", 277, 283], ["IgG", "PROTEIN", 45, 48], ["IgM", "PROTEIN", 98, 101], ["IgGPos", "PROTEIN", 277, 283], ["CP donors", "TEST", 17, 26], ["IgG", "TEST", 45, 48], ["CP donors", "TEST", 70, 79], ["IgM", "TEST", 98, 101], ["samples", "TEST", 160, 167], ["CP donors", "TEST", 185, 194], ["IgGNeg", "TEST", 200, 206], ["IgMNeg", "TEST", 211, 217], ["IgGNeg", "TEST", 236, 242], ["IgMPos", "TEST", 247, 253], ["IgGPos", "TEST", 277, 283], ["IgMNeg", "TEST", 288, 294]]], ["In contrast, all FFP samples were IgGNegand 80% (8/10) were IgMNeg.", [["FFP samples", "ANATOMY", 17, 28], ["FFP samples", "CANCER", 17, 28], ["all FFP samples", "TEST", 13, 28], ["IgGNegand", "TEST", 34, 43]]], ["These data suggest that LFA tests possess a high degree of sensitivity (87.3% IgG, 50.8% IgM) and specificity (100.0% IgG, 80.0% IgM) for detecting SARS-CoV-2 specific antibodies.", [["LFA", "GENE_OR_GENE_PRODUCT", 24, 27], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 148, 158], ["LFA", "PROTEIN", 24, 27], ["IgG", "PROTEIN", 78, 81], ["IgM", "PROTEIN", 89, 92], ["IgG", "PROTEIN", 118, 121], ["IgM", "PROTEIN", 129, 132], ["SARS-CoV-2 specific antibodies", "PROTEIN", 148, 178], ["SARS-CoV", "SPECIES", 148, 156], ["These data", "TEST", 0, 10], ["LFA tests", "TEST", 24, 33], ["sensitivity", "TEST", 59, 70], ["IgG", "TEST", 78, 81], ["IgM", "TEST", 89, 92], ["specificity", "TEST", 98, 109], ["IgG", "TEST", 118, 121], ["IgM", "TEST", 129, 132], ["SARS", "TEST", 148, 152], ["CoV", "TEST", 153, 156], ["high degree", "OBSERVATION_MODIFIER", 44, 55]]], ["Given all CP donors were collected more than 14 days since date of last symptom, when the IgM tests would have performed, it is not surprising that the IgM results were low since IgM immunoglobins likely develop early in response to infection [8].Results ::: Main textWeak antibody bands may identify low titer CP donors.", [["infection", "DISEASE", 233, 242], ["donors", "ORGANISM", 13, 19], ["IgM", "GENE_OR_GENE_PRODUCT", 152, 155], ["IgM", "GENE_OR_GENE_PRODUCT", 179, 182], ["IgM", "PROTEIN", 90, 93], ["IgM", "PROTEIN", 152, 155], ["IgM", "PROTEIN", 179, 182], ["textWeak antibody bands", "PROTEIN", 264, 287], ["all CP donors", "PROBLEM", 6, 19], ["last symptom", "PROBLEM", 67, 79], ["the IgM tests", "TEST", 86, 99], ["the IgM", "TEST", 148, 155], ["IgM immunoglobins", "PROBLEM", 179, 196], ["infection", "PROBLEM", 233, 242], ["Main textWeak antibody bands", "TEST", 259, 287], ["low titer CP donors", "PROBLEM", 301, 320], ["infection", "OBSERVATION", 233, 242], ["antibody bands", "OBSERVATION", 273, 287]]], ["Recent studies suggest that a significant percentage of convalescent individuals may have low SARS-CoV-2 IgG or IgM titers [4, 9].", [["convalescent", "ORGANISM", 56, 68], ["individuals", "ORGANISM", 69, 80], ["SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 94, 108], ["IgM", "GENE_OR_GENE_PRODUCT", 112, 115], ["IgG", "PROTEIN", 105, 108], ["IgM", "PROTEIN", 112, 115], ["Recent studies", "TEST", 0, 14], ["convalescent individuals", "PROBLEM", 56, 80], ["low SARS", "PROBLEM", 90, 98], ["CoV", "TEST", 99, 102], ["IgM titers", "TEST", 112, 122], ["significant", "OBSERVATION_MODIFIER", 30, 41]]], ["We also inferred from conducting LFA assays that potential differences in antibody levels may occur in the CP donor population.", [["LFA", "PROTEIN", 33, 36], ["potential differences in antibody levels", "PROBLEM", 49, 89], ["the CP donor population", "PROBLEM", 103, 126]]], ["However, LFA tests are designed to perform qualitative, and not quantitative, analysis as stated in the manufacturer\u2019s instructions.", [["LFA", "PROTEIN", 9, 12], ["LFA tests", "TEST", 9, 18]]], ["Nevertheless, to document this phenomenon, trained experimenters subjectively delineated positive results as \u2018strong\u2019 or \u2018weak\u2019 relative to the band intensity produced by each CP donor sample (Fig. 1c).Results ::: Main textTo confirm reproducibility, we re-tested random samples (n = 16) to explore whether CP donor samples could provide reproducible results (Fig. 2d, Table 1).", [["samples", "ANATOMY", 316, 323], ["this phenomenon", "PROBLEM", 26, 41], ["random samples", "TEST", 264, 278], ["CP donor samples", "PROBLEM", 307, 323], ["reproducibility", "OBSERVATION_MODIFIER", 234, 249]]], ["Between replicates of paired results, 56.25% (9/16) of samples were consistently positive, 6.25% (1/16) was consistently negative, and 37.5% (6/16) were inconsistent.", [["samples", "ANATOMY", 55, 62], ["samples", "CANCER", 55, 62], ["samples", "TEST", 55, 62]]], ["With regard to inconsistency, these bands were almost always visually weak (4/6).", [["these bands", "PROBLEM", 30, 41]]], ["These data suggest that certain CP donors may have low levels of SARS-CoV-2 antibodies and may account for inconsistency between results, while data available from the manufacturer did report any difference related to batches (n = 3), operators (n = 2), runs (n = 2) or time (15 days).Discussion ::: Main textOur study analyzed blood samples from COVID19 convalescent plasma donors to determine whether antibodies are detected using a LFA in this population.", [["blood samples", "ANATOMY", 328, 341], ["plasma", "ANATOMY", 368, 374], ["CP donors", "ORGANISM", 32, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 65, 75], ["blood samples", "ORGANISM_SUBSTANCE", 328, 341], ["convalescent", "ORGANISM", 355, 367], ["plasma", "ORGANISM_SUBSTANCE", 368, 374], ["donors", "ORGANISM", 375, 381], ["SARS-CoV-2 antibodies", "PROTEIN", 65, 86], ["antibodies", "PROTEIN", 403, 413], ["LFA", "PROTEIN", 435, 438], ["These data", "TEST", 0, 10], ["certain CP donors", "PROBLEM", 24, 41], ["low levels of SARS", "PROBLEM", 51, 69], ["CoV-2 antibodies", "TEST", 70, 86], ["Our study", "TEST", 309, 318], ["blood samples", "TEST", 328, 341], ["plasma donors", "TEST", 368, 381], ["antibodies", "PROBLEM", 403, 413]]], ["We found that the CLUNGENE\u00ae SARS-COV-2 VIRUS (COVID-19) IgG/IgM LFA test possesses high sensitivity and specificity for COVID19 antibodies.", [["IgG", "GENE_OR_GENE_PRODUCT", 56, 59], ["IgM", "GENE_OR_GENE_PRODUCT", 60, 63], ["COVID19 antibodies", "GENE_OR_GENE_PRODUCT", 120, 138], ["IgG", "PROTEIN", 56, 59], ["IgM", "PROTEIN", 60, 63], ["LFA", "PROTEIN", 64, 67], ["COVID19 antibodies", "PROTEIN", 120, 138], ["the CLUNGENE\u00ae SARS", "TEST", 14, 32], ["COV", "TEST", 33, 36], ["VIRUS", "TEST", 39, 44], ["COVID", "TEST", 46, 51], ["IgG/IgM LFA test", "TEST", 56, 72], ["high sensitivity", "PROBLEM", 83, 99], ["COVID19 antibodies", "PROBLEM", 120, 138]]], ["The LFA test was easy to use with properly trained staff.", [["LFA", "PROTEIN", 4, 7], ["The LFA test", "TEST", 0, 12], ["LFA", "ANATOMY", 4, 7]]], ["Results were interpretable within 15 min and the internal procedural control confirmed that sufficient specimen volume, adequate membrane wicking and correct procedural technique were used.", [["specimen", "ANATOMY", 103, 111], ["membrane", "ANATOMY", 129, 137], ["membrane", "CELLULAR_COMPONENT", 129, 137], ["the internal procedural control", "TREATMENT", 45, 76], ["specimen volume", "TEST", 103, 118], ["correct procedural technique", "TREATMENT", 150, 178]]], ["Since documented positive PCR tests or comparison to other antibody testing platforms were unavailable, we cannot state that the 7 negative donors in fact were infected or if they have antibody.", [["donors", "ORGANISM", 140, 146], ["positive PCR tests", "TEST", 17, 35], ["other antibody testing platforms", "TEST", 53, 85], ["antibody", "PROBLEM", 185, 193], ["infected", "OBSERVATION", 160, 168]]], ["Even if CP donor infection data were available, it may also be possible, and is probable, that some CP donors produced low amounts of antibodies that is specific to the immunological response unique to each individual, thus, below the detection limit of the LFA.", [["infection", "DISEASE", 17, 26], ["CP donors", "ORGANISM", 100, 109], ["antibodies", "PROTEIN", 134, 144], ["LFA", "PROTEIN", 258, 261], ["CP donor infection data", "PROBLEM", 8, 31], ["some CP donors", "PROBLEM", 95, 109], ["low amounts of antibodies", "PROBLEM", 119, 144], ["infection", "OBSERVATION", 17, 26], ["low amounts", "OBSERVATION_MODIFIER", 119, 130], ["LFA", "ANATOMY", 258, 261]]], ["The IgG results are consistent with the manufacturer\u2019s 97.4% clinical performance data which showed positive IgG agreement with known positive RT-PCR test.", [["IgG", "GENE_OR_GENE_PRODUCT", 4, 7], ["IgG", "GENE_OR_GENE_PRODUCT", 109, 112], ["IgG", "PROTEIN", 4, 7], ["IgG", "PROTEIN", 109, 112], ["The IgG", "TEST", 0, 7], ["the manufacturer\u2019s", "TEST", 36, 54], ["clinical performance data", "TEST", 61, 86], ["known positive RT-PCR test", "PROBLEM", 128, 154], ["consistent with", "UNCERTAINTY", 20, 35]]], ["The IgM results are consistent with recently published data which shows that IgM can persist more than 23 days after symptom onset and can be earlier, synchronous or later than IgG.Conclusions ::: Main textMost (90%) COVID19 convalescent donors seroconverted, demonstrating the potential of LFA tests to identify antibody positive individuals that have recovered from COVID19.", [["IgM", "GENE_OR_GENE_PRODUCT", 4, 7], ["IgM", "GENE_OR_GENE_PRODUCT", 77, 80], ["IgG", "GENE_OR_GENE_PRODUCT", 177, 180], ["donors", "ORGANISM", 238, 244], ["LFA", "GENE_OR_GENE_PRODUCT", 291, 294], ["COVID19", "GENE_OR_GENE_PRODUCT", 368, 375], ["IgM", "PROTEIN", 4, 7], ["IgM", "PROTEIN", 77, 80], ["IgG", "PROTEIN", 177, 180], ["LFA", "PROTEIN", 291, 294], ["COVID19", "PROTEIN", 368, 375], ["The IgM", "TEST", 0, 7], ["IgM", "PROBLEM", 77, 80], ["convalescent donors", "TEST", 225, 244], ["LFA tests", "TEST", 291, 300], ["antibody positive individuals", "PROBLEM", 313, 342], ["COVID19", "TREATMENT", 368, 375], ["consistent with", "UNCERTAINTY", 20, 35], ["IgM", "OBSERVATION", 77, 80]]], ["Confirming suspected SARS-CoV-2 cases using antibody detection at the point of care could help inform the patient and the community as to the relative risk to future SARS-CoV2- exposure and a better understanding of disease exposure.", [["SARS", "DISEASE", 166, 170], ["SARS-CoV-2", "ORGANISM", 21, 31], ["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113], ["CoV", "TEST", 26, 29], ["antibody detection", "TEST", 44, 62], ["disease exposure", "PROBLEM", 216, 232]]], ["However, a coherent description of the immunological response and antiviral antibody activity (i.e. neutralizing activity) is warranted to definitively use antibody presence to prognose future disease potential [10].", [["antiviral antibody", "PROTEIN", 66, 84], ["the immunological response", "PROBLEM", 35, 61], ["antiviral antibody activity", "TREATMENT", 66, 93]]], ["This study highlights the relevance of serological testing to support accurate estimates of the extent of the COVID-19 pandemic and the potential to assess a patient response to SARS-CoV-2 infection using antibody detection.LimitationsOur study has several limitations, including but not limited to:Samples were not tested for virus neutralization; therefore neutralizing activities of the detected IgG antibodies are not known.The small sample size of patients and the absence of documented PCR test results makes it difficult to determine the relationship between antibody response and clinical course.More detailed investigation of the reproducibility of the test is warrented.", [["infection", "DISEASE", 189, 198], ["patient", "ORGANISM", 158, 165], ["SARS-CoV-2", "ORGANISM", 178, 188], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 399, 413], ["patients", "ORGANISM", 453, 461], ["IgG antibodies", "PROTEIN", 399, 413], ["patient", "SPECIES", 158, 165], ["patients", "SPECIES", 453, 461], ["SARS-CoV", "SPECIES", 178, 186], ["This study", "TEST", 0, 10], ["serological testing", "TEST", 39, 58], ["the COVID", "TEST", 106, 115], ["SARS", "PROBLEM", 178, 182], ["CoV-2 infection", "PROBLEM", 183, 198], ["antibody detection", "TEST", 205, 223], ["Our study", "TEST", 235, 244], ["Samples", "TEST", 299, 306], ["virus neutralization", "PROBLEM", 327, 347], ["neutralizing activities", "TEST", 359, 382], ["the detected IgG antibodies", "TEST", 386, 413], ["documented PCR test", "TEST", 481, 500], ["antibody response", "TEST", 566, 583], ["the test", "TEST", 658, 666], ["small", "OBSERVATION_MODIFIER", 432, 437], ["sample", "OBSERVATION_MODIFIER", 438, 444], ["size", "OBSERVATION_MODIFIER", 445, 449]]]]}